Bioengineering approaches in immunotherapy:from basic to translational applications by Damo, Martina
POUR L'OBTENTION DU GRADE DE DOCTEUR ÈS SCIENCES
acceptée sur proposition du jury:
Prof. F. G. van der Goot Grunberg, présidente du jury
Prof. J. A. Hubbell, directeur de thèse
Prof. D. Speiser, rapporteur
Prof. S. Turley, rapporteuse
Prof. N. Harris, rapporteuse
Bioengineering approaches in immunotherapy:
from basic to translational applications
THÈSE NO 6909 (2016)
ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE
PRÉSENTÉE LE 15 MARS 2016
 À LA FACULTÉ DES SCIENCES DE LA VIE
CHAIRE MERCK-SERONO EN TECHNOLOGIES D'ADMINISTRATION DE MÉDICAMENTS
PROGRAMME DOCTORAL EN BIOTECHNOLOGIE ET GÉNIE BIOLOGIQUE 
Suisse
2016
PAR
Martina DAMO

?
?
?
?
Abstract 
Immunotherapies have been developed with the aim of modulating the components of the 
immune system to provide therapeutic benefit. 
 
Vaccination has been regarded to as the most attractive immunotherapy for cancer because of 
its ability to instruct immune cells to recognize and kill tumor cells. Exosomes are one of the 
most recent discoveries translated from basic biology into experimental vaccine therapy of 
cancer. Exosomes are 30-150 nm membrane vesicles released by many cell types. In 
particular, dendritic cell (DC)-derived exosomes (Dexo) inherit the molecules that make DCs 
able to activate antigen-specific immunity. As a consequence, Dexo have been tested in 
clinical trials for the vaccination of melanoma and lung carcinoma patients, however resulting 
in poor therapeutic outcomes due to weak immunogenicity. We therefore developed a 
protocol for the production of Dexo with improved immunogenic properties by exploiting the 
physiological ability of DCs to mature into immunostimulatory cells in the presence of 
antigens and immunogenic signals. We cultured Dexo-producing DCs with a murine 
melanoma cell lysate, that provided tumor antigens, and poly(I:C), a synthetic nucleic acid 
analog that provided immunogenic signals. The result was a Dexo vaccine capable of eliciting 
robust tumor-specific immunity in melanoma-bearing mice, leading to significantly reduced 
tumor growth and enhanced survival of experimental mice. These data indicate our strategy as 
a valuable improved alternative to currently available protocols for the production of potent 
tumor-tailored Dexo vaccines. 
 
A healthy immune system recognizes and eliminates potentially harmful agents avoiding 
collateral damage to normal self tissues, which are spared from immune aggression via the 
establishment of immune tolerance to self antigens. Tolerance is developed in both central 
lymphoid organs (central tolerance) and peripheral lymphoid and non-lymphoid organs 
(peripheral tolerance). The liver has recently been attributed an important role in peripheral 
tolerogenesis to circulating extracellular antigens, mainly due to the antigen scavenging 
properties of liver sinusoid endothelial cells. However, even though hepatocytes are the most 
abundant cell type of the liver and possess enzymatic activities necessary for processing of 
blood-borne molecules, their ability to take up and induce tolerance to extracellular antigens 
has yet to be explored. In this thesis we show for the first time in vitro and in vivo that 
hepatocytes efficiently take up, process and present extracellular antigens on MHC-I 
complexes inducing CD8+ T cell tolerance. We also show that the negative regulatory PD-
1/PD-L1 pathway is involved in hepatocyte-dependent tolerogenesis. Therefore, we propose 
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that hepatocytes are instrumental in the establishment and maintenance of liver-mediated 
peripheral tolerance towards extracellular antigens reaching the liver through the 
bloodstream. 
 
In addition, this thesis also provides evidence that hepatocytes are capable of directly 
expressing antigens specific of other peripheral tissues, a process known as promiscuous gene 
expression. Promiscuous gene expression allows to broaden the pool of self antigens 
presented to T lymphocytes in central and peripheral lymphoid organs, thus increasing the 
likelihood of inducing T cell tolerance to self antigens. We describe here for the first time that 
Deaf1, a transcription factor involved in promiscuous gene expression, is significantly 
expressed in murine hepatocytes, together with other well characterized peripheral tissue-
restricted antigen-coding genes, such as insulin. Even though preliminary, these data further 
suggest a central role of hepatocytes in peripheral tolerogenesis and confirm the relevance of 
hepatocyte-targeted approaches as valuable immunotherapy candidates for the treatment of 
autoimmunity and hepatic chronic infections. 
 
Key words: immunotherapy, cancer, exosomes, hepatocyte, tolerance, peripheral tissue-
specific antigen. 
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Riassunto 
L’immunoterapia è stata introdotta allo scopo di modulare il sistema immunitario e fornire 
beneficio terapeutico. 
 
La vaccinazione è considerata l’immunoterapia più interessante per il cancro grazie alla sua 
capacità di istruire le cellule immunitarie a riconoscere ed uccidere le cellule tumorali. Gli 
exosomi sono tra le scoperte più recenti della biologia cellulare ad essere state applicate come 
vaccini sperimentali per il cancro. Gli exosomi sono vescicole membranose di 30-150 nm 
rilasciate da molteplici tipi cellulari. In particolare, gli exosomi derivati da cellule dendritiche 
(CD) (Dexo) ereditano le molecole che permettono alle CD di attivare risposte immunitarie 
antigene-specifiche. Di conseguenza, i Dexo sono entrati in sperimentazione clinica per la 
vaccinazione di pazienti affetti da melanoma e carcinoma del polmone, dando tuttavia scarsi 
risultati terapeutici a causa della loro debole immunogenicità. Abbiamo quindi messo a punto 
un protocollo per la produzione di Dexo più immunogenici sfruttando la capacità fisiologica 
delle CD di maturare in cellule immunogeniche in presenza di antigeni e segnali 
immunostimolatori. Le CD sono state coltivate con un lisato di cellule di melanoma murino, 
fonte di antigeni tumorali, e poly(I:C), un analogo sintetico degli acidi nucleici usato come 
segnale immunogenico. Ne è risultato un Dexo vaccino capace di stimolare una robusta 
risposta immunitaria anti-tumorale in topi affetti da melanoma, di ridurre significativamente 
la crescita tumorale e aumentare la sopravvivenza dei topi trattati. I dati indicano che la nostra 
strategia è una valida alternativa ai protocolli attualmente disponibili per la produzione di 
Dexo vaccini efficaci e specifici. 
 
Un sistema immunitario sano riconosce ed elimina agenti potenzialmente pericolosi evitando 
danni collaterali ai tessuti normali, risparmiati dall’aggressione immunitaria grazie alla 
tolleranza verso gli antigeni del self. La tolleranza si sviluppa sia in organi linfoidi centrali 
(tolleranza centrale) che in organi linfoidi e non-linfoidi periferici (tolleranza periferica). Di 
recente, al fegato è stato riconosciuto un ruolo importante nello sviluppo di tolleranza 
periferica verso antigeni extracellulari circolanti nel sangue, soprattutto per le proprietà 
fagocitiche delle cellule endoteliali sinusoidali epatiche. Tuttavia, anche se gli epatociti sono 
le cellule epatiche più numerose e possiedono attività enzimatiche per la degradazione di 
molecole derivanti dal sangue, la loro capacità di endocitare antigeni extracellulari e indurre 
tolleranza non è ancora stata esplorata. In questa tesi si dimostra per la prima volta sia in vitro 
che in vivo che gli epatociti endocitano, degradano e presentano sull’MHC-I antigeni 
extracellulari inducendo tolleranza nelle cellule T CD8+. Inoltre, si dimostra che le interazioni 
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tra PD-1 e PD-L1 sono coinvolte nel processo tollerogenico da parte degli epatociti. 
Proponiamo quindi che gli epatociti svolgono un ruolo di primaria importanza nello sviluppo 
e nel mantenimento della tolleranza periferica nei confronti di quegli antigeni che 
raggiungono il fegato attraverso la circolazione sanguinea. 
 
Inoltre, in questa tesi si dimostra anche che gli epatociti sono capaci di esprimere antigeni 
specifici di altri tessuti periferici, un processo noto come espressione genica promiscua e che 
permette di aumentare la capacità di presentazione di antigeni del self ai linfociti T negli 
organi linfoidi centrali e periferici, incrementando di conseguenza la probabilità di indurre 
tolleranza delle cellule T agli antigeni del self. Riportiamo qui per la prima volta che Deaf1, 
un fattore di trascrizione coinvolto nell’espressione genica promiscua, è espresso dagli 
epatociti, assieme ad altri geni che esprimono antigeni tissutali periferici, come l’insulina. 
Anche se preliminari, questi dati contribuiscono all’ipotesi che gli epatociti abbiano un ruolo 
centrale nello sviluppo di tolleranza periferica e confermano l’importanza di approcci che 
targhettano gli epatociti come validi candidati per l’immunoterapia delle malattie autoimmuni 
e delle infezioni epatiche croniche. 
 
Parole chiave: immunoterapia, cancro, exosomi, epatocita, tolleranza immunologica, 
antigene tissutale periferico. 
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Résumé 
L’immunothérapie a été développée dans le but de moduler les composants du système 
immunitaire et de fournir ainsi des bénéfices thérapeutiques. 
 
La vaccination est considérée comme l’immunothérapie la plus attractive contre le cancer, de 
par sa capacité à éduquer les cellules immunitaires à reconnaître et tuer les cellules tumorales. 
Les exosomes sont parmi les plus récentes découvertes de la biologie cellulaire ayant été 
appliquées comme vaccin expérimental contre le cancer. Ce sont des vésicules membranaires 
de 30-150 nm sécrétées par plusieurs types cellulaires. En particulier, les exosomes dérivés 
des cellules dendritiques (CD) (Dexo) héritent des molécules permettant aux CDs d’activer 
une immunité spécifique à l’antigène. De ce fait, les Dexo ont été testés en essais cliniques 
sur des patients atteints de mélanomes et carcinomes pulmonaires, avec des résultats 
thérapeutiques limités en raison de leur faible immunogénicité. Par conséquent, nous avons 
développé un protocole permettant la production de Dexo plus immunogènes en exploitant la 
capacité physiologiques des CDs à mûrir en cellules immunostimulantes en présence 
d’antigènes et de signaux immunogéniques. Nous avons cultivé les CDs avec un lysat 
cellulaire de mélanome murin, fournissant les antigènes tumoraux, et poly(I :C), un analogue 
synthétique d’acides nucléiques utilisé comme signal immunogénique. Il en résulte un Dexo 
vaccin capable de stimuler une réponse immunitaire robuste dans des souris atteintes de 
mélanome, réduisant significativement la croissance tumorale et augmentant l’espérance de 
vie des souris traitées. Ces données montrent que notre stratégie est une alternative valide aux 
protocoles actuels de production de vaccins Dexo efficaces et spécifique à la tumeur.  
 
Un système immunitaire sain reconnaît et élimine les agents dangereux en évitant les 
dommages collatéraux sur les tissus, qui sont épargnés grâce l’établissement d’une tolérance 
immunitaire aux antigènes du soi. La tolérance est développée à la fois dans les organes 
lymphoïdes centraux (tolérance centrale) et les organes lymphoïdes et non-lymphoïdes 
périphériques (tolérance périphérique). Le foie a récemment été attribué d’un rôle important 
dans la tolérogénèse périphérique aux antigènes extracellulaires circulants dans le sang, 
principalement dû aux propriétés phagocytiques des cellules endothéliales sinusoïdales 
hépatiques. Cependant, bien que les hépatocytes soient le type cellulaire le plus abondant du 
foie et possèdent des activités enzymatiques nécessaires à la dégradation des molécules et des 
antigènes, leur aptitude à endocytoser les antigènes et induire de la tolérance reste à explorer. 
Dans cette thèse, nous avons montré pour la première fois in vitro et in vivo que les 
hépatocytes endocytosent, dégradent et présentent efficacement les antigènes extracellulaires 
?
?
?
?
sur les complexes MHC-I, ce qui induit la tolérance des cellules T CD8+. Nous avons 
également montré que la régulation négative de la voie de signalisation PD-1/PD-L1 est 
impliquée dans la tolérogénèse dépendante des hépatocytes. Ainsi, nous suggérons que les 
hépatocytes sont essentiels dans l’établissement et la maintenance de la tolérance 
périphérique médiée par le foie contre les antigènes extracellulaires provenant du sang. 
 
De plus, cette thèse démontre également que les hépatocytes sont capables d’exprimer 
directement des antigènes spécifiques d’autres tissus périphériques. Ce processus est appelé 
« l’expression promiscuitaire de gènes», et permet d’élargir la collection des antigènes du soi 
présentés aux lymphocytes T dans les organes lymphoïdes centraux et périphériques ; il 
permet donc d’accroître la probabilité d’induire la tolérance des cellules T aux antigènes du 
soi. Nous décrivons ici pour la première fois que Deaf1, un facteur de transcription impliqué 
dans l’expression génique promiscuitaire, est significativement exprimé dans les hépatocytes 
murins, parmi d’autres gènes codant pour des antigènes spécifiques des tissus périphériques, 
tel que l’insuline. Bien que préliminaires, ces données appuient le rôle central des hépatocytes 
dans la tolérogénèse périphérique et confirme la pertinence des approches ciblées sur les 
hépatocytes dans le développement d’immunothérapies pour les maladies auto-immunes et les 
infections hépatiques chroniques. 
 
Mots clés: immunothérapie, cancer, exosomes, hépatocyte, tolérance immunitaire, antigène 
spécifique d’autres tissus périphériques. 
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1.1 Motivation  
Immunotherapies comprise several therapeutic approaches that aim at providing benefits by 
modulating the immune system. The unique advantage of using the immune system for 
therapeutic purposes over other therapies derives from its intrinsic capacity to discriminate 
self from non-self, thus providing a tool able to specifically attack and eliminate harmful 
agents limiting collateral damage to healthy tissues 1. Basic and translational research for the 
development of immunotherapies have significantly improved the treatment of two major 
classes of diseases, cancer and autoimmune pathologies. 
 
Cancer is a heterogeneous group of diseases that arise when normal cells acquire a 
phenotype characterized by abnormal and uncontrolled growth and invasiveness as a result of 
progressive accumulation of genetic mutations 2. In 2012, 14.1 million people were diagnosed 
with cancer and 8.2 million people died because of cancer worldwide. While the incidence of 
cancer has been increasing, the death rate among cancer patients has been constantly 
declining since the early 90’s 3. The reduction of cancer deaths is the result of multiple 
factors. Most importantly, oncological research has provided new insights into the 
mechanisms of carcinogenesis and has allowed the translation of such knowledge into novel 
therapies. In particular, the role of the immune system in the control of tumor development 
has been recognized and exploited for the development of therapies aimed at enhancing anti-
cancer immunity. Unlike pre-clinical research, clinical trials for cancer immunotherapy have 
given disappointing results, and thus oncological research and novel therapies are greatly 
needed 1,4. In this Ph. D. thesis we applied bioengineering approaches to improve the 
immunogenicity of dendritic cell-derived exosome-based vaccines, that had been previously 
tested in clinical trials for the immunotherapy of cancer 7,8. The data presented here show 
encouraging results obtained in a murine model of melanoma treated with the improved 
exosome formulation we developed. Due to the positive therapeutic outcomes we observed as 
compared to previous publications and the ease of manufacturing of our system, the exosome 
immunotherapy approach described in this thesis could be easily translated into human 
application. 
 
Autoimmune diseases are a group of more than 80 pathologies characterized by 
abnormal and exaggerated immunity against self tissues. Type 1 diabetes, rheumatoid 
arthritis, multiple sclerosis and systemic lupus erythematosus represent some of the most 
common autoimmune pathologies. It is calculated that 3 to 8% of the population worldwide is 
affected by an autoimmune disease 5. The pathogenesis of autoimmunity is the direct 
consequence of an immune dysfunction. Therefore, immunotherapy aimed at suppressing 
?
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immunity and resetting immune homeostasis has been considered the most straightforward 
treatment for affected individuals 1. Even though research has provided a wealth of new 
information on the physiology of the immune system and on some of the mechanisms of 
autoimmunity, clinical applications of autoimmune disease immunotherapies have resulted in 
incomplete therapeutic benefits for the patients 1,6. Therefore, it is imperative to develop new 
knowledge and possibly novel therapeutic tools for autoimmunity. 
For this Ph. D. thesis, we took advantage of engineering strategies to modify model 
protein antigens and study how hepatocytes, previously thought to contribute poorly to the 
modulation of immune responses towards extracellular antigens 9, instead, play an important 
role in the establishment of immune tolerance towards exogenous antigens. These results are 
of particular interest in light of the fact that the liver, mostly known for its blood-filtering and 
metabolic functions, has been recently associated with immunomodulatory functions 10. The 
observations described in this thesis not only contribute to a better understanding of immune 
physiology, but also open the way to the development of hepatocyte-targeting therapeutic 
strategies for the treatment of autoimmune diseases, immunity against protein therapeutics 
and hepatic chronic viral infections. 
Last, this Ph. D. thesis also provides new insights into basic mechanisms of immune 
tolerance involving the liver, which we found to contain cells expressing peripheral tissue-
specific antigens, suggesting that hepatic cells might have a role similar to other cells located 
in lymphoid tissues in the maintenance of self tolerance 11-15. These data further support liver-
targeting therapeutics as promising candidates for novel autoimmune disease 
immunotherapies. 
 
 
1.2 Background 
1.2.1 Immunity vs. Tolerance: the two sides of the same system 
The immune system is responsible for maintaining the integrity of the organism both against 
exogenous insults (pathogen infections) and endogenous threats (cancer). The capability of 
the immune system to eliminate harmful agents is the result of a delicate balance between 
immunity and tolerance, as the activation of an immune response (immunity) should occur 
after recognition of non-self or mutated-self components leading to their elimination but 
avoiding damage to normal self components (tolerance). This capacity to discriminate self 
from non-self or mutated-self is the fundamental feature of a healthy immune system and, as 
such, it is established early during the development of adaptive immune cells in central 
lymphoid organs and continuously guaranteed by immune regulatory mechanisms and check-
points in peripheral lymphoid and non-lymphoid organs 16.  
?
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Unlike innate immune responses, that are elicited by conserved pathogen-associated 
molecular patterns (PAMPs) and that lead to the activation of general innate host defense 
mechanisms such as inflammation, adaptive responses are tailored for specific non-self 
components, resulting in the production of antibodies and cellular responses targeted to that 
particular intruder 17-20. The specificity and magnitude of adaptive immune responses, 
especially for T lymphocytes, are the result of three types of signal that need to be co-
delivered to adaptive immune cells in order to induce their functional activation: antigen 
presentation, co-stimulation and secreted mediators (cytokines) (Fig. 1.1) 21. 
 
 
Figure 1.1 Signals leading to T cell activation. Antigen presentation (peptide/MHC), co-stimulation 
(CD28, CD80 and CD86) and secreted factors (cytokines) are the three signals that altogether shape 
and orchestrate the type of immune response necessary to protect our body from a specific threat 
(adapted from Kapsenberg, M. L., Nat. Rev. Immunol., 2003). 
 
T lymphocytes express T cell receptors (TCRs) able to recognize an antigen loaded 
onto major histocompatibility complex (MHC) molecules on the surface of antigen-presenting 
cells (APCs). MHC class I (MHC-I) molecules are expressed by every nucleated cell of the 
organism and allow the display of cellular peptides derived from intracellular protein turnover 
(direct presentation) and, in some subsets of cells, endocytosis of extracellular antigens 
(cross-presentation). In both cases, cognate peptide/MHC-I complexes are recognized by 
CD8+ T lymphocytes (Fig. 1.2a,b) 22,23. MHC class II (MHC-II) molecules, instead, are 
expressed by dedicated cell subsets with professional APC functions, including cells of the 
innate immune system like dendritic cells (DCs) and some non-hematopoietic cells with 
enhanced antigen-presenting properties. Antigen presentation on the MHC-II requires antigen 
uptake from the extracellular environment, followed by lysosomal degradation and 
complexing of the antigen-derived epitopes to MHC-II molecules, which are then translocated 
?
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to the cell membrane. Cognate peptide/MHC-II complexes are recognized by the TCR of 
CD4+ T lymphocytes (Fig. 1.2c) 22. 
 
Figure 1.2 Antigen presentation pathways. (a) Direct antigen presentation: intracellular antigens are 
processed by the proteasome and loaded on MHC-I molecules to be presented to CD8+ T lymphocytes. 
(b) Antigen cross-presentation: extracellular antigens are phagocytosed and processed by proteasomal 
degradation for presentation to CD8+ T cells in the context of the MHC-I.  (c) Extracellular antigens are 
endocytosed, digested in endosomes and loaded on MHC-II complexes for presentation to CD4+ T 
lymphocytes (adapted from Neefjes, J. et al, Nat. Rev. Immunol., 2011 and Joffre, O. P. et al., Nat. Rev. 
Immunol., 2012). 
 
In case of ongoing infections, tissue damage or developing cancerous lesions, danger 
signals are shed and sensed by innate immune cells, especially DCs. Pathogen-derived danger 
signals, such as PAMPs, and cell-derived danger signals, such as death-associated molecular 
patterns (DAMPs), bind to and trigger the activation of pattern recognition receptors (PRRs), 
among which Toll-like receptors (TLRs). Signal transduction originated from PRR triggering 
induces several changes in the phenotype of APCs, resulting in their maturation 21. One of the 
?
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hallmarks of DC maturation is the improvement of antigen-presenting and adaptive immune 
cell stimulatory capabilities, exemplified by the upregulation of MHC-I and II molecules and 
of surface co-stimulatory molecules, such as CD80 and CD86.  CD80 and CD86, in turn, bind 
to and activate CD28, which is constitutively expressed on T lymphocytes and whose 
activation promotes T cell survival and migration towards inflamed tissues 24-26. 
The cytokine microenvironment in which T cells recognize their cognate antigens and 
are co-stimulated determines the nature of the immune response developed against that 
antigen. Cytokines are initially secreted by APCs in response to the danger signals received 
and shape the type of immune response necessary to clear that particular invading agent. As 
an example, interleukin-12 (IL-12) is secreted during infections by intracellular pathogens 
and is crucial for the skewing of naïve CD4+ T cells into pro-inflammatory T helper 1 (Th1) 
lymphocytes. Th1-polarized lymphocytes, in turn, participate in the orchestration of cellular 
immunity, mainly by further stimulating APC maturation via CD40L upregulation and by 
releasing interferon-γ (IFN-γ), IL-2 and tumor necrosis factor-α (TNF-α) 21 (Fig. 1.1). These 
latter cytokines stimulate cellular immunity by inducing T cell expansion and acquisition of 
cytotoxic functions by CD8+ T lymphocytes that, upon recognition of their cognate antigen 
presented on the MHC-I of infected cells, lyse their targets by secretion of perforin and 
Granzyme-B 27. 
 
1.2.2 Anatomy and physiology of central and peripheral tolerance 
The antigen specificity of the TCR is the result of gene recombination and selection processes 
occurring during the development of T cell precursors in the thymus. As progenitors migrate 
from the bone marrow into the thymus to begin their maturation into naïve T lymphocytes, 
expression of recombination-activating gene 1 and 2 (RAG1 and RAG2) activates somatic 
recombination of the genes coding for the TCR α and β chains 28. Somatic recombination 
allows random rearrangements of the segments composing the TCR-coding genes and is 
therefore responsible for the diversity of the TCR repertoire. It is calculated that the TCR 
repertoire can reach approximately 1018 possible rearrangements, which guarantee the 
development of T cell clones potentially able to recognize any non-self antigen presented on 
the MHC 29,30. 
As a side effect of TCR random rearrangements, thymocytes unable to bind 
peptide/MHC ligands with proper affinity (defined “useless”) or, most importantly, 
potentially dangerous auto-reactive thymocytes recognizing self peptides presented on the 
MHC with too strong affinity are also developed. To maximize the functional diversity of the 
TCR repertoire and minimize the risk of autoimmune T cell clones reaching peripheral 
tissues, TCR affinity is tested during thymocyte development by binding to self peptide/MHC 
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complexes presented on the surface of thymic APCs. Thymocytes with a useless TCR die by 
neglect, and only those thymocytes whose TCR has a certain affinity for self peptide/MHC 
molecules receive survival signals and complete their maturation process (positive selection) 
(Fig. 1.3) 31-33. On the contrary, binding of a TCR to a self antigen/MHC complex with too 
strong affinity induces clonal deletion by apoptosis of the corresponding thymocyte (negative 
selection), since strong binding capacity is recognized as a sign of auto-reactivity (Fig. 1.3) 34-
38. Moreover, some other potential auto-reactive T cell clones can be deviated towards a 
regulatory phenotype, giving rise to natural T regulatory (Treg) cells instead of being deleted 
(Fig. 1.3) 39. 
 
Figure 1.3 Selection processes undergone by T cell progenitors in the thymus. The TCR repertoire 
generated by recombination of the TCR-coding genes is carefully scanned in the thymus. As a result, 
precursors bearing a TCR unable to ligate self antigen/MHC complexes are eliminated as “useless” 
clones by death by neglect, while survival of those thymocytes able to recognize self antigen/MHC 
complexes with moderate affinity is promoted (positive selection). Deletion or skewing towards a 
regulatory phenotype is instead established for the potential auto-reactive T cell precursors bearing a 
TCR binding self antigen/MHC complexes with too high affinity (negative selection) (adapted from 
Hogquist, K. A. et al., Nat. Rev. Immunol., 2005). 
 
Positive selection, clonal deletion and clonal deviation occur in discrete thymic 
microenvironments and are made possible by the interaction of thymocytes with APCs of the 
thymic stroma, especially thymic epithelial cells (TECs) and thymic DCs 40. Processing and 
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presentation of self intracellular and extracellular antigens on MHC-I and MHC-II molecules, 
respectively, by cortical TECs (cTECs) allows for positive selection of functional thymocyte 
clones. About 10% of the T cell precursors are positively selected and can thus migrate 
towards the thymic medulla, where medullary TECs (mTECs) and DCs are mainly 
responsible for antigen presentation (Fig. 1.4a) 31-33. 
The thymic medulla is considered the specialized compartment for the establishment 
of central tolerance, as highlighted by the autoimmune phenotype of murine models bearing 
thymic medullary defects. A common feature of these murine strains is the high susceptibility 
to autoimmunity or inflammation, as a result of impaired clonal deletion of T cell precursors 
and reduced frequency of Treg cells. The immune dysfunctions observed in these mice have 
been associated to reduced expression of the autoimmune regulator gene (AIRE) in mTECs 41-
43. 
 
Figure 1.4 Molecular mechanisms of central tolerance. (a) T cell precursors expressing a TCR 
capable of binding self antigen/MHC complexes displayed on cTECs are positively selected and 
migrate from the thymic cortex to the medulla. In the thymic medulla, promiscuous expression of 
peripheral tissue-specific antigens (PTAs) induced by AIRE in mTECs and antigen presentation by 
both mTECs and DCs allows for negative selection of potential auto-reactive thymocytes. (b) In situ 
hybridization of a murine thymic section showing spread distribution of AIRE transcripts in the 
medulla but anatomically restricted localization of the mRNA from 3 representative PTAs (dermokine, 
Dmkn; serine protease inhibitor Kazal-type 3, Spink3; calcium-activated chloride channel family 
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member 3, Clca3) (adapted from Hogquist, K. A. et al., Nat. Rev. Immunol., 2005 and Klein, L. et al., 
Nat. Rev. Immunol., 2014). 
 
As a transcription factor, AIRE is responsible for the promiscuous gene expression in 
mTECs of otherwise peripheral tissue-specific antigens (PTAs). Expression of PTAs in the 
thymic medulla allows for a broad representation of self antigens expressed at different sites 
or at different times in the organism, and it is thus crucial in determining which thymocyte 
clones might need to be deleted or deviated because of their TCR specificity and affinity 44-46. 
The key role of AIRE in the establishment of tolerance is further underscored by the onset of 
the human autoimmune disease autoimmune polyendocrinopathy-candidiasis-ectodermal 
dystrophy (APECED) in individuals with mutations in the AIRE gene locus. Mouse models 
have confirmed that AIRE deficiencies cause increased numbers of activated T cells in the 
periphery and consequential autoimmune phenotype 47. 
The molecular mechanisms by which AIRE promotes promiscuous gene expression in 
mTECs are still under investigation, even though the expression pattern of PTAs in the 
thymic medulla clearly indicates that AIRE is only one of the molecules involved in the 
process. For example, even though AIRE expression is widely distributed in mTECs, the 
thymic medulla appears to be organized in discrete areas where expression of clustered PTAs 
is anatomically restricted (Fig. 1.4b). Moreover, AIRE expression is localized to mTECs, but 
PTAs are efficiently presented by thymic DCs, probably as a consequence of antigen 
spreading from mTECs to DCs via gap junctions, exosomes or apoptotic bodies (Fig. 1.4a) 
40,48,49.  
There are limits to the ability of central tolerance of purging the T cell repertoire of 
all the possible auto-reactive clones in development. In fact, not every PTA is expressed in 
the thymic medulla and deletion or deviation typically occur for high-affinity TCR-bearing 
cells but not for lower affinity self-reactive T cell clones. As a result, potential auto-reactive T 
cells still reach peripheral tissues, thus requiring additional peripheral tolerogenic 
mechanisms to preserve the organism from self aggression. Moreover, additional peripheral 
tolerance is necessary to avoid immunity against innocuous non-self antigens to which our 
body is continuously exposed, such as environmental antigens, food molecules, metabolic 
products, or protein therapeutics 48. 
One of the most intuitive ways peripheral tolerance can be achieved is antigen 
ignorance by antigen-specific T lymphocytes. Antigen ignorance is achieved for those auto-
antigens expressed and presented on the MHC at levels that are below the activation threshold 
of naïve self-reactive T cells, since only T cell clones bearing a TCR with low affinity for self 
peptide/MHC complexes manage to escape clonal deletion in the thymus. Antigens 
anatomically restricted to immunologically privileged sites where T cells do not have access, 
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like the eye and the testis, are also ignored by lymphocytes 50. Naïve T cells, in fact, 
recirculate between blood and secondary lymphoid organs after exiting the thymus. 
In secondary lymphoid organs, T lymphocytes are continuously exposed to antigens 
presented on the MHC by migratory lymphoid organ-homing DCs or by resident APCs 
presenting antigens derived from lymphatic or blood drainage from local tissues or direct 
expression in situ 51,52. In the lymph nodes (LNs), for example, multiple subsets of resident 
cells of both hematopoietic lineage, such as DCs, or non-hematopoietic lineage, such as 
lymphatic endothelial cells of the stroma, are capable of antigen presentation to T cells 52,53. 
Importantly, since antigen drainage or migratory DCs would only provide presentation of 
local antigens, in situ expression of PTAs and their presentation on the MHC is also 
employed by LN resident hematopoietic and stromal cells as a way to increase the pool of 
presented self antigens 11-15,52. Of note, non-lymphoid organs, especially the liver, have also 
been attributed important immunological functions. In the liver, for example, both sinusoid 
endothelial cells and hepatocytes have direct access to the large amount of circulating 
extracellular antigens, that can be scavenged, processed and presented on the MHC to T 
lymphocytes 9,54-56.  
In the absence of an ongoing infection, antigen presentation without co-stimulatory 
signals and pro-inflammatory mediators results in tolerance rather than immunity, as a 
consequence of suboptimal stimulation of the antigen-specific T cells, leading to their 
deletion, anergy or skewing towards an induced Treg phenotype. Unlike deleted cells, anergic 
T cells survive antigen exposure in a hyporesponsive nonproliferative state. The faith decision 
of peripherally tolerized T cells between deletion or anergy is dependent upon antigen 
persistence, dose and localization. Limited exposure to small doses of antigen is likely to 
induce clonal deletion, while prolonged exposure to high-dose antigens has been associated to 
anergy induction 57-59. 
T cells with immune suppressive functions, Treg cells, are also important players in 
the maintenance of peripheral tolerance. Identified as CD4+CD25+FoxP3+, Tregs originate 
either from the thymus as a result of central tolerance and clonal deviation (natural Tregs) or 
from peripheral tissues as a consequence of suboptimal stimulation and phenotypic skewing 
(inducible Tregs) 60. Treg cells expand and activate in response to TCR triggering in an 
antigen-specific manner, but their suppressive functions appear to be non-specific as they 
locally interfere with inflammatory responses by releasing suppressive cytokines (IL-10 and 
transforming growth factor- β, TGF-β), consuming IL-2, exerting cytotoxic functions on 
APCs and T cells or dampening APC maturation 61-64. The result of Treg-driven suppressive 
activity on T cells is hypoproliferation, reduced survival and defective effector functions. 
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1.2.3 The enemy inside: cancer, autoimmunity and the logic of immunotherapy 
Cancer and autoimmune diseases are both pathologic manifestations occurring when the 
immune system fails to maintain functional homeostasis in the organism. Inadequate 
immunity and escape of immunosurveillance are considered crucial steps for transformed 
cells to be able to grow into clinically apparent tumors. In contrast, autoimmune diseases are 
a heterogenous group of pathologies characterized by self-reactive immunity, which develops 
when tolerance towards self components is broken. Aberrant immune responses against 
protein therapeutics are often also included in the group of autoimmune diseases 1,65. Due to 
the fundamental role played by the immune system in the development of autoimmunity and 
cancer, therapeutic approaches manipulating the components of the immune system 
(immunotherapy) have been proposed and developed with the aim of targeting pathogenic 
cells, either auto-reactive lymphocytes or cancerous cells, while limiting the damage to 
healthy tissues 1. 
 
1.2.3.1 The enemy inside (I): cancer 
Cancer cells originate from normal cells in which multiple genetic lesions accumulate over 
time, leading to the wide range of metabolic, phenotypic and antigenic alterations that  
differentiate tumor cells from their healthy counterparts 2. Since precursor cancer cells derive 
from normal tissues, they express antigens to which the immune repertoire has been tolerized 
and are thus spared from immune attack. As soon as mutations accumulate in the DNA of 
transformed cells, aberrant antigens (tumor-associated antigens, TAAs) can be expressed, 
thus making cancerous cells recognizable by the immune system 66. The ability of the immune 
system to detect and eliminate cells bearing pre-tumoral alterations is referred to as 
immunosurveillance and is vital in preventing cancer precursors from growing into 
established cancers. When immunosurveillance fails, either because of the selective pressure 
exerted by the immune system promoting the survival of non-immunogenic tumor cell clones 
(immunoselection) or because of active immune suppression (immunosubversion), tumors 
become clinically detectable 67,68. 
Cancer cells and immune cells are in a close relationship, as they are two of the major 
components of the tumor microenvironment 69. In particular, different populations of immune 
cells in the tumor microenvironment significantly shape the balance between pro-tumor and 
anti-tumor immunity. On one hand, DCs, natural killer (NK) and NK-T cells, CD4+ T 
lymphocytes and effector CD8+ T lymphocytes contribute to immune recognition of the 
tumor cells and to their elimination, mainly by the activation of cytotoxic functions. On the 
other hand, myeloid-derived suppressor cells, Treg cells and exhausted T lymphocytes 
negatively affect anti-tumor immunity. Therefore, immunotherapy approaches have been 
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applied for the treatment of cancer with the aim of eliciting anti-cancer immunity, reducing 
tumor growth and invasion, and ultimately eradicating tumors 4,70.  
Cancer immunotherapy has taken advantage of several treatment possibilities in the 
past decades. Vaccination has been regarded to as the most attractive immunotherapy for the 
treatment of cancer, because of its ability to stimulate all the components of the anti-tumor 
response, including CD8+ and CD4+ T lymphocytes, NK and NK-T cells, and to counteract 
the recruitment of immunosuppressive cells. Moreover, vaccination can induce both effector 
CD8+ T lymphocytes, recognizing tumor cells, and long-lasting memory CD8+ T 
lymphocytes, controlling tumor relapse 71-73 (Fig. 1.5). Several vaccine protocols have been 
tested in clinical trials, including the use of tumor cells (either autologous or allogeneic), 
peptides or whole proteins and DNA vaccines. However, these approaches have generated 
tumor regression in a limited number of patients 58. Ex vivo-generated DCs loaded with tumor 
antigens have also been exploited as vaccination tool to improve anti-tumor immunity 74-76. 
Even though promising, DC vaccines display important disadvantages, including 
manufacturing limitations, safety issues associated with the use of cell-based therapies and 
variable immunological outcomes of ex vivo manipulation on the DC phenotype. In fact, DC 
vaccines have shown limited therapeutic efficacy in clinical trials 77. 
 
Figure 1.5 Generation and regulation of anti-tumor immunity. Immune cells are actively involved 
in the recognition and elimination of tumor cells. When transformed cells manage to escape 
immunosurveillance, they grow into established tumors. Vaccination is a promising therapy to enhance 
anti-tumor immunity by activating tumor-specific CD4+ and CD8+ T lymphocytes, B lymphocytes, NK 
and NK-T cells and counteracting the immunosuppressive effects of myeloid-derived suppressor and 
Treg cells (adapted from Mellman, I., Coukos, G. & Dranoff, G., Nature, 2011). 
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The reasons for the limited clinical efficacy of cancer vaccines are several, in line 
with the complexity of tumor diseases. In order for a vaccine to elicit eradicating immunity, 
tumor antigens must be presented by APCs under immunogenic conditions to tumor antigen-
specific T cells and anti-tumor immune cells must be able to reach the tumor site where 
transformed cells can be recognized and destroyed. Therefore, the immunogenic profile of a 
cancer vaccine dramatically affects its capability to stimulate an anti-cancer immune response 
1. In addition, tumor cells can develop mechanisms to escape or suppress immunity. For 
example, cancer cells have been shown to downregulate the expression of MHC-I molecules, 
thus avoiding engagement of CD8+ T lymphocytes, or to directly promote inactivation of 
immune cells via the expression of the inhibitory receptor PD-1 ligand 1 (PD-L1) or the 
secretion of inhibitory mediators. Suppressive immune cells also play a significant role in 
counteracting anti-tumor immunity 69. 
 
1.2.3.2 Exosomes in cancer immunotherapy 
Exosomes are 30-150 nm extracellular membrane vesicles released by most nucleated cells 
and derived from the endocytic compartment. Exosomes have been shown to selectively 
incorporate both proteins and nucleic acids from the cells of origin and are thus considered to 
participate in intercellular communication. In fact, exosomes can both engage in receptor-
ligand interactions with the surface of their target cells initiating signal transduction and fuse 
with or be endocytosed by their targets transferring new membrane and cytosolic material 
(Fig. 1.6) 78,79. 
 
Figure 1.6 Transfer of proteins and nucleic acids via exosomes. Exosomes participate in 
intercellular communication systems by interacting directly with ligands on the surface of target cells 
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or by delivering their cargo of proteins and nucleic acids into target cells upon membrane fusion or 
endocytosis (adapted from Raposo, G. & Stoorvogel, W., J. Cell Biol., 2013). 
 
Since exosomes originating from either hematopoietic or non-hematopoietic cells 
have shown immune modulating properties, they have been proposed for the development of 
vaccine protocols in immunotherapy applications. DC-derived exosomes (Dexo) have elicited 
particular interest as vaccines since they carry key immunologically relevant DC-derived 
components (antigens, MHC-I and II molecules, co-stimulatory molecules, cellular adhesion 
molecules and integrins) and their immunological properties can be modified according to the 
activation state of the producing DCs 79-81. 
Research in the field of cancer immunotherapy has benefited the most from the 
development of Dexo-based vaccines, proposed as one possible alternative to DC vaccines. 
Several studies showed that DCs pulsed with tumor peptides could secrete exosomes able to 
stimulate peptide-specific cytotoxic responses and to negatively affect tumor growth in 
murine models 78,82,83. In an attempt to replicate the promising findings of the pre-clinical 
tests, phase I clinical trials have been conducted to evaluate the efficacy of subcutaneous 
immunization with Dexo derived from DCs pulsed with tumor-derived peptides in melanoma 
and lung carcinoma patients. Even though these trials have provided useful information on the 
manufacturing and safety of Dexo vaccine therapies in humans, therapeutic efficacy was 
poor, mainly because of weak immunogenicity 7,8. 
Novel strategies to enhance the immunogenicity of Dexo are currently under 
investigation. The most promising approach tested in pre-clinical models so far has been the 
purification of Dexo from DCs loaded with whole tumor antigens instead of peptides and 
matured in the presence of danger signals, since multiple antigenic epitopes (either free 
peptides or peptide/MHC complexes), co-stimulatory signals and cytokines can be generated 
in the DCs, incorporated into exosomes and delivered into the vaccinated host 83-85. 
 
1.2.3.3 The enemy inside (II): autoimmunity 
Immunotherapy of autoimmune diseases is focused on the suppression of aberrant or 
exaggerated immune responses. For many autoimmune diseases the pathogenic mechanisms 
and the antigens recognized by the immune system have yet to be identified. For this reason, 
non-specific immunotherapies have been adopted in the clinics, such as immunosuppressive 
cytokines or monoclonal antibodies aimed at modulating immune cell functions. Due to their 
non-specific nature, all of these therapies have been associated with important toxicity and 
side effects, mainly represented by increased susceptibility to infections and cancer 1. 
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Only for those few autoimmune diseases for which the self antigens involved have 
been identified, such as type 1 diabetes, multiple sclerosis and rheumatoid arthritis, safer 
antigen-specific tolerogenic immunotherapies have been proposed. Intravenous infusion of 
soluble peptides, oral or nasal administration of peptides and intravenous administration of 
antigen-coupled apoptotic cells have been attempted in pre-clinical models with the goal of 
providing antigen presentation in the absence of immunogenic stimuli. Results have been 
disappointing, either because of lack of efficacy or because of severe toxic side effects 86-88. 
As a better understanding of the basic mechanisms leading to immune tolerance is 
acquired, novel and safer therapeutic technologies can be developed. For example, the 
discovery that an organ such as the liver, which is easily targettable via the intravenous route, 
contains cells capable of presenting antigens to CD4+ and CD8+ T lymphocytes without co-
stimulation 89, has opened the way to the search for immunotherapies employing liver-
targeted antigens. 
 
 
1.3 Accomplishments 
In this Ph. D. thesis we addressed distinct biological questions on immune physiology and 
immunotherapy applications by taking advantage of bioengineering approaches. 
 
The aim of the project presented in Chapter 2 was to develop an improved vaccine 
formulation based on Dexo for the treatment of melanoma, recently published in Scientific 
Reports. Dexo have elicited a great amount of interest in the cancer immunotherapy 
community because of their immunogenicity and potential adaptability to different cancer 
diseases. In fact, Dexo have previously entered clinical trial as therapeutic vaccines for 
melanoma and lung carcinoma 7,8. Since the Dexo vaccines tested in these clinical trials 
resulted in poor therapeutic benefits due to limited anti-tumor immune responses, we propose 
an approach to increase the immunogenicity of Dexo that takes advantage of the intrinsic 
capacity of DCs to acquire immunostimulatory functions upon antigen loading and danger 
signal sensing. With this strategy, we obtained a Dexo vaccine capable of stimulating anti-
melanoma immunity, significantly reducing tumor growth and enhancing the survival of 
melanoma-bearing mice. 
 
In the project described in Chapter 3, we took a step back from direct translational 
applications and employed bioengineering techniques to obtain a version of a model antigen 
(ovalbumin) with enhanced binding to endocytotic receptors. We used this modified version 
of ovalbumin we the aim of studying the biology of extracellular antigen uptake in 
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hepatocytes and the immunological consequences of such mechanism. We were able to 
observe that, unlike in previous reports 9, hepatocytes are efficient antigen cross-presenting 
cells leading to antigen-specific CD8+ T cell tolerance in mice. Since hepatocytes represent 
the most abundant cell type of the liver and are involved in the metabolic and detoxification 
functions of the liver, we suggest that hepatocyte cross-presentation is a key mechanism by 
which tolerance is maintained towards blood-borne harmless molecules to which our body is 
continuously exposed. These findings could be helpful in the development of novel 
tolerogenic therapies taking advantage of hepatocyte-targeted strategies for the treatment of 
autoimmunity or immunity against protein therapeutics. These data have been included in two 
manuscripts that will be soon sent for peer review. 
  
In the project presented in Chapter 4, we continued investigating the role of the liver 
in the establishment of peripheral tolerance. Previous reports have shown that non-
hematopoietic stromal cells of the LNs express PTAs that induce T cell tolerance upon 
antigen presentation on the MHC 11-15. Since the liver contains cells that phenotypically 
resemble lymphoid endothelial cells of the LNs, the aim of this project was to investigate 
whether non-hematopoietic cells of the liver express tissue-restricted antigens and participate 
in active tolerance induction. Here, we describe preliminary findings that confirm our 
hypothesis. Sorted murine liver cells, both hepatocytes and liver sinusoid endothelial cells, 
were found to be negative for the expression of AIRE but hepatocytes were found to be 
positive for another transcription factor-coding gene (deformed epidermal autoregulatory 
factor 1, Deaf1), that has been recently associated with promiscuous gene expression and 
regulation of immunity and autoimmunity 15,90. Expression of some of the best characterized 
PTAs was also detected in hepatocytes, suggesting that active peripheral tolerance via 
promiscuous gene expression might be occurring in the liver. Even though we have not yet 
investigated the correlation between the expression of Deaf1 and PTAs in hepatocytes and we 
are only beginning to study whether MHC presentation of such antigens occurs and 
influences immune cell fate, we propose the liver as the first non-lymphoid organ to be 
described to express PTAs and to participate in active peripheral tolerance through 
promiscuous gene expression. 
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2.1 Abstract 
Dendritic cell (DC)-derived exosomes (Dexo) contain the machinery necessary to activate 
potent antigen-specific immune responses. As promising cell-free immunogens, Dexo have 
been tested in previous clinical trials for cancer vaccine immunotherapy, yet resulted in 
limited therapeutic benefit. Here, we explore a novel Dexo vaccine formulation composed of 
Dexo purified from DCs loaded with antigens and matured with either the TLR-3 ligand 
poly(I:C), the TLR-4 ligand LPS or the TLR-9 ligand CpG-B. When poly(I:C) was used to 
produce exosomes together with ovalbumin (OVA), the resulting Dexo vaccine strongly 
stimulated OVA-specific CD8+ and CD4+ T cells to proliferate and acquire effector functions. 
When a B16F10 melanoma cell lysate was used to load DCs with tumor antigens during 
exosome production together with poly(I:C), we obtained a Dexo vaccine capable of inducing 
robust activation of melanoma-specific CD8+ T cells and the recruitment of cytotoxic CD8+ T 
cells, NK and NK-T cells to the tumor site, resulting in significantly reduced tumor growth 
and enhanced survival as compared to a Dexo vaccine formulation similar to the one 
previously tested on human patients. Our results indicate that poly(I:C) is a particularly 
favorable TLR agonist for DC maturation during antigen loading and exosome production for 
cancer immunotherapy. 
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2.2 Introduction 
Immunotherapy for cancer aims at stimulating tumor-specific immune responses to prevent, 
treat or eradicate malignancies 1,2. Several approaches have been exploited clinically for 
cancer immunotherapy, including the use of DCs for therapeutic vaccination. As professional 
APCs, DCs represent a favorable candidate for immunotherapy purposes due to their ability 
to take up, process and present antigens and to sense danger signals to initiate an effective 
cancer-specific immune response. However, DC-based therapies are far from optimal, since 
ex vivo or in vivo manipulation of patient-derived DCs is still time-consuming, costly and 
associated with risks and a high rate of failure 3,4. 
In recent years, alternative approaches to the use of DCs in cancer vaccination have 
been investigated, including the use of exosomes. Exosomes are 30-150 nm membrane 
vesicles originating from intracellular multivesicular bodies and secreted into the extracellular 
space by most eukaryotic cell types 5,6. In particular, exosomes originating from DCs (Dexo) 
contain several immunologically relevant components, such as antigens, MHC class I and II 
molecules (often complexed with antigenic epitopes), co-stimulatory molecules (e.g., CD80, 
CD86, CD40), cellular adhesion molecules (e.g., ICAM-1) and integrins 7,8. Since exosomes 
can transfer their protein and nucleic acid content from a secreting cell to a target cell, Dexo 
are considered to be important intercellular communication vehicles exploited by DCs in the 
orchestration of immune responses 7-10. 
Murine Dexo have been shown to be able to stimulate antigen-specific CD4+ and 
CD8+ T cells both in vitro and in vivo and to enhance anti-cancer immunity in vivo 11-17. 
Antigen-loaded Dexo derived from the DCs of cancer patients have been tested in phase I 
clinical trials for the treatment of melanoma and non-small cell lung carcinoma. Those 
clinical trials proved the feasibility and safety of Dexo-based vaccination in human cancer 
patients but did not show significant tumor growth control or regression in the treated 
candidates 18-20. One hypothesis is that these antigen-loaded Dexo did not contain the 
activation signals required to elicit and activate cytotoxic effector cells that would be able to 
recognize and kill transformed cells. 
Maturation of DCs via treatment with TLR ligands as adjuvants to activate danger 
signal-sensing pathways coupled to antigen loading of DCs instead of exosomes has been 
proposed as a possible solution to improve the immunogenic profile of Dexo. Recently, it was 
shown that treatment of DCs with LPS (a TLR-4 ligand) or Pam3 (a TLR-1/2 ligand) leads to 
secretion of Dexo with an increased ability to stimulate cytotoxic NK and CD8+ T cells and to 
significantly affect tumor growth in vivo 16,21,22. However, LPS is not clinically viable and the 
effect of other adjuvants, already proposed for clinical use in immunotherapies, has yet to be 
explored in the development of Dexo-based vaccines. 
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In this project, in an attempt to further improve the immune stimulatory properties of 
Dexo and to provide a vaccination tool easily transferrable to clinical development for both 
infectious diseases and cancer, we compared poly(I:C) (a TLR-3 ligand) and CpG-B (a TLR-
9 ligand) to LPS as adjuvants for DC maturation during Dexo production 23-28. Our results 
indicate that Dexo produced upon treatment of DCs with the model antigen ovalbumin 
(OVA) and poly(I:C) (Dexo(OVA+pIC)) robustly activate OVA-specific Th1 immune 
responses, characterized by the release of the pro-inflammatory cytokines IFN-γ and TNF-α 
by CD4+ T lymphocytes and associated with the stimulation of OVA-specific cytotoxic CD8+ 
T cells but negligible production of OVA-specific antibodies. Most importantly, therapeutic 
vaccination targeted to the tumor-draining lymph nodes (tdLNs) of B16F10 melanoma-
bearing mice with Dexo released by DCs co-cultured with oxidized necrotic B16F10 cells as 
source of melanoma antigens and matured with poly(I:C) (Dexo(B16+pIC)) raised both 
melanoma-specific effector CD8+ T cells in the tdLNs, spleen and tumor mass and tumor-
infiltrating NK and NK-T cells, significantly reducing tumor growth and increasing the 
survival rate of diseased mice. 
 
 
2.3 Results 
2.3.1 Characterization of DC-derived exosomes produced in the presence of LPS, 
CpG-B or poly(I:C) 
DCs express a wide range of pattern-recognition receptors, among which TLR-3, TLR-4 and 
TLR-9 are good candidates as adjuvant targets to elicit potent cytotoxic T cell responses in 
mice and humans for cancer as well as infectious disease vaccination 25-29. In an attempt to 
improve the immunogenic profile of Dexo and test their ability to raise antigen-specific 
immune responses against the model antigen OVA, Dexo were harvested from the 
supernatant of bone marrow-derived DCs (BMDCs) either left untreated (Dexo(unt)), treated 
with OVA (Dexo(OVA)) or treated with OVA and matured with either the TLR-4 ligand LPS 
(Dexo(OVA+LPS)), the synthetic oligonucleotide CpG-B ligand of TLR-9 
(Dexo(OVA+CpGB)) or the synthetic dsRNA analog poly(I:C) ligand of TLR-3 
(Dexo(OVA+pIC)). 
Transmission electron microscopy and dynamic light scattering (DLS) analysis of 
Dexo(unt), Dexo(OVA), Dexo(OVA+LPS), Dexo(OVA+CpGB) and Dexo(OVA+pIC) 
samples confirmed the presence of 30-150 nm cup-shaped vesicles, proving that TLR 
stimulation of exosome-secreting DCs does not affect Dexo physical characteristics (Fig. 
2.1a,b). While typical exosomal markers such as the regulators of vesicular trafficking Alix 
and Tsg101 were revealed by western blot in all the Dexo preparations, full-length OVA 
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could not be detected, suggesting the presence of only processed OVA peptides (Fig. 2.1c). In 
fact, OVA-related peptides, measured by mass spectrometry as albumin peptides, could be 
detected more abundantly in those Dexo formulations prepared from OVA-treated BMDCs as 
compared to Dexo(unt) samples (Fig. 2.1d). 
 
Figure 2.1 Exosomes are purified from the supernatant of DCs cultured in the presence of the 
model antigen ovalbumin and activated with different Toll-like receptor ligands. Exosomes were 
purified from the supernatant of untreated BMDCs (Dexo(unt)) or of BMDCs treated with OVA 
(Dexo(OVA)) or from the supernatant of BMDCs treated with OVA and matured with LPS 
(Dexo(OVA+LPS)), CpG-B (Dexo(OVA+CpGB) or poly(I:C) (Dexo(OVA+pIC)). (a) Example of 
transmission electron microscopy of one of the Dexo samples after purification from the supernatant of 
BMDCs confirms the expected physical characteristics of exosomal vesicles. (b) Diameter of exosomes 
was measured by DLS analysis of the different Dexo samples. (c) Presence of the exosome-specific 
markers Alix (100 kDa) and Tsg101 (46 kDa) and of full-length OVA protein (45 kDa) was detected 
by western blot to confirm the identity of bona-fide exosomes and loading of intact OVA in Dexo 
samples. 50 ng and 5 ng of OVA were used as positive control for detection of full-length OVA. (d) 
Presence of OVA-derived peptides was detected in Dexo samples by mass spectrometry. Abundance of 
OVA-related peptides in Dexo(OVA), Dexo(OVA+LPS), Dexo(OVA+CpGB) and Dexo(OVA+pIC) 
samples is normalized to the background abundance of OVA-related peptides detected in Dexo(unt) 
samples (relative abundance). 
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2.3.2 Screening of the immunogenic profile of Dexo(unt), Dexo(OVA), 
Dexo(OVA+LPS), Dexo(OVA+CpGB) and Dexo(OVA+pIC) in an OT-I adoptive 
transfer model of vaccination  
Antigen-specific cytotoxic CD8+ T cells play a major role in anti-cancer immunity by directly 
recognizing and killing transformed cells. To compare the ability of the Dexo formulations 
produced from BMDCs incubated in the presence of LPS, CpG-B or poly(I:C) to activate an 
antigen-specific cellular immune response in vivo, we took advantage of an OT-I adoptive 
transfer model of vaccination (Fig. 2.2a). Recipient mice were vaccinated either intravenously 
(i.v.) or intradermally (i.d.) in the four footpads with 50 μg of either Dexo(unt), Dexo(OVA), 
Dexo(OVA+LPS), Dexo(OVA+CpGB) or Dexo(OVA+pIC) 1 day after receiving i.v. 106 
CFSE-labeled naïve OT-I cells, transgenic CD8+ T cells specific for the OVA257–264 
immunodominant epitope SIINFEKL. 6 days after adoptive transfer, OT-I cells were 
harvested from the spleens and brachial, axillary ad inguinal LNs of recipient mice and 
analyzed by flow cytometry for proliferation and expression of markers indicative of the 
acquisition of T cell effector functions. 
Proliferation of the OT-I cells, measured by flow cytometric analysis of CFSE 
dilution, was significantly increased both in the spleen and the LNs of those mice vaccinated 
with a Dexo(OVA+pIC) formulation (62.8% and 57.7% of proliferated OT-I cells in the 
spleens and 46.4% and 44.7% in the LNs of mice vaccinated i.v. or i.d., respectively) as 
compared to those mice vaccinated i.v. or i.d. with the other Dexo formulations (Fig. 2.2b). 
Both i.v. and i.d. vaccination with Dexo(OVA+pIC) also increased the percentage of CD62L-
CD44+ effector memory OT-I cells up to 14.1% and 12.1%, respectively, in the spleens and 
up to 21.4% and 20.0%, respectively, in the LNs (Fig. 2.2c). Acquisition of effector functions 
by adoptively transferred OT-I cells was further confirmed by their expression of IFN-γ 
(Supplementary Fig. 2.1). 
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Figure 2.2 Vaccination with exosomes from OVA-loaded and poly(I:C)-activated DCs strongly 
activates proliferation and acquisition of effector functions of adoptively transferred OT-I OVA-
specific CD8+ T cells in vivo. (a) CFSE-labeled OT-I CD8+ T cells (CD45.2+) were intravenously 
transferred into CD45.1+ recipient mice on day 0. Recipient mice were vaccinated on day 1 with 50 μg 
of the indicated Dexo formulation or saline. On day 6, spleens and brachial, axillary ad inguinal LNs 
were collected to analyze OT-I cells. (b) Proliferation was measured by flow cytometry as dilution of 
CFSE dye in adoptively transferred CD45.2+CD3ε+CD8α+ OT-I cells retrieved from the spleen (left) 
and LNs (right). (c) Acquisition of the CD62L-CD44+ effector memory phenotype of adoptively 
transferred CD45.2+CD3ε+CD8α+ OT-I cells was measured by flow cytometric analysis of cells 
harvested from the spleen (left) and LNs (right). Data represent mean ± s.e.m. from 2 independent 
experiments (n = 10). Statistical analysis was performed by one-way ANOVA and Bonferroni post-hoc 
test correction. In (b) statistics represent comparisons between Dexo(OVA+pIC) i.v. with both 
Dexo(OVA+LPS) i.v. and Dexo(OVA+CpGB) i.v. groups or between Dexo(OVA+pIC) i.d. with both 
Dexo(OVA+LPS) i.d. and Dexo(OVA+CpGB) i.d. groups. In (c) statistics represent comparisons 
between the indicated experimental groups. * P < 0.05 ** P < 0.01 and **** P < 0.0001. 
 
These results prove that in an OT-I adoptive transfer model of vaccination, 
Dexo(OVA+pIC), i.e. Dexo generated from BMDCs cultured in the presence of OVA and 
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matured by the TLR-3 agonist poly(I:C), efficiently stimulate antigen-specific CD8+ T cells to 
expand and to acquire effector functions. The overall immune stimulatory effect of 
Dexo(OVA+pIC) on OT-I cells was significantly higher than the effect of the Dexo vaccines 
purified from LPS- or CpG-B-matured BMDCs, demonstrating the higher efficacy of TLR-3 
stimulation for the induction of cellular immune responses by Dexo vaccines.  Interestingly, 
comparison of the i.v. and i.d. routes of administration showed that, unlike usual vaccine 
formulations, Dexo vaccines are equally immunogenic when administered either i.v. or i.d.  
 
2.3.3 Increased induction of OVA-specific endogenous CD4+ and CD8+ T cell 
immune responses by Dexo(OVA+pIC) vaccination 
Although the OT-I adoptive transfer model of vaccination showed a significant increase in the 
ability of Dexo(OVA+pIC) vaccination to activate OVA-specific CD8+ T cells compared to 
other Dexo formulations, we wanted to test if the same vaccine was also able to initiate an 
endogenous OVA-specific Th1 response.  Since other groups have previously used i.v. 
administration of Dexo-based vaccines, and Dexo formulations obtained with LPS-matured 
DCs have previously been shown to elicit beneficial antigen-specific immune responses 16,21, 
we sought to compare our Dexo(OVA+pIC) formulation administered either i.v. or i.d. into 
the four footpads to i.v. administration of either Dexo(unt), Dexo(OVA) or 
Dexo(OVA+LPS). To do so, the immune system of C57BL/6 recipient mice was first primed 
on day 0 and then boosted twice on day 14 and 40 with 50 μg of the indicated Dexo vaccine, 
as shown in Fig. 2.3a. 
We monitored the frequency of OVA257–264 (SIINFEKL)-specific CD8+ T cells 
throughout the experimental period by H-2Kb/SIINFEKL pentamer staining and flow 
cytometric analysis of circulating lymphocytes on day 19 and of splenocytes and brachial, 
axillary ad inguinal LN cells on day 45. As compared to vaccination with the other Dexo 
vaccine formulations tested, vaccination with Dexo(OVA+pIC) resulted in significantly 
increased frequencies of circulating SIINFEKL-specific CD8+ T lymphocytes already 19 days 
after priming, with up to 0.47% and 0.52% of pentamer positive viable CD3+CD8+ T cells 
upon i.v. and i.d. vaccination, respectively (Fig. 2.3b, top left). The difference in the 
frequencies of SIINFEKL-specific CD8+ T cells between mice administered with 
Dexo(OVA+pIC) and those administered with the other Dexo vaccines was even more 
significant at the end of the experimental timeline 45 days after priming. At this time point, in 
the spleens of the mice vaccinated with i.v. or i.d. Dexo(OVA+pIC) we detected 0.22% and 
0.21% of pentamer positive viable CD3+CD8+ T lymphocytes, respectively, as compared to 
0.0062% detected in the spleens of mice vaccinated with i.v. Dexo(OVA+LPS) (Fig. 2.3b, top 
right). In the LNs, Dexo(OVA+pIC) vaccination induced 0.19% SIINFEKL-specific CD8+ T 
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lymphocytes when performed either i.v. or i.d., as compared to only 0.082% upon i.v. 
administration of Dexo(OVA+LPS) (Fig. 2.3b, bottom). 
The acquisition of cytotoxic effector functions by OVA-specific CD8+ T lymphocytes 
in Dexo vaccinated mice was measured after splenocytes and brachial, axillary ad inguinal 
LN cells were restimulated for 6 hr in the presence of SIINFEKL peptide. Cytotoxic effector 
functions were evaluated by intracellular staining of IFN-γ and Granzyme-B and flow 
cytometric analysis of CD3+CD8+ lymphocytes. In mice vaccinated with i.v. or i.d. 
Dexo(OVA+pIC), we measured a significantly higher frequency of IFN-γ+ or Granzyme-B+ 
CD3+CD8+ splenocytes (Fig. 2.3c). 0.031% and 0.026% of IFN-γ+ CD3+CD8+ splenocytes 
were detected in mice vaccinated with Dexo(OVA+pIC) either i.v. or i.d., respectively, as 
compared to 0.0085% measured in mice receiving i.v. Dexo(OVA+LPS) vaccination (Fig. 
2.3c, left). While in the spleens of mice vaccinated with i.v. Dexo(OVA+LPS) we detected 
0.038% of Granzyme-B+ CD3+CD8+ T cells, in mice vaccinated with i.v. or i.d. 
Dexo(OVA+pIC) we measured 0.25% and 0.15% of Granzyme-B+ CD3+CD8+ splenocytes, 
respectively (Fig. 2.3c, right).  Similar trends were also observed in the LNs of vaccinated 
mice, with i.v. or i.d. administration of Dexo(OVA+pIC) resulting in a significantly higher 
frequency of IFN-γ+ or Granzyme-B+ CD3+CD8+ T lymphocytes as compared to the other 
Dexo formulations tested (Supplementary Fig. 2.2a).  
To evaluate acquisition of the Th1 phenotype by OVA-specific CD4+ T lymphocytes, 
splenocytes and brachial, axillary ad inguinal LN cells from vaccinated mice were 
restimulated for 6 hr in the presence of OVA, stained for IFN-γ and TNF-α and analyzed by 
flow cytometry. In mice vaccinated with i.v. or i.d. Dexo(OVA+pIC), we measured a 
significantly higher frequency of IFN-γ+ or TNF-α+ CD3+CD4+ lymphocytes as compared to 
mice vaccinated with the other Dexo formulations (Fig. 2.3d). 0.31% and 0.25% of IFN-γ+ 
CD3+CD4+ splenocytes were measured in mice vaccinated with Dexo(OVA+pIC) either i.v. 
or i.d., respectively, as compared to 0.064% detected in mice receiving i.v. Dexo(OVA+LPS) 
vaccination (Fig. 2.3d, left). Vaccination with Dexo(OVA+pIC) also significantly raised 
TNF-α+ CD3+CD4+ splenocytes up to 0.083% and 0.11% upon i.v. or i.d. administration, 
respectively (Fig. 2.3d, right). Similarly to the spleen, the frequencies of IFN-γ+ and TNF-α+ 
CD3+CD4+ lymphocytes were also significantly higher in the LNs of mice vaccinated with 
Dexo(OVA+pIC) (Supplementary Fig. 2.2b). Significantly increased expression and release 
of the Th1 cytokines IFN-γ and TNF-α by the splenocytes of mice vaccinated with i.v. or i.d. 
administration of Dexo(OVA+pIC) was further confirmed by ELISA (Fig. 2.3e, left, and 
Supplementary Fig. 2.2c). Secretion of IL-10, instead, was limited, and differences were not 
significant among the different vaccine treatments tested, thus confirming skewing towards a 
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Th1 immune response rather than Th2 by vaccination with Dexo(OVA+pIC) (Fig. 2.3e, 
right). 
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Figure 2.3 Vaccination with exosomes from OVA-loaded and poly(I:C)-activated DCs induces the 
expansion and acquisition of effector functions of endogenous OVA-specific CD4+ and CD8+ T 
cells with negligible OVA-specific antibody titers in vivo. (a) Wild-type mice were vaccinated i.v. or 
i.d. with 50 μg of the indicated Dexo formulation or saline on day 0 (prime), 14 (boost I) and 40 (boost 
II). On day 45, spleens and brachial, axillary ad inguinal LNs were collected to analyze OVA-specific 
T cell responses, and blood was sampled to measure the titer of OVA-specific IgG antibodies in the 
serum. (b) Pentamer staining and flow cytometric analysis were used to measure the frequency of 
SIINFEKL-specific CD8+ T lymphocytes in the blood of vaccinated mice on day 19 (top left) or at the 
end of the experimental time on day 45 in the spleen (top right) and LNs (bottom) in the population of 
viable CD3ε+CD8α+ cells. (c) Splenocytes from vaccinated mice were collected on day 45 to measure 
acquisition of effector functions by SIINFEKL-specific CD8+ T lymphocytes as detected by 
intracellular staining for IFN-γ (left) and Granzyme-B (right) and flow cytometric analysis. (d) 
Splenocytes from vaccinated mice were collected on day 45 to measure acquisition of effector 
functions by OVA-specific CD4+ T lymphocytes as detected by intracellular staining for IFN-γ (left) 
and TNF-α (right) and flow cytometric analysis. (e) Splenocytes from vaccinated mice were collected 
on day 45 to measure IFN-γ or IL-10 secreted in the cell supernatant by ELISA upon restimulation in 
the presence of OVA. (f) Blood from vaccinated mice was collected on day 45 and the titer of OVA-
specific IgG antibodies in the serum was measured by ELISA. Data represent mean ± s.e.m. from 2 
independent experiments (n = 10). Statistical analysis was performed by one-way ANOVA and 
Bonferroni post-hoc test correction. * P < 0.05 ** P < 0.01, *** P < 0.001, **** P < 0.0001 and n.s. = not 
significant for comparisons of Dexo(OVA+pIC) administered i.v. or i.d. with Dexo(OVA+LPS). 
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Even though vaccination with Dexo(OVA+pIC) stimulated a greater OVA-specific 
Th1 immune response as compared to Dexo(unt), Dexo(OVA) and Dexo(OVA+LPS), none 
of the Dexo formulations tested was able to induce the production of OVA-specific antibodies 
(Fig. 2.3f), thus confirming the absence of free intact OVA contaminating the Dexo 
formulations, rather suggesting the presence of OVA or OVA-derived peptides encapsulated 
inside exosomes or bound to MHC class I and class II molecules on the surface of exosomes, 
as previously shown by other groups 16,30,44. 
These data indicate that poly(I:C)-induced maturation of DCs cultured in the presence 
of an antigen improves the ability of DC-released Dexo to stimulate antigen-specific cellular 
rather than humoral immune responses. In particular, vaccination with Dexo(OVA+pIC) 
stimulates the expansion and activation of endogenous OVA-specific CD4+ and CD8+ T cells, 
skewing the former towards the pro-inflammatory Th1 phenotype and stimulating the latter to 
acquire cytotoxic functions more potently than Dexo derived by DC maturation induced by 
TLR ligands previously used by other groups, most notably LPS 16.  
 
2.3.4 Isolation of DC-derived exosomes containing B16F10 antigens and their use as 
a therapeutic vaccine in the B16F10 melanoma model 
Dexo vaccination had previously entered clinical trials for the treatment of melanoma 
patients, resulting in poor therapeutic benefit 18. We therefore sought to test whether our 
poly(I:C)-based Dexo vaccine could improve the efficacy of Dexo vaccination in a clinically 
relevant setting of therapeutic vaccination in melanoma-bearing mice, taking advantage of the 
B16F10 model. Based on the higher immunogenicity of Dexo produced with poly(I:C) as 
compared to Dexo produced with either LPS or CpG-B as shown in Fig. 2.2 and 2.3, we 
chose to only utilize poly(I:C) for the production of a Dexo vaccine that could be compared to 
a Dexo formulation resembling those tested in the clinical trials produced from DCs cultured 
in the presence of tumor antigens but without adjuvants. To produce DC-derived exosomes 
carrying native B16F10 antigens instead of the model antigen OVA, we adopted the protocol 
developed by Chiang et al. to pulse patient-derived DCs with autologous tumor antigens 31,32. 
To do so, B16F10 cells were incubated with 60 μM HOCl buffer to induce oxidation-
dependent necrosis of the tumor cells, thus allowing the release of melanoma antigens in an 
immunogenic fashion (Fig. 2.4a). Following the same procedure utilized for the production of 
our OVA-containing Dexo vaccine formulations, HOCl-oxidized B16F10 cells were cultured 
together with BMDCs in the presence or not of poly(I:C) to harvest Dexo(B16+pIC) or 
Dexo(B16), respectively. As an experimental control, we also purified exosomes from DCs 
matured with poly(I:C) in the absence of oxidized B16F10 cells (Dexo(pIC)). 
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Figure 2.4 HOCl-oxidized B16F10 melanoma cells can be used as a source of tumor antigens for 
the production of DC exosomes containing melanoma-derived epitopes. (a) B16F10 melanoma 
cells were resuspended in 60 μM HOCl HBSS buffer and incubated at 37°C for 1 hr to induce 
oxidation of the tumor cells. After incubation, cells were stained with a viability dye and analyzed by 
flow cytometry. As controls, viability of B16F10 cells before incubation (t = 0) or B16F10 cells 
resuspended in HBSS buffer was also analyzed.  Numbers indicate the frequency of dead cells gated in 
the total population of B16F10 cells. (b) Dexo were purified from the supernatant of DCs preincubated 
with oxidized B16F10 obtained as in (a) with or without poly(I:C) (Dexo(B16+pIC) and Dexo(B16), 
respectively) or with poly(I:C) only as a control (Dexo(pIC)) following the described protocol for 
exosomes isolation. After purification, the size of Dexo was measured by DLS analysis. (c) Presence of 
the exosome-specific markers Alix (100 kDa) and Tsg101 (46 kDa) (intravesicular) and CD81 (26 
KDa) (vesicle membrane) and of the full-length melanoma-derived protein TRP-2 (59 kDa) was 
detected by western blot analysis of Dexo(unt), Dexo(B16), Dexo(pIC) and Dexo(B16+pIC) digested 
or not with proteinase K to confirm purification of bona-fide exosomes and exosomal localization of 
the antigens. (d) Surface staining for MHC-I, MHC-II, CD80 and CD86 and flow cytometric analysis 
of Dexo(unt), Dexo(B16), Dexo(pIC) and Dexo(B16+pIC). Percentages represent the frequency of 
positive events among CD81+CD63+ particles. Data in (d) represent mean ± s.e.m. from 2 independent 
experiments (n = 6). Statistical analysis was performed by one-way ANOVA and Bonferroni post-hoc 
test correction to compare Dexo(B16), Dexo(pIC) and Dexo(B16+pIC). ** P < 0.01 and n.s. = not 
significant. 
 
DLS and western blot analysis of Dexo(B16), Dexo(pIC) and Dexo(B16+pIC) were 
used to confirm the presence of vesicles with size (30-150 nm in diameter) and markers (Alix, 
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Tsg101 and CD81) indicative of bona-fide exosomes (Fig. 2.4b,c). To prove exosomal 
packaging of melanoma antigens in Dexo(B16) and Dexo(B16+pIC), we probed Dexo(B16), 
Dexo(pIC) and Dexo(B16+pIC) samples for the B16F10-derived tyrosinase-related protein 2 
(TRP-2). To provide information about the localization of the melanoma-derived TRP-2, 
Dexo samples were digested with proteinase K (PK) or left untreated before western blot 
analysis. While detection of the intra-exosomal markers Alix and Tsg101 was not affected by 
digestion with PK, the exosomal membrane-spanning antigen CD81 could not be revealed 
after treatment of the exosomes with PK, indicating its export to the extra-vesicular space. 
Similarly to Alix and Tsg101, TRP-2 was also protected from the enzymatic activity of PK, 
indicating its intra-exosomal localization, in this case at its expected full-length molecular 
weight, as contrasted to that observed in Fig. 2.1c with OVA (Fig. 2.4c). 
Differences among Dexo(B16), Dexo(pIC) and Dexo(B16+pIC) could be detected by 
flow cytometry in their surface expression of the antigen-presenting complex MHC-II, which 
was significantly enriched especially on Dexo(B16+pIC), as a consequence of strong DC 
maturation upon incubation with oxidized tumor cells in the presence or not of poly(I:C) (Fig. 
2.4d). 
We proceeded to test whether therapeutic i.d. vaccination with Dexo(B16) or 
Dexo(B16+pIC) could result in any beneficial outcome in B16F10 tumor-bearing mice. 
Vaccination with Dexo(pIC) was chosen as a control to test the melanoma specificity of the 
immune responses raised by Dexo(B16) and Dexo(B16+pIC) vaccination. For this purpose, 
105 B16F10 cells were inoculated subcutaneously (s.c.) between the scapulae in C57BL/6 
mice on day 0 and left to engraft and grow for 4 days. On day 4, 7, 11 and 15, mice were 
either administered with saline or vaccinated with 50 μg of Dexo(B16), Dexo(pIC) or 
Dexo(B16+pIC) i.d. in the frontal footpads to improve vaccine efficacy by targeting the 
immune cells of the tdLNs 33. Tumor growth was measured until 18 days after inoculation of 
the B16F10 cells, when the anti-melanoma immune response in the tumor mass, spleen and 
tdLNs was also analyzed. To determine the survival rate, vaccinated tumor-bearing mice were 
also kept until death occurred or euthanasia was necessary due to ethical reasons. In the case 
of mice surviving with no sign of debilitating sickness, experiments were ended 60 days after 
implantation of the tumor cells (Fig. 2.5a). 
Interestingly, all of the Dexo formulations tested were able to significantly reduce the 
growth of B16F10 tumors as compared to vehicle administration. Most importantly, 
vaccination with Dexo(B16+pIC) proved the combination of loading with melanoma antigens 
and stimulation with poly(I:C) for DC-derived exosome production beneficial, resulting in 
significant reduction of tumor growth not only as compared to saline treatment but also as 
compared to vaccination with either Dexo(B16) or Dexo(pIC) (Fig. 2.5b, left). The Dexo 
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vaccines also improved the survival rate of B16F10 tumor-bearing mice and, even though 
therapeutic vaccination with Dexo(B16+pIC) could not prevent B16F10 tumors from 
growing, it did slow tumor progression, improving long-term survival of vaccinated mice, 
with 58% of Dexo(B16+pIC)-vaccinated mice showing no sickness symptoms at the end of 
the experimental time of 60 days (Fig. 2.5b, right). 
To dissect the immunological effects behind the benefits provided by Dexo 
vaccination, we chose the melanoma-derived protein TRP-2 as a representative antigen to 
analyze the immune response elicited against B16F10 tumor cells upon Dexo vaccination. 
The frequency of TRP-2180–188 (SVYDFFVWL)-specific CD3+CD8+ T lymphocytes was 
measured in the cells from the tdLNs, spleens and tumor masses of vaccinated mice 18 days 
after tumor cells were inoculated by pentamer staining and flow cytometry. All of the Dexo 
vaccine formulations tested were able to increase the frequency of TRP2-specific CD8+ T 
cells as compared to saline treatment, but only vaccination with Dexo(B16+pIC) resulted in 
significantly increased TRP2-specific CD8+ T lymphocytes as compared to saline and to the 
other Dexo formulations, not only in the tdLNs (1.32%) and spleens (0.94%) but also in the 
tumor masses of treated mice (9.7%) (Fig. 2.5c). Of note, the TRP2-specific CD8+ T cells 
induced by vaccination with Dexo(B16+pIC) also showed increased expression of the 
effector memory phenotype markers CD62L-CD44+, with 22.28%, 0.94% and 88.1% of 
CD62L-CD44+ TRP2-specific CD8+ T lymphocytes detected in the tdLNs, spleens and tumor 
masses, respectively (Fig. 2.5d). The acquisition of effector functions by B16F10-specific 
CD8+ T cells was further confirmed by restimulating ex vivo for 6 hr tdLN cells and 
splenocytes from vaccinated mice with oxidized B16F10 cells (obtained as in Fig. 2.4a) and 
staining for intracellular IFN-γ and TNF-α for flow cytometric analysis. Cells from mice 
receiving Dexo(B16+pIC) vaccination responded more strongly to B16F10 antigen-specific 
restimulation, resulting in 0.062% and 0.176% of  IFN-γ+ CD3+CD8+ T lymphocytes and 
0.0073% and 0.024% of IFN-γ+TNF-α+ CD3+CD8+ T cells in the tdLNs and spleens, 
respectively (Fig. 2.5e). 
Interestingly, tdLN-targeted administration of our Dexo vaccines resulted in 
favorable recruitment and stimulation of cytotoxic CD45+ cells infiltrating the tumors, 
especially when Dexo(B16+pIC) vaccine was administered. In the population of tumor-
infiltrating CD8+ T lymphocytes, effector memory CD62L-CD44+ cells were significantly 
increased (65.1%), while exhausted PD-1+ cells were significantly reduced (45.95%), in mice 
vaccinated with Dexo(B16+pIC) (Fig. 2.5f, top). Even though the difference was not 
statistically significant, also NK cells showed a trend toward increased frequency in the 
population of hematopoietic cells infiltrating the tumors of Dexo(B16+pIC)-treated mice 
(15.5%) as compared to mice administered with saline or the other Dexo formulations (Fig. 
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2.5f, bottom left). NK-T cells, instead, were significantly more represented among CD45+ 
tumor-infiltrating cells (3.57%) upon Dexo(B16+pIC) vaccination (Fig. 2.5f, bottom right). 
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Figure 2.5 Therapeutic vaccination with tumor cell antigen-loaded exosomes from poly(I:C)-
activated DCs significantly reduces the growth of B16F10 tumors and improves the survival of 
tumor-bearing mice by activating melanoma-specific CD8+ T cells and promoting tumor 
infiltration of cytotoxic cells. (a) B16F10 melanoma cells were inoculated subcutaneously between 
the scapulae of C57BL/6 mice on day 0. To target the tdLNs, recipient mice were vaccinated i.d. in the 
frontal footpads with 50 μg of the indicated Dexo formulation or saline on day 4 (prime), 7 (boost I), 
11 (boost II) and 15 (boost III). (b) Tumor volumes (left) and survival rate (right) were measured from 
day 0 to day 18 and from day 0 to day 60 after tumor inoculation, respectively. (c) Frequencies of TRP-
2180–188 (SVYDFFVWL)-specific CD8+ T lymphocytes in the population of viable CD3ε+CD8α+ cells 
harvested on day 18 from the tdLNs (left), spleen (middle) and tumor mass (right). (d) Frequencies of 
CD62L-CD44+ effector memory TRP2-specific CD8+ T lymphocytes harvested on day 18 from the 
tdLNs (left), spleen (middle) and tumor mass (right). (e) Acquisition of effector functions by B16F10-
specific CD8+ T lymphocytes as indicated by intracellular staining of IFN-γ and TNF-α and flow 
cytometric analysis. (f) Frequencies of tumor-infiltrating CD62L-CD44+ effector memory and 
exhausted PD-1+ CD8+ T lymphocytes in the population of total viable CD45+CD3ε+CD8α+ cells (top). 
Frequencies of tumor-infiltrating NK cells (bottom left) and NK-T cells (bottom right) among viable 
CD45+CD3ε-NK1.1+ or CD45+CD3ε+NK1.1+ cells, respectively. Data represent mean ± s.e.m. from 2 
independent experiments (n = 15). Statistical analysis of tumor volumes in (b) was performed by 
unpaired t test comparing Dexo(B16+pIC) group with either saline, Dexo(B16) or Dexo(pIC) group. * 
P < 0.1; **** P < 0.0001. Statistical analysis of survival rates in (b) was performed by Log-rank Mantel-
Cox test comparing Dexo(B16+pIC) group with saline, Dexo(B16) and Dexo(pIC) groups. * P < 0.05; 
**** P < 0.0001. Statistical analysis of data in (d), (e) and (f) was performed by one-way ANOVA and 
Bonferroni post-hoc test correction. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 and n.s. = not 
significant for comparisons of Dexo(B16+pIC) with Dexo(B16) and Dexo(pIC). 
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Confocal microscopy of tumor sections revealed that even though all the Dexo 
vaccines tested were capable of recruiting CD45+ hematopoietic cells and, especially, CD3+ 
cells at the tumor site as compared to saline treatment, Dexo(B16+pIC) vaccination induced 
greater hematopoietic recruitment and, most importantly, infiltration of the tumor mass by 
lymphocytes (Fig. 2.6, top). Confirming the flow cytometry data described in Fig. 2.5f, the 
majority of tumor-infiltrating CD3+ cells in the tumors harvested from Dexo(B16+pIC)-
vaccinated mice was also PD-1- (Fig. 2.6, bottom). 
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Figure 2.6. Vaccination with tumor cell antigen-loaded exosomes from poly(I:C)-activated DCs 
induces massive recruitment and infiltration of the tumor mass by PD-1- lymphocytes. (a) Tumor 
sections from C57BL/6 mice vaccinated as indicated in Fig. 2.5a with the indicated Dexo formulation 
or saline and euthanized on day 18 were stained for either CD45 and CD3ε (top) or CD45 and PD-1 
(bottom) and imaged by confocal microscopy. (b) Higher magnification of the area in the rectangular 
dashed outline in tumor sections of C57BL/6 mice vaccinated with Dexo(B16+pIC) shown in (a). T = 
intratumoral area. Representative images from 2 independent experiments are shown (n = 15). Scale 
bar = 50 μm. 
 
These data indicate that the purification of exosomes containing antigens from a 
specific tumor cell type, in our case the B16F10 melanoma cells, is feasible. Moreover, tdLN-
targeted therapeutic vaccination with exosomes derived from DCs loaded with B16F10 
antigens and matured with poly(I:C) shows a beneficial capacity of stimulating B16F10-
specific effector CD8+ T cells and recruiting effector T lymphocytes, NK and NK-T cells to 
the tumor site resulting in smaller tumors and prolonged survival of tumor-bearing mice. 
 
 
2.4 Discussion 
DC-derived exosomes represent an attractive alternative to DC-based vaccines for 
immunotherapy in cancer patients 5,7,20. Dexo display immunologically active components 
derived from DCs but, as vesicles, they constitute a non-living cell-free vaccine tool. 
Importantly, pre-clinical use of Dexo vaccines in murine tumor models, especially melanoma, 
has shown the ability of Dexo to stimulate strong antitumoral adaptive immunity, resulting in 
the suppression of tumor growth 11-17. On the basis of these promising pre-clinical results, 
clinical trials were conducted to test therapeutic vaccination with Dexo in patients with late-
stage melanoma and non-small cell lung carcinoma. For vaccination in the human subjects, 
Dexo were produced from autologous DCs and were loaded either directly or indirectly with 
tumor peptides in the absence of any adjuvants. Even though such clinical trials proved the 
feasibility of large-scale production of antigen-loaded autologous DC-derived exosomes for 
use in humans, they failed to prove therapeutic benefits of the vaccination protocol since 
tumor-specific immunity was elicited only in a limited number of the treated patients 18-20. 
Other groups have tried to improve the immunogenicity of Dexo vaccines by 
developing a formulation that could more effectively induce anti-tumor cytotoxic responses. 
Use of Dexo rather than tumor cell-derived exosomes and their loading with intact antigens 
rather than with peptides was shown to induce more potent antitumor immunity related to the 
activation of a broader repertoire of antigen-specific immune cell clones in vivo. Moreover, 
incubation with TLR ligands, either during exosome production (LPS) or after exosome 
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purification (Pam3 or poly(I:C)), resulted in the induction of beneficial pro-inflammatory Th1 
responses both in vitro and in vivo in tumor-bearing animals 16,17,21,25. 
The goal of this study was to exploit the intrinsic properties of DCs to take up and 
process antigens and sense danger signals to mount strong antigen- and adjuvant-tailored 
immune responses. To do so, we produced exosomes from antigen-loaded DCs that were 
matured with different TLR ligands, to explore the effects of DC stimulation with different 
danger signals on the immunogenicity of the exosomes that they secrete. As TLR ligands for 
DC maturation, we chose TLR agonists that could result in efficient stimulation of Th1 
responses both in mice and in humans and that could be easily transferrable to a clinical 
setting, such as the TLR-3 agonist poly(I:C) and the TLR-9 agonist CpG-B 25,27-29. Future 
studies will also explore alternative and possibly more potent TLR agonists for the production 
of novel Dexo-based vaccine formulations, either as single adjuvant or in combination. 
Among other candidates, the TLR-4 ligand monophosphoryl lipid A (MPLA) component of 
LPS is of particular interest as it has shown a promising profile in terms of both safety and 
immunogenicity in several clinical trials for cancer immunotherapy 39. 
Our results show that exosomes purified from the supernatant of DCs loaded with the 
model antigen OVA and matured with poly(I:C) (Dexo(OVA+pIC)) are significantly more 
potent activators of antigen-specific Th1 responses than exosomes purified from CpG-B- or 
LPS-matured DCs, both in an OT-I transfer model of vaccination and in an endogenous 
model of vaccination. While adoptively transferred OT-I cells responded to Dexo(OVA+pIC) 
vaccination with vigorous proliferation but only modest acquisition of effector phenotype 
(CD62L-CD44+) and functions (IFN-γ expression) (Fig. 2.2),  endogenous OVA-specific 
CD4+ and CD8+ T cells strongly expanded and synthesized Th1 cytokines upon 
Dexo(OVA+pIC) administration (Fig. 2.3). Interestingly, vaccination with Dexo(OVA+pIC) 
elicited an anti-OVA cellular response in the absence of detectable OVA-specific antibodies 
(Fig. 2.3f). The lack of humoral response is consistent with the measurement of no intact 
OVA antigen being present in the Dexo vaccines we produced, and rather indicates the 
presence of OVA or OVA-derived peptides encapsulated inside exosomes or bound to MHC 
class I and class II molecules on the surface of exosomes that could be transferred or 
presented to APCs and T cells initiating the antigen-specific immune response in vivo, as 
previously published 10,16,30,44.  
The efficient stimulation of antigen-specific cellular responses by a poly(I:C)-based 
Dexo vaccine is highly attractive in the context of therapeutic vaccination for cancer 
immunotherapy. We thus compared the outcome of a therapeutic vaccination protocol with 
Dexo produced from B16F10 antigen-loaded DCs with or without poly(I:C)-driven 
maturation. The B16F10-Dexo vaccines were produced by loading the DCs with a B16F10 
?
?
?
??
cell lysate obtained by oxidation-induced necrosis, rather than with a single melanoma 
antigen, to stimulate a polyclonal immune response against the tumor cells and provide 
additional cell-derived danger signals to the DCs other than poly(I:C). In fact, DC pulsing 
with oxidized tumor cells has been previously shown to enhance the immunogenicity of 
tumor lysates, resulting in more potent T cell responses in murine models of ovarian cancer 
and in effective broad anti-tumor immunity and therapeutic beneficial effects in ovarian 
cancer patients 31,32. Even though we cannot exclude that a part of the exosomes we purify 
after co-culturing the DCs with oxidized B16F10 cells is derived from the tumor cells rather 
than from the DCs, our data show that we are able to purify exosomal vesicles containing 
antigens from the melanoma cells (like TRP-2), so that they can act as antigen carriers upon 
vaccination (Fig. 2.4). In contrast to the results with Dexo from OVA-pulsed DCs, we did 
find full-length TRP-2 in the Dexo from DCs pulsed with oxidized B16F10 cells (Fig. 2.1c 
and Fig. 2.4c). This may be due to differential efficiency of the antigen processing 
mechanisms within the DCs between two protein antigens, to differences in the processing 
mechanisms of free versus cellular antigens, or to presence of exosomes derived from the 
tumor cells themselves. The intact TRP-2 antigen was not carried over as soluble 
contaminant, in that it was protected from degradation by extravesicular proteinase K, thus 
demonstrating its presence within the Dexo particles (Fig. 2.4c). More importantly, 
significant enrichment of MHC-II molecules could be detected on the surface of 
Dexo(B16+pIC) particles, indicating not only that treatment of exosome-secreting DCs with 
oxidized tumor cells and poly(I:C) provides strong maturation signals but also that the 
secreted Dexo inherit improved antigen-presenting and immune stimulatory capabilities from 
their cells of origin (Fig. 2.4d). 
To maximize the therapeutic effect of Dexo vaccines, we chose to administer Dexo 
intradermally only at those anatomic sites suitable to target the vaccine to the immune cells of 
the tdLNs, as it was previously published that targeting the tdLNs provides a more beneficial 
outcome than targeting the non-tdLNs 33-35. Indeed, tdLN-targeted vaccination with 
Dexo(B16+pIC) resulted in reduced tumor growth and prolonged survival of tumor-bearing 
mice, associated with significantly higher frequencies of melanoma-specific cytotoxic CD8+ 
T cells and of CD62L-CD44+ effector memory CD8+ T, NK and NK-T cells and lower 
frequencies of PD-1+ exhausted CD8+ T cells infiltrating the tumors as compared to all the 
other Dexo vaccine formulations we tested (Fig. 2.5 and 2.6). Of note, only vaccination with 
Dexo(B16+pIC) stimulated massive infiltration of hematopoietic cells, and in particular of 
PD-1- lymphocytes, into the tumor mass of treated mice (Fig. 2.6). 
Vaccination with Dexo(pIC), i.e. exosomes produced from poly(I:C)-matured DCs in 
the absence of tumor antigens, was also capable of stimulating a melanoma-specific immune 
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response resulting in reduced tumor growth and prolonged survival as compared to 
vaccination with Dexo(B16). This finding is not completely unexpected, as locally 
administered immune adjuvants in cancer immunotherapy are known to contribute to tumor-
associated inflammation leading to the enhancement of protective immunity 40-43. In our 
experimental setting of tdLN-targeted vaccination, the simultaneous presence in the tdLNs of 
Dexo(pIC)- or Dexo(B16+pIC)-delivered danger signals and of tumor-derived antigens (both 
draining from the tumor site and carried by Dexo) resulted in beneficial anti-cancer immunity, 
more effectively stimulated by vaccination with Dexo(B16+pIC). 
Previous groups showed that the adjuvants used to induce DC maturation during 
exosome production can bind to the exosome membrane and can thus be co-injected with the 
Dexo vaccine, directly activating APCs in vivo as a by-stander effect 21. We provide further 
evidence that small amounts of poly(I:C) are in fact consistently found in poly(I:C)-Dexo 
vaccines after purification (Supplementary Fig. 2.3a). Upon Dexo vaccination, poly(I:C) 
molecules could participate in the induction of immune cell activation and tumor growth 
arrest by direct engagement of TLR-3 molecules expressed by myeloid DCs and T cells and 
by tumor cells, respectively, even though exposure to nucleases may lead to their rapid 
degradation in vivo 37,38. Nevertheless, exosomes isolated from antigen-loaded DCs matured 
with poly(I:C) have more potent stimulatory effects on antigen-specific CD8+ T lymphocytes 
than equivalent doses of free poly(I:C) and such effects cannot be abrogated by specifically 
blocking the TLR-3, thus excluding that the immunogenic effect of poly(I:C)-based Dexo 
depends exclusively on the adjuvant molecules contaminating each Dexo formulation 
(Supplementary Fig. 2.3b). We instead speculate that the DC-derived molecular components 
of Dexo, such as MHC complexes, co-stimulatory molecules, adhesion molecules and pro-
inflammatory signals, together with antigenic epitopes as well as adjuvant molecule carry-
over all concomitantly participate in positively affecting the immunogenic properties of a 
Dexo vaccine. 
In summary, we provide evidence that exosomes produced from antigen-loaded DCs 
matured with the TLR-3 agonist poly(I:C) are more potent immunogens than exosomes 
produced with LPS for TLR-4 or CpG-B for TLR-9. We show that the purification of DC-
derived exosomes carrying epitopes from melanoma cells is feasible and is able to produce 
potent antitumoral immunity, leading to tumor growth control in 58% of the animals treated. 
This approach is potentially transferrable to any type of clinically relevant tumor cell for the 
development of potent tumor-tailored Dexo vaccines. 
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2.5 Supplementary figures 
Supplementary Fig. 2.1 
 
Supplementary figure 2.1 Vaccination with exosomes from OVA-loaded and poly(I:C)-activated 
DCs strongly activates proliferation and acquisition of effector functions of adoptively 
transferred OT-I OVA-specific CD8+ T cells in vivo. (a) Effector functions of transferred 
CD45.2+CD3ε+CD8α+ OT-I cells harvested from the spleen (left) or LNs (right) of mice vaccinated as 
indicated in Fig. 2.1a with the indicated Dexo formulation or saline were evaluated by detecting IFN-γ 
expression by intracellular staining and flow cytometry. (b) Representative flow cytometric plots of LN 
cells stained for viability and CD3ε, CD8α, CD45.2 and IFN-γ to identify adoptively transferred IFN-γ+ 
OT-I cells in mice vaccinated as in Fig. 2.1a with the indicated Dexo formulation administered i.d. or 
saline. Numbers represent the frequency of IFN-γ+ events in the population of viable 
CD45.2+CD3ε+CD8α+ OT-I cells. Data represent mean ± s.e.m. from 2 independent experiments (n = 
10). Statistical analysis was performed by one-way ANOVA and Bonferroni post-hoc test correction 
between the indicated experimental groups. * P < 0.05. 
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Supplementary Fig. 2.2 
 
Supplementary figure 2.2 Vaccination with exosomes from OVA-loaded and poly(I:C)-activated 
DCs induces the expansion and acquisition of effector functions of endogenous OVA-specific 
CD4+ and CD8+ T cells with negligible OVA-specific antibody titers in vivo. (a) LN cells from mice 
vaccinated as in Fig. 2.3a with the indicated Dexo formulation or saline were collected on day 45 to 
measure acquisition of effector functions by SIINFEKL-specific CD8+ T lymphocytes as detected by 
intracellular staining for IFN-γ (left) and Granzyme-B (right) and flow cytometric analysis. (b) LN 
cells from mice vaccinated as in Fig. 2.3a with the indicated Dexo formulation or saline were collected 
on day 45 to measure acquisition of effector functions by OVA-specific CD4+ T lymphocytes as 
detected by intracellular staining for IFN-γ (left) and TNF-α (right) and flow cytometric analysis. (c) 
Splenocytes from vaccinated mice were collected on day 45 to measure TNF-α secreted in the cell 
supernatant by ELISA. Data represent mean ± s.e.m. from 2 independent experiments (n = 10). 
Statistical analysis was performed by one-way ANOVA and Bonferroni post-hoc test correction. ** P < 
0.01, *** P < 0.001, **** P < 0.0001 and n.s. = not significant for comparisons of Dexo(OVA+pIC) with 
Dexo(OVA+LPS). 
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Supplementary Fig. 2.3 
 
Supplementary figure 2.3 Exosomes purified from poly(I:C)-activated DCs contain poly(I:C) 
carry-over but show greater antigen-specific immune stimulatory properties than equivalent 
doses of poly(I:C). (a) To detect and quantify poly(I:C) molecules in Dexo samples, murine TLR-3 
reporter HEK-293T cells were treated with exosomes purified from poly(I:C)-activated DCs either 
loaded with OVA (Dexo(OVA+pIC)) or oxidized B16F10 cells (Dexo(B16+pIC)) or no antigen 
(Dexo(pIC)). As a control to test the assay quantification, reporter cells were either treated with a 
known amount of poly(I:C) (1 μg/μL) or left untreated.  (b) OVA-specific OT-I cells were co-cultured 
in the presence of bone-marrow-derived DCs and treated with 25 μg of the indicated Dexo formulation 
or with a dose of poly(I:C) equivalent to the amount of active poly(I:C) measured in the Dexo 
formulation as in (a). The TLR-3 specific inhibitor CU CPT 4a was also added in the indicated co-
culture conditions to test the involvement of poly(I:C)-triggered TLR-3 activation in the stimulation of 
OT-I cells by Dexo. Activation of the OT-I cells was measured by flow cytometric analysis of viable 
CD25+CD3ε+CD8α+ OT-I cells. Data represent mean ± s.e.m. from two independent experiments (n = 
6). Statistical analysis was performed by one-way ANOVA and Bonferroni post-hoc test correction. 
**** P < 0.0001. 
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Supplementary Fig. 2.4 
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Supplementary figure 2.4 Therapeutic vaccination with tumor cell antigen-loaded exosomes from 
poly(I:C)-activated DCs significantly reduces the growth of B16F10 tumors and improves the 
survival of tumor-bearing mice by activating melanoma-specific CD8+ T cells and promoting 
tumor infiltration of cytotoxic cells. (a) Representative flow cytometry dot plots of TRP-2180–188 
(SVYDFFVWL)-specific CD8+ T lymphocytes (top) and of CD62L-CD44+ effector memory TRP2-
specific CD8+ T lymphocytes (bottom) harvested on day 18 from the tdLNs (left), spleen (middle) and 
tumor mass (right) of mice vaccinated as in Fig. 2.5a with Dexo(B16+pIC). Numbers indicate the 
frequency of gated cells among viable CD3ε+CD8α+ cells (b) Representative flow cytometry dot plots 
of tumor-infiltrating CD62L-CD44+ effector memory (left) and exhausted PD-1+ CD8+ T lymphocytes 
(right) in mice treated as in Fig. 2.5a with the indicated Dexo formulation or saline. Numbers represent 
the frequency of gated events among viable CD45+CD3ε+CD8α+ cells. (c) Representative dot plots of 
tumor-infiltrating NK (CD3ε-NK1.1+) and NK-T (CD3ε+NK1.1+) cells from mice vaccinated as in Fig. 
2.5a with the indicated Dexo formulation or saline. Numbers represent the frequency of gated events 
among viable CD45+ cells. Representative data from 2 independent experiments (n = 15). 
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2.6 Materials and methods 
2.6.1 Reagents 
Chemicals and reagents were purchased from Sigma-Aldrich (Buchs, Switzerland), unless 
specifically indicated. RPMI 1640 GlutaMAX, IMDM GlutaMAX and DMEM GlutaMAX 
media, FBS, penicillin/streptomycin, 2-Mercaptoethanol and HBSS buffer were purchased 
from Life Technologies (Carlsbad, CA). Chemically defined X-VIVO 15 medium was from 
Lonza (Basel, Switzerland). Abs for western blot were purchased from Sigma-Aldrich or Bio-
Rad (Hercules, CA). Live/dead fixable cell viability reagents for flow cytometry were from 
Life Technologies. PE-labeled H-2Kb/SIINFEKL and H-2Kb/TRP-2180–188 (SVYDFFVWL) 
pentamers were purchased from Proimmune (Oxford, UK). Abs used in flow cytometry were 
from eBioscience (Vienna, Austria) or BioLegend (Lucerne, Switzerland). 
 
2.6.2 Production of OVA-loaded DC-derived exosomes (Dexo) 
Bone-marrow derived DCs (BMDCs) were generated by culturing total bone marrow cells 
from 8-10 week old female C57BL/6 mice (Harlan Laboratories, Gannat, France) in RPMI 
1640 GlutaMAX medium supplemented with 10% FBS, 100 IU/mL penicillin-streptomycin, 
50 μM 2-Mercaptoethanol and 20 ng/mL recombinant murine GM-CSF (PeproTech, Rocky 
Hill, NJ) at 37°C 5% CO2. On day 3, a volume of complete medium equal to the original 
culture volume was added to the cells. On day 6, BMDCs were harvested, washed in PBS and 
cultured for OVA antigen loading. To produce Dexo(unt), BMDCs were cultured in complete 
medium at 37°C 5% CO2 for 12 hr. To produce OVA-loaded Dexo, BMDCs were cultured in 
complete medium supplemented with 300 μg/mL endo-grade chicken OVA (Hyglos, Bernried 
am Starnberger See, Germany) at 37°C 5% CO2 for 12 hr. After 12 hr, BMDCs were 
harvested, washed extensively in PBS to eliminate serum and free OVA and cultured in X-
VIVO 15 medium for the production of Dexo(unt) and Dexo(OVA) or X-VIVO 15 medium  
supplemented with either 50 ng/mL LPS, 8 μg/mL CpG-B 1826 oligonucleotide (5′-
TCCATGACGTTCCTGACGTT-3′ from Microsynth, Balgach, Switzerland), or 50 μg/mL 
poly(I:C) (InvivoGen, San Diego, CA) for the production of Dexo(OVA+LPS), 
Dexo(OVA+CpGB) or Dexo(OVA+pIC), respectively. On day 8, exosomes were isolated by 
serial (ultra)centrifugation. 
 
2.6.3 Isolation of Dexo 
The supernatant of BMDCs was collected and centrifuged first at 300 × g for 5 min at 4°C 
and then at 2000 × g for 10 min at 4°C, passed through 0.22 μm filters (Millipore, Billerica, 
MA) and subsequently spun at 110,000 × g for 90 min at 4°C using a Beckman Coulter (Brea, 
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CA) ultracentrifuge. Exosome pellets were resuspended in PBS and frozen at -80°C prior to 
use. 
 
2.6.4 BCA, transmission electron microscopy, dynamic light scattering analysis and 
flow cytometry of Dexo 
Total protein concentration of Dexo samples was measured by BCA assay (Thermo Fisher 
Scientific, Waltham, MA) following the manufacturer’s instructions and it was used to 
determine the dose of Dexo for in vitro and in vivo studies. For transmission electron 
microscopy, 20 μg of Dexo were serially diluted in PBS and samples were transferred onto 
carbon-coated Formvar grids (SPI Supplies, Structure Probe Inc., West Chester, PA). Dexo 
were then fixed in 1% glutaraldehyde, stained in uranyl-oxalate pH 7 and imaged with a 
Tecnai Spirit (FEI, Hillsboro, OR) transmission electron microscope. For dynamic light 
scattering analysis, exosomes samples were diluted in PBS and analysed with a Zetasizer 
instrument (Malvern, UK). For flow cytometric analysis, 25 μg of Dexo were adsorbed on 
magnetic beads coated with anti-CD81 Ab (Life Technologies). After washing, Dexo were 
stained with Abs specific for the surface markers CD63, H-2Kb (MHC-I), I-A/I-E (MHC-II), 
CD80 and CD86 in 2% FBS PBS solution. Samples were acquired on an LSR II cytometer 
(BD Biosciences) and data analyzed with FlowJo software (Tree Star). 
 
2.6.5 Mass spectrometry (LC-MS/MS) and Western blot analysis 
20 μg of Dexo were boiled at 70°C for 10 min in Laemmli buffer (Bio-Rad) and loaded onto a 
12% polyacrylamide gel (Bio-Rad) for SDS-Page. For LC-MS/MS analysis, after 
electrophoresis gels were stained with SimplyBlue stain (Life Technologies) and the protein 
bands of interest were sliced and digested in trypsin solution prior to injection into LC-MS. 
Data analysis was performed using the Scaffold_4.4.4 software (Proteome Software, Portland, 
OR). For western blot, after SDS-Page proteins were transferred onto an Immobilon PVDF 
membrane (Millipore) and the membrane was blocked in 5% skim milk PBS solution O/N at 
4°C. Membranes were then incubated with primary Abs specific for Alix, CD81, OVA, TRP-
2 or Tsg101 diluted in 5% skim milk PBS for 1 hr at RT, washed in 0.05% Tween-20 PBS 
and incubated with horseradish peroxidase-conjugated secondary Abs diluted in 5% skim 
milk PBS for 1 hr at RT. After extensive washing in 0.05% Tween-20 PBS, protein bands 
were visualized using SuperSignal West Pico Chemiluminescent substrate (Thermo Fisher 
Scientific) according to manufacturer’s instructions. For proteinase K digestion of Dexo 
samples, 20 μg of Dexo were incubated at 37°C in 50 μg/mL proteinase K (Qiagen, Limburg, 
The Netherlands) PBS solution for 10 min followed by 15 min at 95°C to deactivate the 
enzyme. Samples were then prepared as indicated above for SDS-Page and western blot. 
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2.6.6 Mice 
C57BL/6 female mice and CD45.2+ OT-I transgenic female mice (8 to 12 weeks of age) were 
obtained from Harlan Laboratories, CD45.1+ C57BL/6-Ly5.1 female mice (8 to 12 weeks of 
age) were purchased from Charles River (Saint-Germain-Nuelles, France). Animals were 
housed in pathogen-free conditions at the animal facility of the Ecole Polytechnique Fédérale 
de Lausanne and all experiments were performed in accordance with Swiss law and with 
approval from the Cantonal Veterinary Office of Canton de Vaud, Switzerland (Authorization 
number 2935). 
 
2.6.7 Vaccination studies 
For the OT-I adoptive transfer model of vaccination, on day 0, CD45.2+ OT-I cells were 
purified from the spleen and LNs of OT-I transgenic mice by negative selection of CD8α+ T 
cells using the EasySep mouse CD8α T cell isolation kit (Stemcell Technologies, Grenoble, 
France) following the manufacturer’s instructions. For CFSE labeling, OT-I cells were 
incubated in 1 μM CFSE (Life Technologies) PBS solution at 5 × 106 cells/mL at RT for 6 
min and labeling reaction was quenched by adding an equal volume of 10% FBS PBS. 
CD45.1+ C57BL/6-Ly5.1 recipient mice were anesthetized with isoflurane and 106 OT-I 
cells/mouse were administered by tail vein injection. On day 1, recipient mice were 
anesthetized with isoflurane and vaccinated either intravenously by tail vein injection or 
intradermally into the 4 footpads with a dose of 50 μg of the indicated Dexo formulation. On 
day 6, recipient mice were euthanized to collect splenocytes and LN cells. 
For the endogenous vaccination model, C57BL/6 mice were anesthetized with isoflurane and 
administered either intravenously into the tail vein or intradermally into the 4 footpads with 
50 μg of the indicated Dexo formulation on day 0, 14 and 40. Blood was sampled on day 19 
performing a small cut on the tail to collect peripheral lymphocytes and perform pentamer 
staining. On day 45, mice were euthanized to collect splenocytes, LN cells and blood serum. 
 
2.6.8 Ex vivo restimulation, surface and intracellular staining and flow cytometry 
Splenocytes were obtained by gently disrupting the spleen through a 70-μm cell strainer 
(Corning, NY), followed by extensive washing and red blood cell lysis. LNs were first 
digested for 45 min in RPMI 1640 GlutaMAX medium supplemented with 1 mg/mL 
Collagenase D (Roche, Basel, Switzerland). 
Intracellular IFN-γ of OT-I cells was determined after 2 hr of PMA (50 ng/mL)/ionomycin (1 
μg/mL) treatment followed by 2 hr of BFA treatment (5 μg/mL) of the splenocytes and LN 
cells. For T cell antigen-specific restimulation and intracellular cytokine staining, cells were 
cultured for 6 hr at 37 °C in the presence of 1 μg/mL SIINFEKL (GenScript, Piscataway, NJ) 
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or 100 μg/mL OVA grade V protein for CD8+ T cell or CD4+ T cell restimulation, 
respectively, with the addition of 5 μg/mL BFA for the last 3 hr of culture.  
Cells were then processed, counted and stained for viability and immunological markers to be 
analyzed by flow cytometry. Cells were first stained using Live/Dead fixable cell viability 
reagents (Life Technologies) according to the manufacturer’s instructions and then stained 
with Abs specific for the surface markers CD45.2, CD3ε, CD4, CD8α, CD62L and CD44. 
Staining with PE-labeled H-2Kb/SIINFEKL pentamer was performed according to the 
manufacturer’s instructions. For intracellular cytokine staining, cells were fixed in 2% 
paraformaldehyde solution, washed with 0.5% saponin (Sigma-Aldrich) in 2% FBS PBS 
solution, and incubated with Abs specific for IFN-γ, Granzyme-B and TNF-α diluted in 
saponin solution. After washing, cells were resuspended in 2% FBS PBS solution for 
analysis. Samples were acquired on an LSR II cytometer (BD Biosciences) and data analyzed 
with FlowJo software (Tree Star). Alternatively, splenocytes were restimulated for 4 days in 
the presence of 100 μg/mL OVA grade V protein for the measurement of IFN-γ, TNF-α and 
IL-10 released in the supernatant by ELISA using Ready-SET-go! ELISA kits from 
eBioscience. OVA-specific antibody ELISAs on serum samples were performed as described 
previously 36. All cells were cultured in IMDM GlutaMAX medium supplemented with 10% 
FBS and 100 IU/mL penicillin-streptomycin.  
 
2.6.9 Culture and oxidation of B16F10 cells 
B16F10 (CRL-6475) cells were obtained from the American Type Culture Collection and 
cultured according to the instructions. Cells were checked for Mycoplasma prior to use; no 
additional authentication was performed. The procedure to obtain oxidation-dependent 
necrosis of tumor cells was previously published 31. Briefly, B16F10 cells were resuspended 
at 106 cells/mL in 60 μM HOCl solution, obtained by diluting the stock NaOCl in HBSS 
buffer, and incubated at 37°C for 1 hr. Cells were extensively washed in HBSS and either 
analyzed for viability using Live/Dead fixable cell viability reagent followed by flow 
cytometry or used for Dexo production or ex vivo restimulation. 
 
2.6.10 Production of B16F10 antigen-loaded Dexo 
BMDCs were differentiated as described above. On day 6, cells were cultured in complete 
medium together with HOCl-oxidized B16F10 cells (1:1) at 37°C 5% CO2 for 12 hr. After 12 
hr, BMDCs were harvested, washed extensively in PBS and cultured in X-VIVO 15 medium 
for the production of Dexo(B16) or X-VIVO 15 medium  supplemented with 50 μg/mL 
poly(I:C) for the production of Dexo(B16+pIC). For the production of Dexo(pIC), BMDCs 
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were only cultured with X-VIVO 15 medium  supplemented with 50 μg/mL poly(I:C). On 
day 8, we proceeded to isolate Dexo by serial (ultra)centrifugation as indicated above. 
 
2.6.11 B16F10 tumor vaccination studies 
On day 0, C57BL/6 mice were anesthetized with isoflurane and their back was shaved. 105 
B16F10 cells resuspended in 100 μL of PBS were inoculated subcutaneously between the 
scapulae of each mouse. On day 4, 7, 11 and 15 mice were anesthetized with isoflurane and 
vaccinated intradermally into the 2 frontal footpads with 50 μg of the indicated Dexo 
formulation. Tumors were measured with a digital caliper until day 18 after tumor 
inoculation, and volumes (V) were calculated as ellipsoids (V = π/6 × length × width × 
height). For survival rate assessment, mice were kept until death occurred or sacrifice was 
necessary due to sickness or tumor volumes > 1 cm3, as required by Swiss law. In the case of 
mice surviving with no sign of debilitating sickness, experiments were ended 60 days after 
implantation of the tumor cells. For immunological readouts and imaging by confocal 
microscopy, vaccinated tumor-bearing mice were euthanized on day 18 after tumor 
inoculation to collect cells from the spleen, tdLNs and tumor mass. Splenocytes and tdLN 
cells were obtained as described above. Tumors were processed as previously published 33. 
For restimulation with oxidized B16F10 cells and intracellular cytokine staining, splenocytes 
and tdLN cells were cultured for 6 hr at 37 °C in the presence of 105 HOCl-oxidized B16F10 
cells, with the addition of 5 μg/mL BFA for the last 3 hr of culture. Cells were then processed, 
counted and stained for viability and immunological markers to be analyzed by flow 
cytometry. Cells were first stained using Live/Dead fixable cell viability reagents and then 
stained with Abs specific for the surface markers CD45, CD3ε, CD8α, CD62L, CD44, PD-1 
and NK1.1 Staining with PE-labeled H-2Kb/TRP-2180-188 pentamer was performed according 
to the manufacturer’s instructions. For intracellular staining of IFN-γ and TNF-α, cells were 
processed as indicated above. Samples were acquired on an LSR II cytometer and data 
analyzed with FlowJo software. For imaging by confocal microscopy, tumors were fixed in 
4% paraformaldehyde solution and frozen in OCT (Sakura, Osaka, Japan). 10 μm-thick 
sections were sliced and stained with primary Abs specific for CD45, CD3ε and PD-1 and 
fluorescently labeled secondary Abs (Life Technologies). Samples were mounted using 
ProLong Gold antifade reagent with DAPI (Life Technologies) and imaged with a LSM 700 
inverted confocal microscope (Zeiss, Jena, Germany). 
 
2.6.12 TLR-3 reporter assay and OT-I in vitro activation 
Murine TLR-3 reporter HEK-293T cells were purchased from InvivoGen and cultured as 
indicated by the manufacturer’s instructions. For the reporter assay, 2 × 104 cells were 
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cultured with serial dilutions of poly(I:C) as standard curve or 10 μg of the indicated Dexo 
formulation for 24 hr at 37°C 5% CO2. Engagement of TLR-3 resulting in NF-κB activation 
was measured by QUANTI-Blue colorimetric assay (InvivoGen) as indicated by the 
manufacturer’s instructions. To measure in vitro activation of OT-I cells by Dexo, 105 OT-I 
cells were cultured in IMDM GlutaMAX medium supplemented with 10% FBS and 100 
IU/mL penicillin-streptomycin together with 2 × 104 BMDCs in the presence of 25 μg of the 
indicated Dexo formulation or of a dose of free poly(I:C) equivalent to the amount of active 
poly(I:C) detected in the correspondent Dexo sample or left untreated for 24 hr at 37°C 5% 
CO2. To block poly(I:C)/TLR-3 interactions, the TLR-3 specific inhibitor CU CPT 4a (Bio-
Techne, Minneapolis, MN) was added to the culture media at 27 μM concentration, as 
previously published 45. After incubation, cells were stained for viability using Live/Dead 
fixable cell viability reagents and with Abs specific for the surface markers CD3ε, CD8α and 
CD25. Samples were acquired on an LSR II cytometer and data analyzed with FlowJo 
software. 
 
2.6.13 Statistics 
Statistically significant differences between experimental groups were determined by one-
way ANOVA followed by Bonferroni post-hoc test correction.  * P < 0.05, ** P < 0.01, *** P < 
0.001, **** P < 0.0001 and n.s. = not significant. For tumor volumes, differences between 
groups were determined by unpaired t test. * P < 0.1; **** P < 0.0001. For survival rate, 
differences between groups were determined by Log-rank Mantel-Cox test. * P < 0.05; **** P 
< 0.0001. Statistical analyses were performed using Prism software (v6.0f, GraphPad 
Software, San Diego, CA). 
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3.1 Abstract 
Peripheral tolerance participates in the protection of the organism from developing immunity 
against auto-antigens and harmless exogenous antigens. Resident cells of lymphoid and non-
lymphoid organs contribute to the maintenance of peripheral tolerance. The liver, in 
particular, has been attributed an important role in establishing tolerance towards circulating 
extracellular antigens, mainly because of the antigen scavenging properties of liver sinusoid 
endothelial cells. Nonetheless, hepatocytes are the most abundant cell type of the liver, 
express MHC-I molecules, lack co-stimulatory signals, and have been shown in vivo to 
induce tolerance to expressed antigens. However, the ability of hepatocytes to take up and 
induce tolerance to extracellular antigens has yet to be elucidated. In our study we describe 
for the first time in vitro that murine primary hepatocytes efficiently scavenge and present 
extracellular antigens on MHC-I complexes, a process known as cross-presentation. 
Moreover, we show in vivo that hepatocyte-dependent cross-presentation of the model antigen 
ovalbumin (OVA) induces apoptosis and emperipolesis of OVA-specific CD8+ OT-I cells, 
resulting in deletional tolerance. Non-deleted hepatocyte-educated OT-I cells, instead, acquire 
an anergic phenotype, characterized by poor response to vaccination with adjuvanted OVA. 
We also confirm that the PD-1/PD-L1 pathway is involved in the establishment of 
hepatocyte-derived cross-tolerance, by observing that the specific blockade of PD-L1 
expressed by OVA cross-presenting hepatocytes could rescue OT-I cells from deletion and 
anergy. Taken together, our findings indicate that hepatocytes can significantly contribute to 
the tolerogenic capacity of the liver by cross-presenting extracellular antigens to CD8+ T 
lymphocytes and employing the negative regulatory PD-1/PD-L1 pathway. 
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3.2 Introduction 
Immunological tolerance prevents the development of adaptive responses against endogenous 
or harmless exogenous antigens. T lymphocytes are selected for antigen specificity and 
affinity during their development in the thymus through the establishment of central 
tolerance, which positively selects functional TCRs and negatively selects potentially 
autoimmune TCRs 1. Even though unwanted lymphocytic clones might escape the selection 
processes of central tolerance, self antigens as well as harmless non-self antigens like 
environmental components, to which the body is exposed, do not elicit immunity in healthy 
individuals. This lack of response is the result of peripheral tolerance mechanisms, which 
through clonal deletion, anergy and the activity of T regulatory cells, protect the organism 
from unwanted immune responses 2,3. 
Unlike central tolerance, peripheral tolerance takes place in both lymphoid and non-
lymphoid peripheral tissues, such as the liver. Each day naïve T lymphocytes pass through the 
hepatic circulation system hundreds of times, yet non-self harmless antigens absorbed into the 
blood that drains from the gut to the liver or newly formed antigens resulting from hepatic 
metabolic activities fail to induce an immune response 4,5. The ability of the liver to induce 
tolerance to circulating extracellular antigens has been mainly attributed to liver sinusoid 
endothelial cells (LSECs). These MHC-II- and MHC-I-expressing blood vessel-lining cells 
represent the first cells to interact with peripheral lymphocytes entering hepatic circulation 
(Fig. 3.1a). In fact, LSECs efficiently scavenge, process and present, in the absence of co-
stimulation, soluble antigens found in the bloodstream to circulating lymphocytes, typically 
resulting in the induction of CD4+ T regulatory cells or anergic CD8+ T lymphocytes 6-11. 
 
Figure 3.1 Liver microanatomy. (a) Hepatic capillaries or sinusoids allow multiple cell-cell and 
molecule-cell interactions. In particular, circulating T lymphocytes make direct contact with 
endothelial cells (LSECs) and hepatocytes (red square). (b) Scanning electron microscopy showing 
lymphocytes (white arrows) in murine hepatic sinusoids. Lymphocyte dendrites make contact with 
hepatocytes through sinusoid fenestrations (black arrows) (adapted from Holz, L. E.  et al., J. 
Autoimmun., 2010 and from Thomson A. W. & Knolle P. A., Nat. Rev. Immunol., 2010). 
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Unlike other organs, where circulating lymphocytes only extravasate and gain access 
to the parenchyma in case of inflammation, the liver microvasculature has a peculiar 
fenestrated endothelium devoid of any basal membrane that allows direct physical contact 
between circulating CD8+ T lymphocytes and the liver MHC-I+ parenchymal cells, 
hepatocytes (Fig. 3.1a,b) 12,13. Hepatocytes are the most abundant cells of the liver, composing 
80% of its mass, and they represent the metabolic unit of the organ as they are responsible for 
the processing of food molecules, drugs, environmental antigens, gut bacterial derivatives and 
potential toxins flowing through the portal vein into the hepatic capillaries or sinusoids 13. As 
most nucleated cells, hepatocytes can present cellular antigens in the context of the MHC-I to 
CD8+ T lymphocytes. It has been reported that hepatocytes possess poor cross-presentation 
capacity in vitro as compared to other liver cells, especially LSECs 8. Nonetheless, several 
publications have shown that direct antigen expression, obtained by either transgenesis or 
viral vector transduction, and subsequent MHC-I-dependent antigen presentation in 
hepatocytes can result in peripheral tolerance in vitro and in vivo. Hepatocyte-induced 
tolerance is believed to be due to suboptimal activation of antigen-specific CD8+ T 
lymphocytes because of lack of CD28 co-stimulation causing clonal deletion of the T cells 14-
21. Moreover, recent reports also described the induction of CD4+CD25+FoxP3+ Treg cells 
upon hepatocyte-dependent antigen expression, thus suggesting a possible involvement of 
other APCs in the tolerogenic mechanisms of this model 22,23. 
Hepatocytes outnumber the other cellular components of the liver and possess 
enzymatic activities necessary for processing of blood-borne molecules and antigens. We thus 
reasoned that hepatocytes might significantly contribute to the establishment of liver-
mediated CD8+ T cell peripheral tolerance by taking up and cross-presenting circulating 
extracellular antigens on MHC-I complexes. In this project, we describe the in vitro and in 
vivo cross-presentation capabilities of murine hepatocytes and report on the immunological 
consequences of hepatocyte-dependent antigen cross-presentation. 
Unlike previous studies, we were able to determine in vitro that markers associated 
with exogenous antigen processing are highly expressed in hepatocytes and localized to 
subcellular organelles competent for processing of extracellular antigens, resulting in cross-
presentation. In vivo antigen cross-presentation by hepatocytes led to a tolerization state 
characterized by clonal deletion of antigen-specific CD8+ T lymphocytes by apoptosis and 
emperipolesis. In fact, Annexin V staining and strong upregulation of the pro-apoptotic 
markers Fas ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL) on the 
surface of T cells indicated pro-apoptotic phenotype of hepatocyte-educated CD8+ T cells. 
Moreover, the detection of antigen-specific T lymphocytes within lysosomal associated 
membrane protein 1 (LAMP-1)-positive compartments of antigen cross-presenting 
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hepatocytes suggested emperipolesis by the T cells. Together with FasL and TRAIL, PD-1 
was also strongly upregulated by the CD8+ T cells undergoing hepatocyte-dependent cross-
tolerance. High expression of PD-1 ligand 1 (PD-L1) could be detected at steady-state 
conditions on liver parenchymal cells and PD-L1 has been involved in intrahepatic deletion of 
activated CD8+ T lymphocytes 24. We therefore hypothesized that PD-1/PD-L1 interactions 
between antigen-specific CD8+ T cells and antigen cross-presenting hepatocytes, respectively, 
could be actively involved in the establishment of cross-tolerance. In fact, blocking PD-L1 on 
the surface of cross-presenting hepatocytes significantly impaired the development of cross-
tolerance.  
 
 
3.3 Results 
3.3.1 Primary hepatocytes efficiently use EEA1- and TAP1-positive cytoplasmic 
compartments for extracellular antigen processing 
Presentation of extracellular antigens requires dedicated subcellular compartments in 
professional APCs, depending on whether antigens will be presented on MHC-I (cross-
presentation) or MHC-II complexes. In particular, cross-presentation is the result of antigen 
uptake mediated by Fc or C-type lectin receptors (such as the mannose receptor), followed by 
antigen proteolytic degradation by proteasomes associated to early endosome antigen 1 
(EEA1)-positive phagosomes (early endosomes), subsequent antigen transportation and 
loading onto MHC-I molecules through transporters associated with antigen processing 
(TAP) and translocation of peptide/MHC-I complexes to the cell plasma membrane via the 
secretory pathway 25-27. 
Physiologically hepatocytes are home to the liver metabolic functions involving 
uptake and processing of molecules found in the extracellular space. We therefore asked 
whether hepatocytes would employ cross-presentation-competent subcellular compartments 
to process soluble extracellular antigens. We first sought to characterize primary murine 
hepatocytes for their expression and distribution of markers associated with cross-
presentation-competent phagosomes. Freshly isolated hepatocytes from C57BL/6 mice were 
stained for mannose receptor 1 (MR), EEA1, TAP1 and H-2Kb and analyzed by confocal 
microscopy. The expression and distribution of these markers indicate their localization either 
on the surface of hepatocytes (MR, H-2Kb) or in subcellular compartments (MR, EEA1, 
TAP1 and H-2Kb) with a similar pattern compared to sorted CD11c+CD8α+ BMDCs, chosen 
as positive reference for their professional antigen cross-presenting functions (Fig. 3.2a). As 
expected, the abundance of MR-, EEA1-, TAP1- and H-2Kb-positive organelles is higher in 
professional cross-presenting CD11c+CD8α+ BMDCs (Fig. 3.2a). 
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To test whether the subcellular compartments described in Fig. 3.2a are used by 
hepatocytes to process protein antigens found in the extracellular space, we cultured primary 
hepatocytes in the presence of DQ-Ovalbumin (DQ-OVA) and analyzed the mean fluorescent 
intensity (MFI) and localization of the fluorescent signal derived from its proteolytic 
degradation. Hepatocytes actively degrade proteins added to their supernatant, as DQ-OVA 
becomes fluorescent when cells are incubated at 37°C but not at 4°C (Fig. 3.2b). As expected, 
the magnitude of antigen processing in BMDCs is much greater than in hepatocytes as 
indicated by the MFI of DQ-OVA, but the kinetics appear to be similar between the two cell 
types with DQ-OVA fluorescence peaking within the first 12 hr of culture and slowly 
decreasing over time until reaching background signal levels after 60 hr in culture without 
further addition of the antigen (Fig. 3.2b). By confocal microscopy, we could localize the 
fluorescent signal originating from the degradation of DQ-OVA in the proximity of or inside 
EEA1+, TAP1+ and H-2Kb+ compartments (Fig. 3.2c). Interestingly, DQ-OVA fluorescence 
could also be detected associated to late endosomes, identified as LAMP-1+ organelles (Fig. 
3.2c), even though quantification of co-localizing signals indicated that DQ-OVA degradation 
is mainly associated to EEA1+ and TAP1+ compartments (2.45 and 2.7 Pearson’s co-
localization coefficient fold increase over LAMP-1, respectively) (Fig. 3.2d). This 
observation prompted us to investigate whether hepatocytes contained phagosomes positive 
for both EEA1 and TAP, which are considered the hallmark of professional cross-presenting 
cells, as these phagosomes retain all the functions necessary for cross-presentation 25-28. 
Interestingly, EEA1+TAP1+ subcellular compartments were found to be abundantly 
distributed in the cytoplasm of primary hepatocytes, even though to a lesser extent as 
compared to sorted CD11c+CD8α+ BMDCs  (Fig. 3.2e). These results are in line with the 
current models of cross-presentation, according to which cross-presenting cells contain 
phagosomes (mainly recognized as EEA1+) equipped with the complete molecular machinery 
necessary to retro-translocate antigens to the cytoplasm for degradation into phagosome-
associated proteasomes and to transport digested peptides into endosomal MHC-I-containing 
compartments, where peptides are loaded onto MHC-I complexes prior to their transportation 
to the cell membrane 25-28. 
To confirm in vivo uptake and processing of blood-borne and extracellular antigens 
by hepatocytes, we injected 100 μg of DQ-OVA intravenously (i.v.) into C57BL/6 mice and 
euthanized animals after 12 hr to harvest liver and spleen, as they represent the major blood 
filtration organs. In the liver, DQ-OVA fluorescence was widely distributed in the 
parenchyma and, unlike previous reports indicating LSECs as the major blood-filtering cells 
of the liver 9,10, mainly localized in hepatocytes, identified as non-hematopoietic (CD45-) non-
endothelial (CD31-) parenchymal cells (Fig. 3.2f, top panels). As expected, DQ-OVA 
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processing in the spleen was mostly detected in cross-presenting DCs, identified as 
CD45+CD11c+CD8α+ cells (Fig. 3.2f, bottom panels). 
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Figure 3.2 Hepatocytes uptake and process extracellular antigens in cross-presentation-
competent phagosomes. (a) Confocal microscopy of primary hepatocytes and sorted CD11c+CD8α+ 
BMDCs from C57BL/6 mice stained for MR, EEA1, LAMP-1, TAP1, H-2Kb, DAPI (both hepatocytes 
and BMDCs) and phalloidin (only hepatocytes). Scale bar = 10 μm.  (b) Flow cytometric analysis of 
primary hepatocytes or BMDCs from C57BL/6 mice cultured in the presence of 20 μg/ml DQ-OVA at 
either 37°C or 4°C for the indicated amount of time. (c) Confocal microscopy of primary hepatocytes 
from C57BL/6 mice cultured for 12 hr in the presence of 20 μg/ml DQ-OVA and stained for EEA1, 
LAMP-1, TAP1, H-2Kb and DAPI. Scale bar = 10 μm.  (d) Quantification of signal co-localization of 
DQ-OVA with either EEA1, LAMP-1, TAP1 or H-2Kb as detected by confocal microscopy in (c). (e) 
Confocal microscopy of primary hepatocytes and sorted CD11c+CD8α+ BMDCs from C57BL/6 mice 
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stained for EEA1, TAP1, DAPI and phalloidin. Scale bar = 10 μm. (f) Confocal microscopy of liver 
and spleen sections from C57BL/6 mice euthanized 12 hr after i.v. administration of 100 μg of DQ-
OVA. Liver sections were stained for CD45, CD31 and DAPI; spleen sections were stained for CD11c, 
CD8α and DAPI. Scale bar = 50 μm. * P < 0.05, ** P < 0.01 and *** P < 0.001 (unpaired t test in (b) and 
one-way ANOVA and Bonferroni post-hoc test correction in (d)). Data in (a,b,c,d) are representative of 
3 independent experiments (mean and s.e.m. in (b,d)). Pictures in (f) are representative of 5 different 
mice. 
 
We thus concluded that murine hepatocytes phenotypically resemble antigen cross-
presenting DCs, since actively processed extracellular antigens can be mostly detected in 
association to EEA1+, TAP1+ and H-2Kb+ cytoplasmic compartments. Most importantly, 
hepatocytes contain EEA1+TAP1+ phagosomes, which are considered a unique feature of 
professional cross-presenting cells. Moreover, scavenging and degradation of blood-borne 
antigens in vivo are the main activities of hepatocytes in the liver and of cross-presenting 
CD45+CD11c+CD8α+ DCs in the spleen. 
 
3.3.2 Poly(N-Acetylgalactosamine) covalent modifications increase the efficiency of 
antigen cross-presentation in primary hepatocytes 
Receptor-mediated endocytosis of extracellular antigens is the first step of the cross-
presentation pathway. Antigen chemical modifications enhancing receptor binding have been 
previously exploited to improve either CD8+ T cell immunity or tolerance following antigen 
cross-presentation 29,30. We therefore decided to test whether an antigen covalently modified 
with polymeric sugar structures (poly(N-Acetylgalactosamine); D.S.W., M.D., J.A.H., 
manuscript in preparation), recognized by several cross-presentation-related receptors such as 
the MR, the fructose receptor and the liver-specific lectin asialoglycoprotein receptor, could 
improve hepatocyte cross-presentation of the model antigen OVA. 
We modified OVA with poly(N-Acetylgalactosamine) (pGal-OVA) and compared its 
cross-presentation to that of unmodified OVA in hepatocytes or BMDCs incubated with 
equimolar doses of the two versions of the antigen (Fig. 3.3a). pGal-OVA resulted in a 
statistically significant 1.2 and 2.1 fold increase of cross-presentation of the OVA-derived 
CD8+ T cell immunodominant epitope SIINFEKL in primary hepatocytes and BMDCs, 
respectively, as compared to OVA, as indicated by staining for H-2Kb/SIINFEKL complexes 
and flow cytometric analysis (Fig. 3.3a). Confocal microscopy confirmed improved 
SIINFEKL cross-presentation by pGal-OVA-treated hepatocytes as compared to OVA-treated 
hepatocytes (Fig. 3.3b). 
We then asked whether cellular processes described in hematopoietic and non-
hematopoietic APCs for cross-presentation, such as endosome acidification and proteasomal 
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degradation 25-28,43, were also employed by hepatocytes for pGal-OVA cross-presentation. We 
therefore treated primary murine hepatocytes with pGal-OVA alone or with pGal-OVA 
together with either chloroquine (an inhibitor of endosomal acidification) or MG132 (a 
proteasome inhibitor) and cultured them in vitro with OT-I cells, transgenic CD8+ T cells 
specific for H-2Kb/SIINFEKL. After 24 hr of co-culture, we analyzed by flow cytometry the 
expression of CD69 by OT-I cells, as an early indicator of antigen sensing and TCR 
triggering. Blockade of either endosomal function or proteasomal protein degradation in 
hepatocytes resulted in statistically significant reduction of the frequency of OT-I cells able to 
experience antigen presentation by hepatocytes, as indicated by CD69 staining. In fact, after 
treatment of hepatocytes with pGal-OVA and either chloroquine or MG132, 7.38% and 
3.98% of the OT-I cells were CD69+, respectively, as compared to 17% of CD69+ OT-I cells 
measured when hepatocytes were incubated with pGal-OVA alone (Fig. 3.3c). 
 
Figure 3.3 Poly(N-Acetylgalactosamine)-modified OVA (pGal-OVA) is processed through 
the cross-presentation pathway more efficiently than OVA. (a) Flow cytometric analysis of primary 
hepatocytes (left) and BMDCs (right) from C57BL/6 mice cultured in the presence of 5 μM OVA 
(open squares) or 5 μM pGal-OVA (black squares) for the indicated amount of time and stained for H-
2Kb/SIINFEKL. (b) Confocal microscopy of primary hepatocytes from C57BL/6 mice cultured for 24 
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hr in the presence of either 5 μM OVA, 5 μM pGal-OVA, 1 nM SIINFEKL or left untreated and 
stained for H-2Kb/SIINFEKL, phalloidin and DAPI. Scale bar = 10 μm. (c) Flow cytometry of OT-I 
cells stained for CD69 after 24 hr in culture with primary hepatocytes pre-treated with either pGal-
OVA alone, with pGal-OVA and chloroquine or pGal-OVA and MG132 or left untreated. * P < 0.05, ** 
P < 0.01  **** P < 0.0001 and n.s. = not significant (one-way ANOVA and Bonferroni post-hoc test 
correction). Data are representative of 3 independent experiments (n = 3; mean and s.e.m. in (a,c)). 
 
Our data indicate that pGal-OVA is processed in hepatocytes via the cellular pathway 
of antigen cross-presentation. Since cross-presentation of pGal-OVA is more efficient than 
that of OVA, we decided to adopt pGal-OVA as model antigen to characterize the OVA-
specific immune response elicited by hepatocyte-dependent cross-presentation in vivo. 
 
3.3.3 Cross-presentation of OVA by hepatocytes results in antigen-specific CD8+ T 
cell tolerance by induction of clonal deletion and anergy 
Scavenger receptors are expressed by a multitude of cells, especially in the liver and in the 
spleen, among which DCs, macrophages and LSECs. In order to discriminate the role of 
hepatocytes in the establishment of cross-tolerance towards extracellular antigens using the 
pGal-OVA antigen, we developed a model of i.v. adoptive transfer of freshly isolated 
hepatocytes. When delivered i.v., CFSE-labeled primary hepatocytes appear to selectively 
home to the spleen and, to a lesser extent, the liver and to survive in those sites for at least 1 
month after infusion (Fig. 3.4). 
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Figure 3.4 Primary hepatocytes survive and home to liver and spleen after i.v. adoptive transfer. 
Confocal microscopy of liver, spleen, lung and kidney sections stained with DAPI from C57BL/6 mice 
administered i.v. with CFSE-labeled C57BL/6 hepatocytes and euthanized at either 24 hr, 14 days or 1 
month after injection. Scale bar = 50 μm. Data are representative of 5 different mice. 
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To study the effects of hepatocyte cross-presentation on antigen-specific T cells in 
vivo, we ex vivo incubated with pGal-OVA hepatocytes isolated from C57BL/6 mice. After 
incubation with pGal-OVA and washing, OVA cross-presenting hepatocytes (Fig. 3.5a) were 
transferred i.v. into recipient CD45.2+ C57BL/6 mice, followed by i.v. administration of 
CFSE-labeled CD45.1+ OT-I cells 6 hr later. 2 weeks after hepatocyte transfer, recipient mice 
were vaccinated with an intradermal (i.d.) dose of OVA and LPS (challenge) into the frontal 
footpads and 4 days after challenge mice were euthanized in order to analyze the phenotype 
of adoptively transferred OT-I cells retrieved from the spleen and the LNs draining the 
vaccination site (dLNs) (Fig. 3.5b). 
95% to 99.7% of the OT-I cells harvested from mice challenged with OVA/LPS on 
day 15 responded to vaccination by proliferating, as detected by flow cytometric analysis of 
CFSE dilution of viable CD45.1+CD3+CD8+ cells in the dLNs and spleen of recipient mice 
(Fig. 3.5c and Supplementary Fig. 3.1a, respectively, top panel). Even though no difference 
was detectable in the proliferative capacity of OT-I cells harvested from vaccinated mice 
administered with either vehicle, untreated hepatocytes or OVA cross-presenting hepatocytes 
on day 0, the frequency of CD45.1+ OT-I cells in the population of total viable CD3+CD8+ 
lymphocytes was significantly reduced to 0.4% in the dLNs of mice treated with OVA cross-
presenting hepatocytes as compared to mice receiving either vehicle (2.3%) or untreated 
hepatocytes (2.2%) on day 0 (Fig. 3.5c, bottom panels). Reduced frequencies of CD45.1+ OT-
I cells in mice pre-treated with OVA cross-presenting hepatocytes were paralleled by lower 
OT-I cell counts (Fig. 3.5c, bottom panels). Significantly reduced frequency and cell counts 
of CD45.1+ OT-I cells were also measured in the population of viable CD3+CD8+ 
lymphocytes isolated from the spleen of recipient mice (Supplementary Fig. 3.1a, bottom 
panels). 
The significantly lower frequencies of CD45.1+ OT-I cells among total CD8+ T 
lymphocytes prompted us to investigate whether non-deleted OT-I cells displayed signature 
markers of apoptosis or reduced survival. In the dLNs of mice administered with pGal-OVA-
treated hepatocytes we could detect significantly higher frequencies of Annexin-V+ (38.6%), 
FasL+ (2.6%), TRAIL+ (5.77%) and KLRG1hiCD127low (6.45%) OT-I cells as compared to 
mice receiving on day 0 either vehicle (20.01%, 0.33%, 1.56% and 0.48%, respectively) or 
untreated hepatocytes (21.7%, 0.38%, 2.12% and 1.77%, respectively) (Fig. 3.5d). Similarly 
to the dLNs, the OT-I cells retrieved from the spleen of recipient mice also showed evidence 
of undergoing apoptosis and reduced survival capacity (Supplementary Fig. 3.1b). 
Moreover, administration of pGal-OVA-treated hepatocytes on day 0 also 
significantly affected the capacity of adoptively transferred OT-I cells to acquire effector 
functions following vaccination, as indicated by statistically lower frequencies of IFN-γ+ and 
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IL-2+ viable CD45.1+CD3+CD8+ OT-I cells in the dLNs (22.2% and 3.5%, respectively), as 
compared to mice administered on day 0 with either vehicle (61.8% and 10.4% of dLN IFN-
γ+ or IL-2+ OT-I cells, respectively) or untreated hepatocytes (55.3% and 7.2% of dLN IFN-γ+ 
or IL-2+ OT-I cells, respectively) (Fig. 3.5e). Similar trends were also detected in the spleen 
of recipient mice (Supplementary Fig. 3.1c). Interestingly, when total dLN cells were 
restimulated ex vivo with SIINFEKL, secreted IFN-γ was significantly reduced to 562.4 
pg/mL in the supernatant of the cells harvested from mice receiving pGal-OVA-treated 
hepatocytes, as compared to 2541.68 pg/mL and 3254.76 pg/mL for mice receiving either 
vehicle or untreated hepatocytes on day 0, respectively (Fig. 3.5f). 
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Figure 3.5 OVA cross-presenting hepatocytes induce CD8+ T cell tolerance via OT-I cell deletion 
and anergy. (a) Confocal microscopy of primary hepatocytes from C57BL/6 mice incubated ex vivo 
for 3 hr with 12.5 μM pGal-OVA and stained for H-2Kb/SIINFEKL and DAPI. Scale bar = 10 μm. (b) 
Adoptive transfer experimental design. (c) Flow cytometric analysis of proliferated (CFSElow-neg) OT-I 
cells (top) or of the frequency and cell counts of CD45.1+ OT-I cells in the population of total viable 
CD3ε+CD8α+ T cells (bottom) harvested from the dLNs of recipient CD45.2+ C57BL/6 mice treated as 
indicated in (b). Numbers in the representative dot plots indicate the frequency of CD45.1+ OT-I cells 
gated in the population of viable CD3ε+CD8α+ cells. (d) Flow cytometry of OT-I cells from the dLNs 
of recipient C57BL/6 mice treated as in (b) stained with either Annexin V, FasL, TRAIL or KLRG-1 
and CD127. (e) Flow cytometric analysis of OT-I cells harvested from the dLNs of recipient C57BL/6 
mice treated as in (b) stained intracellularly for IFN-γ (left) or IL-2 (right). (f) ELISA quantification of 
secreted IFN-γ released by total dLN cells harvested from recipient C57BL/6 mice treated as in (b) and 
restimulated with SIINFEKL. (g) Confocal microscopy of primary hepatocytes incubated with 5 μM 
pGal-OVA (top) or left untreated (bottom) for 24 hr followed by 24 hr of co-culture with CFSE-labeled 
OT-I cells. Cells were stained for LAMP-1 and with DAPI and phalloidin (only bottom panel). Arrows 
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indicate CFSE+ OT-I cells or their debris. Scale bar = 10 μm. * P < 0.05,  **** P < 0.0001 and n.s. = not 
significant for comparisons of pGal-OVA hepatocyte-treated group with either vehicle (plus 
challenge)- or hepatocyte-treated group (one-way ANOVA and Bonferroni post-hoc test correction). 
Data are representative of 2 independent experiments (n = 8; mean and s.e.m. in (c-f)). 
 
Emperipolesis has been described as a mechanism of T cell clonal deletion by 
hepatocytes. During emperipolesis, antigen-specific CD8+ T lymphocytes actively invade 
antigen-presenting hepatocytes after TCR triggering and are subsequently degraded into 
LAMP-1+ organelles 19. OT-I-into-hepatocytes structures reminiscent of emperipolesis could 
be observed in vitro after co-culturing CFSE-labeled OT-I cells with pGal-OVA-treated 
hepatocytes for 24 hr (Fig. 3.5g). Specifically, OT-I cells or their debris were detected inside 
LAMP-1-coated compartments of OVA cross-presenting hepatocytes, while OT-I cells only 
made contact with the surface of untreated hepatocytes (Fig. 3.5g). 
Collectively, our results indicate that antigen cross-presenting hepatocytes 
significantly affect the phenotype of antigen-specific CD8+ T cells inducing T cell deletion, as 
indicated by the reduced frequency of CD45.1+ OT-I cells among viable CD8+ T lymphocytes 
both in the dLNs and spleen of mice administered with pGal-OVA-treated hepatocytes. 
Moreover, non-deleted OT-I cells isolated from the mice receiving pGal-OVA pre-treated 
hepatocytes showed a phenotype reminiscent of anergic T cells, characterized by reduced 
responsiveness to vaccination, as indicated by significantly lower percentages of IFN-γ+ or 
IL-2+ cells. Hepatocyte-educated OT-I cells showed a molecular signature of CD8+ T cell 
deletional tolerance, characterized by upregulation of FasL and TRAIL, and of reduced 
survival and senescence, as indicated by the KLRG1hiCD127low phenotype 55-56. Moreover, 
total dLN cells, and not only OT-I cells, displayed impaired responsiveness to OVA 
vaccination as indicated by significantly reduced secretion of IFN-γ upon restimulation with 
SIINFEKL. Importantly, emperipolesis could be observed in vitro when OT-I cells were 
cultured together with pGal-OVA-treated hepatocytes. As expected from the lack of MHC-II 
expression by hepatocytes, no significant immune effect of pGal-OVA-treated hepatocytes 
could be detected on CD4+ OT-II cells adoptively transferred into recipient mice instead of 
OT-I cells (data not shown). The lack of CD4+ T cell tolerance upon hepatocyte-dependent 
antigen presentation indirectly confirms that the CD8+ T cell clonal deletion and anergy here 
described result from direct interaction between cross-presenting hepatocytes and antigen-
specific CD8+ T lymphocytes (cross-tolerance). 
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3.3.4 PD-1/PD-L1 interactions participate in the establishment of hepatocyte-
dependent cross-tolerance 
PD-1 is a negative regulator of T cell responses and has been especially associated with 
enhanced apoptosis and reduced secretion of pro-inflammatory cytokines of activated 
lymphocytes 31-35. Of note, expression of its receptor PD-L1 in the liver parenchyma has been 
involved in hepatic retention and elimination of CD8+ T cells activated in the periphery 24. 
Since we observed induction of deletion and anergy of OT-I cells by antigen cross-presenting 
hepatocytes (Fig. 3.5c-g), we asked whether these effects could be ascribed to the PD-1/PD-
L1 pathway. 
43.1% of the OT-I cells isolated from the dLNs of mice treated as in Fig. 3.5b and 
receiving OVA cross-presenting hepatocytes were PD-1+, significantly more frequent than in 
the dLNs of mice receiving either vehicle or untreated hepatocytes, where only 14.2% and 
12.4% of the OT-I cells were PD-1+, respectively (Fig. 3.6a, bottom left). Of note, the 
majority of the PD-1+ OT-I cells in mice administered with pGal-OVA pre-treated 
hepatocytes were apoptotic, as shown by the significantly higher frequency of Annexin-
V+PD-1+ OT-I cells (70.6%) as compared to what observed in mice receiving either vehicle 
(45.4%) or untreated hepatocytes (44.8%) on day 0 (Fig. 3.6a, bottom right). Similar results 
were also observed for the OT-I cells isolated from the spleen of vaccinated mice treated with 
OVA cross-presenting hepatocytes on day 0 (Supplementary Fig. 3.2a). 
PD-1 interacts with at least two receptors, PD-L1 and PD-L2. While expression of 
PD-L2 is restricted to activated lymphocytes and APCs, PD-L1 is widely expressed in 
lymphoid and non-lymphoid tissues 31,36-38. Hepatocytes have previously been reported to 
express basal levels of PD-L1, which becomes overexpressed upon viral infection or 
treatment with type I and II interferons, leading to CD8+ T lymphocyte apoptosis 39. Unlike 
previous reports, we could detect, at steady state conditions, high expression levels of PD-L1, 
but not PD-L2, on liver parenchymal cells from wild-type untreated C57BL/6 mice (Fig. 
3.6b). 
In order to test whether the interaction between PD-L1 expressed by OVA cross-
presenting hepatocytes and PD-1 upregulated on the surface of hepatocyte-educated OT-I 
cells played a role in the establishment of the cross-tolerance effects observed in Fig. 3.5c-g, 
we compared the tolerogenic effects of pGal-OVA-treated hepatocytes to those of pGal-
OVA-treated hepatocytes incubated with a PD-L1 blocking antibody in the same 
experimental setting shown in Fig. 3.5b. Vaccination with OVA/LPS induced proliferation of 
the OT-I cells in the dLNs and spleen of recipient mice with no significant differences among 
the treatment groups, as indicated by flow cytometric analysis of CFSE dilution of viable 
CD45.1+CD3+CD8+ OT-I cells (Fig. 3.6c and Supplementary Fig. 3.2b, top panel). More 
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importantly, treatment of OVA cross-presenting hepatocytes with a PD-L1 blocking antibody 
prior to their infusion into recipient CD45.2+ C57BL/6 mice significantly reduced the 
induction of deletional tolerance by hepatocytes, since the frequency of CD45.1+ OT-I cells in 
the population of viable CD3+CD8+ lymphocytes was significantly increased in the dLNs of 
mice receiving on day 0 pGal-OVA- and αPD-L1-treated hepatocytes (0.45%) as compared 
to those receiving hepatocytes treated with either only pGal-OVA or with pGal-OVA and an 
isotype control antibody (0.22% and 0.20%, respectively) (Fig. 3.6c, bottom panels). Similar 
results were also observed for the OT-I cell counts (Fig. 3.6c, bottom panels) and were 
paralleled by the frequencies and counts of OT-I cells measured in the spleen of recipient 
mice (Supplementary Fig. 3.2b, bottom panels). 
Confirming reduced CD8+ T cell deletion, pre-treatment of OVA cross-presenting 
hepatocytes with αPD-L1 also significantly reduced the frequency of Annexin-V+, FasL+, 
TRAIL+ and KLRG1hiCD127low OT-I cells isolated from the dLNs and spleen of recipient 
mice (Fig. 3.6d and Supplementary Fig. 3.2c, respectively). In addition, blocking the 
interaction between OT-I-expressed PD-1 and hepatocyte-expressed PD-L1 also significantly 
contrasted the induction of anergy and improved the acquisition of effector functions by non-
deleted OT-I cells, resulting in increased frequencies of IFN-γ+ (47.11%) and IL-2+ (7.53%) 
OT-I cells isolated from dLNs and spleen of recipient mice after OVA/LPS challenge as 
compared to mice receiving either pGal-OVA-treated hepatocytes (24.53% and 3.19% of 
dLN IFN-γ+ and IL-2+ OT-I cells, respectively) or pGal-OVA and isotype control antibody-
treated hepatocytes (29.16% and 4.21% of dLN IFN-γ+ and IL-2+ OT-I cells, respectively 
(Fig. 3.6e and Supplementary Fig. 3.2d). Pretreatment of OVA cross-presenting hepatocytes 
with αPD-L1 also resulted in a trend for increased secretion of IFN-γ by total dLN cells 
harvested from recipient mice and restimulated ex vivo with SIINFEKL, even though 
differences among groups were not statistically significant (Fig. 3.6f). Last, when PD-L1 was 
blocked, emperipolesis of OT-I cells cultured in vitro for 24 hr together with pGal-OVA-
treated hepatocytes was abrogated (Fig. 3.6g). 
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Figure 3.6 PD-1/PD-L1 interactions are involved in hepatocyte-dependent cross-tolerance. (a) 
Flow cytometry of OT-I cells harvested from the dLNs of recipient C57BL/6 mice treated as in Fig. 
3.5b and stained for PD-1 and Annexin V. The frequencies of PD-1+ OT-I cells (bottom left) and of 
Annexin V+PD-1+ OT-I cells (bottom right) are indicated. Numbers in the representative dot plots (top) 
indicate the frequency of Annexin V+ OT-I cells in the population of PD-1+ OT-I cells. (b) Confocal 
microscopy of liver sections from C57BL/6 mice stained for DAPI and either PD-L1 or PD-L2. Scale 
?
?
?
??
bar = 50 μm. (c) Flow cytometry analysis of proliferated (CFSElow-neg) OT-I cells (top) and of the 
frequency of OT-I cells (gated as CD45.1+) in the population of viable CD3ε+CD8α+ T cells and the 
corresponding cell counts (bottom panels) from the dLNs of recipient CD45.2+ C57BL/6 mice infused 
with hepatocytes incubated ex vivo with pGal-OVA (12.5 μM) or with pGal-OVA (12.5 μM) and 100 
μg/ml of either αPD-L1 antibody or isotype control antibody as indicated in Fig. 3.5b. Numbers in the 
representative dot plots indicate the frequency of CD45.1+ cells in the population of viable 
CD3ε+CD8α+ cells. (d) Flow cytometry of OT-I cells harvested from the dLNs of recipient C57BL/6 
mice treated as in (c) and stained with either Annexin V, FasL, TRAIL or KLRG-1 and CD127. (e) 
Flow cytometric analysis of OT-I cells from the dLNs of recipient C57BL/6 mice treated as in (c) 
stained intracellularly for IFN-γ (left) or IL-2 (right). (f) ELISA quantification of secreted IFN-γ 
released by total dLN cells harvested from recipient C57BL/6 mice treated as in (c) and restimulated 
with SIINFEKL. (g) Confocal microscopy of primary hepatocytes incubated with 5 μM pGal-OVA 
(top) or left untreated (bottom) for 24 hr followed by 24 hr of co-culture with CFSE-labeled OT-I cells. 
Cells were stained for LAMP-1 and with DAPI and phalloidin. Arrows indicate CFSE+ OT-I cells or 
their debris. Scale bar = 10 μm. * P < 0.05, ** P < 0.01, *** P < 0.001 and n.s. = not significant for 
comparisons of pGal-OVA hepatocyte-treated group with either vehicle (plus challenge)- or 
hepatocyte-treated group in (a) or for comparisons of pGal-OVA + αPD-L1 antibody hepatocyte-
treated group with either pGal-OVA hepatocyte- or pGal-OVA + iso. ctrl. antibody hepatocyte-treated 
group in (c-f) (one-way ANOVA and Bonferroni post-hoc test correction). Data are representative of 2 
independent experiments (n = 8; mean and s.e.m. in (a,c-f)). 
 
Taken together, our data show that the interaction between PD-1, highly upregulated 
on the surface of CD8+ T cells experiencing antigen cross-presentation by hepatocytes, and 
PD-L1, strongly expressed by hepatocytes, participates to the induction of hepatocyte-
dependent cross-tolerance. In particular, PD-1 overexpression is found to correlate with T cell 
reduced survival and increased apoptosis, as the majority of PD-1+ OT-I cells also stain 
positive for Annexin V in mice administered with OVA cross-presenting hepatocytes. 
Treating OVA cross-presenting hepatocytes with a PD-L1 blocking antibody prior to their 
infusion, significantly interferes with the establishment of hepatocyte-dependent cross-
tolerance, as indicated by increased frequency of CD45.1+ OT-I cells, reduced pro-apoptotic 
OT-I cells, increased IFN-γ- and IL-2-producing OT-I cells and IFN-γ-secreting total dLN 
cells and abrogation of emperipolesis. 
 
3.3.5 Cross-tolerance is a direct effect of hepatocyte-dependent antigen presentation 
and does not require antigen presentation by host APCs 
Prolonged survival of hepatocytes after i.v. administration (Fig. 3.4), lack of CD4+ T cell 
tolerance in the mice administered with pGal-OVA-treated hepatocytes (data not shown), and 
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impaired tolerance after blocking PD-L1 specifically on OVA cross-presenting hepatocytes 
(Fig. 3.6) altogether provide indirect evidence that the establishment of tolerance following 
hepatocyte adoptive transfer is a consequence of hepatocyte cross-presentation. Nevertheless, 
i.v. administered hepatocytes could be phagocytosed, degraded and their antigens, including 
OVA-derived epitopes, could be presented by host scavenger cells in the absence of co-
stimulation, resulting in tolerance induction. 
We confirmed the direct role of hepatocyte-dependent cross-presentation in the 
establishment of CD8+ T cell tolerance by analysing the development of cross-tolerance after 
administration of pGal-OVA-treated TAP1-/- hepatocytes into wild-type (wt) recipients as 
compared to administration of pGal-OVA-treated wt hepatocytes, following the same 
experimental design indicated in Fig. 3.5b. As expected from their genetic defect, ex vivo 
incubation of TAP1-/- hepatocytes with pGal-OVA resulted in significantly lower cross-
presentation of OVA-derived SIINFEKL as compared to wt hepatocytes (Fig. 3.5a and Fig. 
3.7a). 
Upon vaccination, OT-I cells retrieved from the dLNs and spleen of mice receiving 
either pGal-OVA-treated wt hepatocytes or pGal-OVA-treated TAP1-/- hepatocytes responded 
by proliferation (Fig. 3.7b and Supplementary Fig. 3.3a, left panel). Nonetheless, in the dLNs 
of mice administered on day 0 with OVA cross-presenting TAP1-/- hepatocytes, the frequency 
of CD45.1+ OT-I cells in the population of viable CD3+CD8+ lymphocytes was significantly 
greater than in mice infused with cross-presenting wt hepatocytes (0.60% and 0.25%, 
respectively) (Fig. 3.7b, right panel). A similar trend was also observed for the counts of OT-I 
cells (Fig. 3.7b, right panel) and was paralleled by the frequencies and counts of OT-I cells 
measured in the spleen of recipient mice (Supplementary Fig. 3.3a, right panel). In parallel 
with increased frequency, the percentage of FasL+, TRAIL+ or KLRG1hiCD127low OT-I cells 
retrieved from the dLNs or spleen of mice treated with TAP1-/- hepatocytes was also 
significantly decreased as compared to mice receiving wt hepatocytes (Fig. 3.7c and 
Supplementary Fig. 3.3b,c). Moreover, non-deleted OT-I cells from the dLNs or spleen of 
mice treated on day 0 with TAP1-/- hepatocytes responded to OVA/LPS challenge more 
efficiently, as indicated by the frequency of IFN-γ-expressing OT-I cells detected by flow 
cytometry (44.2% as compared to 24.5% in the dLNs) (Fig. 3.7d and Supplementary Fig. 
3.3d). The percentage of IL-2-producing OT-I cells was also significantly increased in both 
the spleen and dLNs of mice receiving OVA cross-presenting TAP1-/- hepatocytes as 
compared to wt hepatocytes (4.94% as compared to 2.76% in the dLNs) (Supplementary Fig. 
3.3e). The frequency of PD-1+ and of Annexin-V+PD-1+ OT-I cells harvested from the dLNs 
or spleen of mice administered with TAP1-/- hepatocytes pre-treated with pGal-OVA was 
significantly reduced as compared to mice administered with pGal-OVA-treated wt 
?
?
?
??
hepatocytes (20.46% as compared to 43.1% of PD-1+ OT-I cells and 44.77% as compared to 
67.2% of PD-1+Annexin-V+ OT-I cells in the dLNs) (Fig. 3.7e and Supplementary Fig. 3.3f). 
Last, impaired OVA cross-presentation by TAP-/- hepatocytes also resulted in a general 
stronger response to vaccination with adjuvanted OVA, as suggested by a trend for increased 
secretion of IFN-γ by total dLN cells upon ex vivo restimulation with SIINFEKL (Fig. 3.7f). 
 
Figure 3.7 CD8+ T cell tolerance is the result of hepatocyte-dependent antigen cross-presentation. 
(a) Confocal microscopy of primary hepatocytes from TAP1-/- C57BL/6 mice incubated ex vivo for 3 hr 
with 12.5 μM pGal-OVA and stained for H-2Kb/SIINFEKL and DAPI. Scale bar = 10 μm. (b) Flow 
cytometry analysis of proliferated (CFSElow-neg) OT-I cells (left) and of the frequency of OT-I cells 
(gated as CD45.1+) in the population of viable CD3ε+CD8α+ T cells and the corresponding cell counts 
(right) from the dLNs of recipient CD45.2+ C57BL/6 mice infused with either wt hepatocytes or TAP1-
/- hepatocytes both incubated ex vivo with pGal-OVA (12.5 μM). (c) Flow cytometry of OT-I cells 
from the dLNs of recipient C57BL/6 mice treated as in (b) stained with either FasL (left) or KLRG-1 
and CD127 (right). (d) Flow cytometry of OT-I cells from the dLNs of recipient C57BL/6 mice treated 
as in (b) stained intracellularly for IFN-γ. (e) Flow cytometry of OT-I cells harvested from the dLNs of 
recipient C57BL/6 mice treated as in (b) stained for PD-1 and Annexin V. The frequencies of PD-1+ 
OT-I cells (left) and of Annexin V+PD-1+ OT-I cells (right) are indicated. (f) ELISA quantification of 
?
?
?
??
secreted IFN-γ released by total dLN cells harvested from recipient C57BL/6 mice treated as in (b) and 
restimulated with SIINFEKL.  * P < 0.05, ** P < 0.01  (unpaired t test). Data are representative of 2 
independent experiments (n = 8; mean and s.e.m. in (b-f)). 
 
Collectively, our data confirm that the development of cross-tolerance in mice 
receiving pGal-OVA-treated hepatocytes depends on the direct interaction between OVA-
specific CD8+ T lymphocytes and OVA cross-presenting hepatocytes, and does not require 
processing of hepatocyte-derived antigens by host APCs. In fact, adoptively transferred 
hepatocytes survive in vivo both in the spleen and liver of recipient mice for at least 1 month 
after transfer (Fig. 3.4). Therefore, when cross-presentation defective TAP1-/- hepatocytes 
were treated with pGal-OVA and infused into recipient mice, the induction of CD8+ T cell 
tolerance was significantly impaired. 
 
 
3.4 Discussion 
The study here described sheds light on the involvement of hepatocytes in the establishment 
of liver-mediated peripheral cross-tolerance towards soluble extracellular antigens. 
Because of its strategic location and microscopic anatomy, the liver has been 
associated with blood-filtering and immune tolerogenic functions. In fact, the liver is placed 
between the blood vessel system collecting gut-derived blood and the systemic circulation, 
and is thus constantly exposed to foreign components, such as food antigens, environmental 
molecules and bacterial components absorbed from the intestinal lumen into the bloodstream. 
In healthy individuals, these foreign components entering the body do not elicit immunity 
5,13,40. The hepatic structure is characterized by a complex network of enlarged capillaries, the 
sinusoids, which are lined by a fenestrated endothelium composed by LSECs and paralleled 
by plates of hepatocytes 40. The immunological properties of the liver have been mainly 
attributed to the ability of LSECs and hepatocytes to interact with circulating lymphocytes, 
even though both LSECs and hepatocytes are non-hematopoietic cells 13. LSECs have been so 
far considered the major cell population responsible for the immunomodulatory functions of 
the liver, as they are in direct contact with circulating lymphocytes, show efficient antigen 
scavenging capacity, express both MHC-I and MHC-II, and have low non-inducible levels of 
co-stimulatory molecules 6-11. On the other hand, hepatocytes only express MHC-I complexes 
and have been attributed poor antigen scavenging capacity in vitro, but efficient CD8+ T cell 
deletion ability in vivo upon direct antigen expression and MHC-I presentation in the absence 
of co-stimulation 14-23. 
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The liver is home to vital metabolic and detoxifying reactions, mostly occurring in 
hepatocytes, and such reactions require uptake and processing of circulating molecules. We 
thus reasoned that hepatocytes could express and utilize the molecular machinery of antigen 
cross-presentation. Cross-presentation of extracellular antigens on the MHC-I has been 
mainly attributed to specialized subsets of hematopoietic cells, in particular lymphoid organ 
resident CD8α+ DCs 41. Nonetheless, in recent years it has been discovered that subsets of 
non-hematopoietic cells are also capable of cross-presentation, among which stromal cells in 
the LNs and LSECs in the liver 8,9,42,43. Cross-presentation requires a dedicated pathway by 
which extracellular antigens are taken up by endocytotic receptors into phagosomes, degraded 
by proteasomal digestion, translocated to endoplasmic structures where peptides are loaded 
onto MHC-I molecules and then subsequently transferred to the cell membrane 25,26,28. 
Unlike previous reports, we were able to show that murine primary hepatocytes 
express high levels of the mannose scavenging receptor 1 (MR) found in other cross-
presenting cells and contain abundant cellular compartments positive for markers associated 
with MHC-I presentation of extracellular antigens, in particular EEA1 and TAP1. 
Interestingly, hepatocytes were found to contain EEA1+TAP1+ phagosomes, which are a 
peculiar characteristic or professional cross-presenting CD11c+CD8α+ cells 25. We also show 
both in vitro and in vivo that hepatocytes actively process extracellular antigens, such as DQ-
OVA, especially in association with EEA1+ and TAP1+ compartments. As expected, the 
efficiency of antigen processing was reduced as compared to CD11c+CD8α+ DCs cells, 
probably due the higher concentration of cross-presentation-competent phagosomes, mostly 
EEA1+TAP1+ compartments, in this DC subset as compared to hepatocytes. 
To study the molecular mechanisms and the immunological outcomes of antigen 
cross-presentation by hepatocytes, we decided to utilize a version of the model antigen OVA 
chemically modified with poly(N-Acetylgalactosamine) (pGal-OVA), which is recognized by 
several scavenger receptors. Since receptor-mediated uptake of an antigen is the initial step of 
the cross-presentation pathway, improved uptake of pGal-OVA also led to enhanced cross-
presentation of the OVA-derived immunodominant epitope SIINFEKL by hepatocytes. 
Presentation of SIINFEKL to antigen-specific OT-I cells by pGal-OVA-treated hepatocytes 
was significantly reduced when endosomal or proteasomal function was blocked using 
specific drug inhibitors. Reduction of the antigen presentation capacity of hepatocytes upon 
treatment with chloroquine or MG132 provides direct evidence that the cellular machinery of 
the antigen cross-presentation pathway is active in hepatocytes and, most importantly, further 
confirms that extracellular antigens enter this pathway after receptor-mediated endocytosis 
into hepatocytes. 
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Scavenger receptors are widely expressed by a variety of cell types in direct contact 
with the blood, including Kupffer cells and LSECs in the liver and macrophages and DCs in 
the spleen 27. In order to specifically characterize the effects of hepatocyte-dependent antigen 
cross-presentation, we adopted an ex vivo system where murine hepatocytes are first isolated 
from the liver of donor mice and incubated with the pGal-OVA antigen, then subsequently 
washed and infused i.v. into recipient mice. Surprisingly, adoptively transferred hepatocytes 
mainly home to the spleen and only to a lesser extent to the liver, while hepatocytes do not 
seed in other blood-filtering organs, including lungs and kidneys. Upon i.v. infusion, 
hepatocytes survive for at least 1 month in host animals, indicating that ex vivo manipulation 
of hepatocytes does not affect their viability. 
When the phenotype of H-2Kb/SIINFEKL-specific OT-I cells was analyzed after an 
immunogenic challenge with OVA and LPS in mice receiving hepatocyte transfer, we 
observed reduced frequencies of the OT-I cells that had previously experienced cognate 
antigen presentation by OVA cross-presenting hepatocytes, suggesting an antigen-specific 
process of T cell deletion. Deletion of the OT-I cells could be attributed to T cell apoptosis, as 
the remaining non-deleted hepatocyte-educated OT-I cells showed a pro-apoptotic phenotype, 
indicated by staining with Annexin V and positivity for FasL and TRAIL, and reduced 
survival capacity, suggested by the increased frequency of OT-I cells displaying the 
KLRG1hiCD127low phenotypic signature of senescent cells 55-56. Not only the non-deleted 
hepatocyte-educated OT-I cells showed reduced survival, but they also responded poorly to 
vaccination, producing low levels of the pro-inflammatory cytokines IFN-γ and IL-2. 
Unresponsiveness to vaccination indicated acquisition of anergic phenotype by the OT-I cells, 
further indicating the establishment of tolerance. Future investigations will elucidate whether 
hepatocyte-dependent anergy represents a terminally differentiated state leading to T cell 
deletion or whether such state can be reversed upon antigen re-encounter under pro-
inflammatory conditions, similarly to LSEC-mediated CD8+ T cell tolerance 11. Of note, the 
significant reduction of IFN-γ secretion by total dLN cells harvested from mice receiving 
OVA cross-presenting hepatocytes as compared to the other treatment groups suggests 
establishment of hepatocyte-dependent cross-tolerance not only of adoptively transferred OT-
I cells but also of endogenous OVA-specific CD8+ T lymphocytes. 
Previous publications have shown that the development of peripheral CD4+ and CD8+ 
T cell tolerance upon intravenous infusion of antigen-coupled cells depends on the apoptotic 
phenotype of the transferred cells causing them to be phagocytosed and their antigens to be 
presented by host APCs in non-inflammatory conditions 44. The prolonged in vivo survival of 
adoptively transferred hepatocytes indirectly rules out uptake of OVA cross-presenting 
hepatocytes by host APCs in our experimental system. In order to provide a direct 
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confirmation that the tolerogenic effects in our experiments were the result of hepatocyte 
cross-presentation, we adoptively transferred pGal-OVA-treated TAP1-/- hepatocytes into wt 
recipient mice together with OT-I cells. Impaired antigen cross-presentation by TAP1-/- 
hepatocytes resulted in significantly reduced OT-I cell tolerance, confirming the direct role of 
hepatocyte cross-presentation in tolerogenesis. Moreover, hepatocyte-dependent antigen 
presentation did not lead to CD4+ T cell tolerance in our experimental setting (data not 
shown), further confirming that the tolerance effect here described is the result of antigen 
presentation on MHC-I molecules by hepatocytes. Opposite to our findings, recent reports 
described the induction of antigen-specific CD4+CD25+FoxP3+ Treg cells upon hepatocyte-
specific antigen expression, suggesting that in the case of an antigen directly expressed by 
hepatocytes, tolerance could result from antigen spreading and MHC-II presentation by other 
host APCs 22,23.  
The liver displays an unusual enrichment of CD8+ T lymphocytes in its parenchyma 
as compared to other organs and the majority of these cells have an activated phenotype. This 
peculiarity has gained the liver the name of T cell graveyard, where activated CD8+ T 
lymphocytes accumulate and die by apoptosis, especially during the contraction phase of an 
immune response 5,45,46. Hepatic expression of PD-L1 has been involved in the retention and 
deletion of activated CD8+ T cells, in line with the negative effects of PD-1 on T cell 
functions 24. PD-1 is upregulated on activated T cells and is therefore considered one of the 
most important signals involved in the resolution phase of an immune response and 
associated with T cell exhaustion 31-35. PD-1 has also been implied in the prevention of 
autoimmunity and maintenance of immune homeostasis since PD-1-deficient mice develop 
spontaneous autoimmune manifestations during their lifetime 47,48. In our experiments, we 
observed increased frequencies of PD-1+ and of apoptotic Annexin-V+PD-1+ OT-I cells in 
those mice administered with pGal-OVA-treated hepatocytes, as compared to the other 
treatment groups. As we also show that the liver parenchyma expresses PD-L1 in steady-state 
conditions, we hypothesized that the direct interaction between antigen-experienced PD-1-
expressing OT-I cells and antigen cross-presenting PD-L1+ hepatocytes is one of the factors 
responsible for the induction of OT-I tolerance. When pGal-OVA-treated hepatocytes were 
incubated with a PD-L1 blocking antibody prior to their infusion into recipient mice, OT-I 
cells could be significantly, but not completely, rescued from deletion and development of 
anergy. Our data provide evidence that the PD-1/PD-L1 pathway is involved in the induction 
of hepatocyte-dependent cross-tolerance, even though other interactions could be involved as 
well. For example, hepatocytes might express ligands of PD-1 different from PD-L1 and, 
most importantly, hepatocyte-educated T cells might bind to PD-L1 molecules expressed on 
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other cells, since PD-L1 is widely expressed in both hematopoietic and non-hematopoietic 
tissues 37. 
Interestingly, PD-1 is also overexpressed by hepatitis B virus (HBV)- and hepatitis C 
virus (HCV)-specific T cells in infected individuals and has been associated with impaired 
anti-viral immunity 49-52. HBV and HCV are hepatotropic viruses developing chronic 
infection in 10% and 80% of adult infected patients, respectively. The peculiar tolerogenic 
properties of the liver environment have been indicated as the leading cause of HBV or HCV 
persistent infection, which results from the inability of the immune system to eliminate 
infected hepatocytes 11,53. Presentation of viral antigens by infected hepatocytes is the result of 
both cross-presentation and direct antigen expression followed by presentation on the MHC-I. 
Nonetheless, it is tempting to speculate that suboptimal priming of virus-specific CD8+ T 
cells by infected antigen-presenting hepatocytes could induce T cell tolerance via the PD-
1/PD-L1 pathway similarly to what we observed in our experiments. Therefore, specific 
abrogation of PD-L1 expression in hepatocytes or blockade of its activity may provide a 
novel targeted therapeutic strategy for patients affected by chronic hepatitis in alternative to 
unspecific inhibition of PD-1/PD-L1 interactions 49. 
Emperipolesis has also been observed in liver sections from patients infected with 
HBV and HCV and has been previously reported to be a mechanism by which CD8+ T cells 
invade hepatocytes after TCR engagement and are destroyed in LAMP-1+ organelles 19. We 
were able to detect OT-I-into-hepatocytes structures forming when pGal-OVA-treated 
hepatocytes were co-cultured in vitro with OT-I cells, suggesting that emperipolesis is an 
additional mechanism of hepatocyte-dependent cross-tolerance. Emperipolesis is an active 
process of cell invasion and elimination, as it has been shown that it does not require 
apoptosis or phagocytosis of the T cells to occur 19. Our data suggest that PD-1/PD-L1 
interactions participate in hepatocyte emperipolesis, since blocking PD-L1 specifically on 
OVA cross-presenting hepatocytes could prevent OT-I invasion of hepatocytes in vitro. 
In summary, we show here for the first time both in vitro and in vivo that hepatocytes 
are efficient non-hematopoietic cross-presenting cells. Hepatocyte-dependent cross-
presentation was found to induce antigen-specific CD8+ T cell tolerance, mainly by clonal 
deletion and anergy of the T cells in a PD-1/PD-L1-dependent fashion. Our data also suggest 
that hepatocyte-dependent tolerogenesis via the PD-1/PD-L1 pathway could be at the origin 
of hepatic viral chronic infections. Because of their anatomic location, their abundancy and 
their intense metabolic activities, we propose that hepatocytes are key players in the 
establishment and maintenance of liver-mediated peripheral tolerance towards both 
endogenous and exogenous extracellular antigens reaching the liver through the bloodstream. 
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Moreover, our data support hepatocytes as ideal candidates for targeted tolerogenic 
immunotherapies. 
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3.5 Supplementary figures 
Supplementary Fig. 3.1 
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Supplementary figure 3.1 OVA cross-presenting hepatocytes induce CD8+ T cell tolerance via 
OT-I cell deletion and anergy. (a) Flow cytometric analysis of proliferated (CFSElow-neg) OT-I cells 
(top) or of the frequency of CD45.1+ OT-I cells in the population of total viable CD3ε+CD8α+ T cells 
and cell counts (bottom) from the spleen of recipient CD45.2+ C57BL/6 mice treated as indicated in 
Fig. 3.5b. Numbers in the representative dot plots indicate the frequency of CD45.1+ OT-I cells in the 
population of viable CD3ε+CD8α+ cells. (b) Flow cytometry of OT-I cells from the spleen of recipient 
C57BL/6 mice treated as indicated in (a) stained with either Annexin V, FasL, TRAIL or KLRG-1 and 
CD127. (c) Flow cytometric analysis of OT-I cells harvested from the dLNs of recipient C57BL/6 mice 
treated as indicated in (a) stained intracellularly for IFN-γ (left) or IL-2 (right). ** P < 0.01, *** P < 
0.001,  **** P < 0.0001 for comparisons of pGal-OVA hepatocyte-treated group with either vehicle (plus 
challenge)- or hepatocyte-treated group (one-way ANOVA and Bonferroni post-hoc test correction). 
Data are representative of 2 independent experiments (n = 8; mean and s.e.m. in (a-c)). 
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Supplementary Fig. 3.2 
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Supplementary figure 3.2 PD-1/PD-L1 interactions are involved in hepatocyte-dependent cross-
tolerance. (a) Flow cytometry of OT-I cells harvested from the spleen of recipient C57BL/6 mice 
treated as in Fig. 3.5b and stained for PD-1 and Annexin V. The frequencies of PD-1+ OT-I cells (left) 
and of Annexin-V+PD-1+ OT-I cells (right) are indicated. (b) Flow cytometry analysis of proliferated 
(CFSElow-neg) OT-I cells (top) and of the frequency of OT-I cells (gated as CD45.1+) in the population of 
viable CD3ε+CD8α+ T cells and of the corresponding cell counts (bottom) from the spleen of recipient 
CD45.2+ C57BL/6 mice infused with hepatocytes incubated ex vivo with pGal-OVA (12.5 μM) or with 
pGal-OVA (12.5 μM) and 100 μg/ml of either αPD-L1 antibody or isotype control antibody as 
indicated in Fig. 3.5b. Numbers in the representative dot plots indicate the frequency of CD45.1+ cells 
in the population of viable CD3ε+CD8α+ cells. (c) Flow cytometry of OT-I cells from the spleen of 
recipient C57BL/6 mice treated as indicated in (a,b) and stained with either Annexin V, FasL, TRAIL 
or KLRG-1 and CD127. (d) Flow cytometric analysis of OT-I cells from the spleen of recipient 
C57BL/6 mice treated as in (a,b) stained intracellularly for IFN-γ (left) or IL-2 (right). * P < 0.05, ** P < 
0.01, *** P < 0.001, **** P < 0.0001 and n.s. = not significant for comparisons of pGal-OVA hepatocyte-
treated group with either vehicle (plus challenge)- or hepatocyte-treated group in (a) or for comparisons 
of pGal-OVA + αPD-L1 antibody hepatocyte-treated group with either pGal-OVA hepatocyte- or 
pGal-OVA + iso. ctrl. antibody hepatocyte-treated group in (b-d) (one-way ANOVA and Bonferroni 
post-hoc test correction). Data are representative of 2 independent experiments (n = 8; mean and s.e.m. 
in (a-d)). 
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Supplementary Fig. 3.3 
 
Supplementary figure 3.3 CD8+ T cell tolerance is the result of hepatocyte-dependent antigen 
cross-presentation. (a) Flow cytometry analysis of proliferated (CFSElow-neg) OT-I cells (left) and of 
the frequency of OT-I cells (gated as CD45.1+) in the population of viable CD3ε+CD8α+ T cells and the 
corresponding cell counts (right) from the spleen of recipient CD45.2+ C57BL/6 mice infused with 
either wt hepatocytes or TAP1-/- hepatocytes both incubated ex vivo with pGal-OVA (12.5 μM). (b) 
Flow cytometry of OT-I cells from the dLNs of recipient C57BL/6 mice treated as indicated in (a) 
stained with TRAIL. (c) Flow cytometry of OT-I cells from the spleen of recipient C57BL/6 mice 
treated as in (a) stained for either FasL, TRAIL or KLRG-1 and CD127. (d) Flow cytometry of OT-I 
cells harvested from the spleen of recipient C57BL/6 mice treated as in (a) stained intracellularly for 
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IFN-γ. (e) Flow cytometry of OT-I cells harvested from the dLNs (right) or spleen (left) of recipient 
C57BL/6 mice treated as in (a) stained intracellularly for IL-2. (f) Flow cytometry of OT-I cells 
harvested from the spleen of recipient C57BL/6 mice treated as in (a) stained for PD-1 and Annexin V. 
The frequencies of PD-1+ OT-I cells (left) and of Annexin-V+PD-1+ OT-I cells (right) are indicated. * P 
< 0.05, ** P < 0.01 and n.s. = not significant (unpaired t test). Data are representative of 2 independent 
experiments (n = 8; mean and s.e.m. in (a-f)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
?
?
?
???
Supplementary Fig. 3.4 
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Supplementary figure 3.4 Flow cytometry gating strategy and representative raw data. (a) Gating 
strategy utilized to identify CD45.1+ OT-I cells in CD45.2+ C57BL/6 mice in Fig. 3.5, 3.6 and 3.7 and 
in Supplementary Fig. 3.1, 3.2 and 3.3. Briefly, lymphocytes were gated according to SSC and FSC 
from total spleen or dLN cells, followed by identification of viable cells, CD3ε+CD8α+ T cells and 
CD45.1+ OT-I cells. (b) Representative histograms of CD45.1+ OT-I cell counts positive for either 
Annexin V (top left), PD-1 (top right), FasL (bottom) or IFN-γ (bottom right) purified from the spleen 
of CD45.2+ C57BL/6 mice receiving either one of the treatments indicated in the legend following the 
experimental schedule described in Fig. 3.5b. 
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3.6 Materials and methods 
3.6.1 Mice 
C57BL/6 mice were obtained from Harlan Laboratories (Gannat, France), TAP1−/− mice 
(B6.129S2-Tap1tm1Arp/J) were purchased from The Jackson Laboratory (Farmington, CT) and 
CD45.1+ OT-I mice were generated by crossing C57BL/6-Tg(TcraTcrb)1100Mjb (OT-I) mice 
(The Jackson Laboratories) with CD45.1+ C57BL/6-Ly5.1 mice (Charles River, Saint-
Germain-Nuelles, France). 8-12 week old female mice were used in all animal experiments. 
Animals were housed in pathogen-free conditions at the animal facility of the Ecole 
Polytechnique Fédérale de Lausanne and all experiments were performed in accordance with 
Swiss law and with approval from the Cantonal Veterinary Office of Canton de Vaud, 
Switzerland. 
 
3.6.2 Cell isolation and antigen loading 
Hepatocytes were isolated from the liver of wt C57BL/6 or TAP1-/- mice as previously 
described 54 and cultured on a feeder layer of 3T3 NIH fibroblasts in DMEM medium 
supplemented with 10% FBS and 100 IU/mL penicillin-streptomycin at 37°C 5% CO2. 
BMDCs were generated by culturing total bone marrow cells from C57BL/6 mice in RPMI 
1640 medium supplemented with 10% FBS, 100 IU/mL penicillin-streptomycin, 50 μM 2-
Mercaptoethanol and 20 ng/mL recombinant murine GM-CSF (PreproTech) at 37°C 5% CO2 
for 6 days. To isolate CD11c+CD8α+ BMDCs, BMDCs were stained with Abs specific for 
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CD11c (BioLegend) and CD8α (Life Technologies) and sorted with a FACSAria cell sorter 
(BD Biosciences). CD45.1+ OT-I cells were purified from the spleen and LNs of CD45.1+ 
OT-I mice by negative selection of CD8α+ T cells using the EasySep mouse CD8α T cell 
isolation kit (Stemcell Technologies) and labeled with CFSE (Life Technologies) following 
manufacturer’s instructions. For in vitro analysis of OVA processing, hepatocytes and 
BMDCs were cultured in complete DMEM or complete RPMI 1640, respectively, 
supplemented with 20 μg/ml DQ-OVA (Life Technologies). For in vitro analysis of 
SIINFEKL cross-presentation, hepatocytes and BMDCs were cultured in 5 μM OVA-, 5 μM 
pGal-OVA- or 1nM SIINFEKL-supplemented complete medium. For ex vivo loading with 
pGal-OVA prior to administration into mice, hepatocytes were isolated from donor mice and 
incubated for 3 hr at 37°C 5% CO2 with 12.5 μM pGal-OVA-supplemented complete DMEM 
(without feeder layer). 
 
3.6.3 In vitro co-culture of hepatocytes and OT-I cells 
Freshly isolated C57BL/6 hepatocytes were cultured in 5 μM pGal-OVA-supplemented 
complete DMEM for 24 hr prior to washing and co-culture with 105 OT-I cells for 24 hr. For 
drug inhibitors, chloroquine was used at 100 μM and MG132 at 10 μM and were added 1 hr 
after addition of the antigen. After co-culture, OT-I cells were harvested and stained with Abs 
specific for the markers CD3ε (eBioscience), CD8α (Life Technologies), and CD69 
(BioLegend). Samples were acquired on an LSR II cytometer (BD Biosciences) and data 
analyzed with FlowJo software (Tree Star). 
 
3.6.4 In vitro emperipolesis 
Freshly isolated C57BL/6 hepatocytes were cultured in 5 μM pGal-OVA-supplemented 
complete DMEM for 24 hr. After washing with PBS, 106 CFSE-labeled OT-I cells in 
complete DMEM were added to the culture for 24 hr. For PD-L1 blockade, 100 μg/ml αPD-
L1 blocking Ab (BioxCell, clone 10F.9G2) or rat IgG isotype control Ab (Abcam) were 
added to the hepatocytes for 30 min prior to washing and addition of OT-I cells. At the end of 
the experimental time, samples were extensively washed in PBS and prepared for confocal 
microscopy. 
 
3.6.5 Confocal microscopy and flow cytometry of primary hepatocytes and BMDCs 
For confocal microscopy, primary hepatocytes were adhered onto 3T3 NIH fibroblast-coated 
glass coverslips and BMDCs were adhered onto poly-L-lysine-coated glass coverslips. At the 
end of the experimental procedures, cells were fixed in 4% paraformaldehyde solution, 
permeabilized in 3% BSA 0.1% saponin PBS and stained with primary Abs specific for MR 
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(AbD Serotec), EEA1 (BioConcept), LAMP-1 (Abcam), TAP1 (Santa Cruz Biotechnology), 
H-2Kb (BioLegend) or H-2Kb/SIINFEKL (eBioscience) followed by fluorescently labeled 
secondary Abs (Life Technologies) and fluorochrome-conjugated phalloidin (Life 
Technologies). Samples were mounted using ProLong Gold antifade reagent with DAPI (Life 
Technologies), imaged with a LSM 700 inverted confocal microscope (Zeiss) and data were 
analyzed with ImageJ software. For flow cytometry, at the end of the experimental 
procedures, hepatocytes or BMDCs were washed in 2% FBS PBS and acquired on an LSR II 
cytometer (BD Biosciences) and data analyzed with FlowJo software (Tree Star). 
 
3.6.6 Hepatocyte adoptive transfer for biodistribution and tolerance studies 
For hepatocyte biodistribution studies, wt C57BL/6 mice were administered i.v. by tail vein 
injection with 106 CFSE-labeled C57BL/6 hepatocytes in 100 μL DMEM. Mice were 
euthanized after 24 hr, 14 d and 1 month to collect liver, spleen, lungs and kidneys for 
confocal microscopy. For tolerance studies, on day 0 recipient wt C57BL/6 mice were 
administered i.v. by tail vein injection with either 106 pGal-OVA-treated or untreated 
hepatocytes in 100 μL DMEM or with 100 μL DMEM (vehicle) followed by i.v. injection of 
3*105 CFSE-labeled CD45.1+ OT-I cells 6 hr later. For PD-L1 blockade, 100 μg/ml αPD-L1 
blocking Ab (BioxCell, clone 10F.9G2) or rat IgG isotype control Ab (Abcam) were added to 
the hepatocytes for 30 min prior to washing and administration into mice. On day 15, 
recipient mice were either vaccinated i.d. with 10 μg endo-grade chicken OVA (Hyglos) + 50 
ng ultra-pure LPS (InvivoGen) in 50 μL saline divided into the two frontal footpads or left 
untreated. On day 19, recipient mice were euthanized to collect spleen and brachial and 
axillary LNs (dLNs). Spleen and dLN single-cell suspensions were either cultured for 6 hr at 
37 °C in the presence of 1 μg/mL SIINFEKL (GenScript) with the addition of 5 μg/mL BFA 
for the last 3 hr of culture for antigen-specific restimulation and intracellular cytokine staining 
or directly stained for flow cytometry. For flow cytometry analysis, cells were first stained 
using Live/Dead fixable cell viability reagents (Life Technologies) followed by surface 
staining with Abs specific for the markers CD45.1 (eBioscience), CD3ε (eBioscience), CD8α 
(Life Technologies), FasL (BioLegend), TRAIL (BioLegend), KLRG-1 (BioLegend), CD127 
(eBioscience) and PD-1 (BioLegend). Staining with biotinylated Annexin V and fluorescently 
labeled streptavidin (Life Technologies) was performed according to the manufacturer’s 
instructions. For intracellular cytokine staining, cells were fixed in 2% paraformaldehyde 
solution, permeabilized in 0.5% saponin 2% FBS PBS solution, and incubated with Abs 
specific for IFN-γ (BioLegend) and IL-2 (eBioscience). Samples were acquired on an LSR II 
cytometer (BD Biosciences) and data analyzed with FlowJo software (Tree Star). dLN cells 
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were restimulated for 4 days in the presence of 1 μg/mL SIINFEKL for the measurement of 
IFN-γ by ELISA using the specific Ready-SET-go! ELISA kit from eBioscience. 
 
3.6.7 Confocal microscopy of tissue sections 
Liver, spleen, lungs and kidneys were harvested after perfusion of euthanized animals with 
HBSS (Life Technologies). Organs were fixed in 4% paraformaldehyde solution and frozen 
in OCT (Sakura). 10 μm-thick sections were sliced and stained with primary Abs specific for 
PD-L1 or PD-L2 (eBioscience) and fluorescently labeled secondary Abs (Life Technologies) 
or left unstained. Samples were mounted using ProLong Gold antifade reagent with DAPI 
(Life Technologies), imaged with a LSM 700 inverted confocal microscope (Zeiss) and 
analyzed with ImageJ software. 
 
3.6.8 Statistics 
Statistically significant differences between experimental groups were determined by one-
way ANOVA followed by Bonferroni post-hoc test correction or by unpaired t test.  * P < 
0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 and n.s. = not significant. Statistical analyses 
were performed using Prism software (v6.0f, GraphPad Software). 
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Chapter 4 
 
Characterization of peripheral 
tissue-specific antigen expression in 
liver cell populations in wild-type and 
autoimmunity-prone mice 
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4.1 Abstract 
Expression of tissue-specific antigens in the thymus allows negative selection of possible 
auto-reactive thymocytes before they reach peripheral organs as naïve T lymphocytes. Tissue-
specific antigens have also been found expressed in CD45+ and CD45- cells of the LNs 
contributing to the maintenance of a self tolerant TCR repertoire. Because of immunological 
similarities between LN stromal cells and hepatic non-hematopoietic cells, especially LSECs 
and hepatocytes, we asked whether promiscuous gene expression of otherwise tissue-
restricted antigens could also occur in hepatic cells as additional mechanism of peripheral 
tolerogenesis. We analyzed the expression of AIRE and Deaf1, the two best known 
transcriptional regulators of promiscuous gene expression, in isolated hepatocytes and LSECs 
from adult C57BL/6 mice and found that Deaf1, but not AIRE, is expressed in hepatocytes 
both at the RNA and at the protein level. LSECs resulted negative for both AIRE and Deaf1. 
Some of the genes coding for peripheral tissue-specific antigens associated to Deaf1-
dependent regulation in LNs, such as Ins1, Ins2, Afp and Tyr, were also found expressed at 
the RNA level in hepatocytes. When we compared hepatocytes from 6 week-old diabetes-
prone NOD female mice to age-matched diabetes-resistant NOD male mice, we could 
observe a trend for reduced relative expression of Deaf1 and Ins1 and, most importantly, 
significantly reduced expression of Ins2. We describe here for the first time that hepatocytes, 
which are non-hematopoietic cells of a non-lymphoid organ, are capable of promiscuous gene 
expression. Our data also suggest a possible alteration of promiscuous gene expression in the 
hepatocytes of diabetes-prone NOD female mice as a possible factor contributing to 
autoimmunity.  
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4.2 Introduction 
Until recently, promiscuous gene expression of PTAs was considered the hallmark of central 
tolerance. In fact, antigens normally expressed in a specific tissue or at a specific time in the 
organism are also expressed in mTECs and are presented on MHC complexes by both mTECs 
and DCs in the thymus (Fig. 1.4). Presentation of PTAs in the thymus allows to survey the 
specificity and affinity of the TCR of developing thymocytes and is crucial for the negative 
selection of those T cell precursors recognizing self peptide/MHC complexes with strong 
affinity 1-5. 
The PTA library expressed in the thymus does not represent all the possible tissue-
specific antigens of the organism. Moreover, since the discrimination between auto-reactive 
and allo-reactive T cells is based on the affinity of the TCR for its cognate peptide/MHC 
complex, T cell clones expressing a low-affinity TCR specific for a self peptide/MHC 
complex can still escape negative selection, complete their maturation into naïve T cells and 
reach the periphery. Once in the periphery, peripheral tolerance mechanisms are responsible 
for avoiding their activation 6. 
Recently, promiscuous gene expression has been reported in LN CD45+ 
hematopoietic cells and CD45- stromal cells, typically distinguished according to their 
staining for podoplanin (gp38) and the endothelial cell marker CD31 into double-negative 
cells (DNs, CD45-gp38-CD31-), lymphatic endothelial cells (LECs, CD45-gp38+CD31+), 
fibroblastic reticular cells (FRCs, CD45-gp38+CD31-) and blood endothelial cells (BECs, 
CD45-gp38-CD31+) (Fig. 4.1a). Different subsets of PTAs have been found expressed in 
CD45+ cells and in stromal LN cells (Fig. 4.1b). Presentation on MHC molecules has been 
characterized for some of these antigens and has been associated with induction of deletional 
tolerance of antigen-specific CD8+ T lymphocytes 7-12.  
An extensive characterization of the molecular mechanisms regulating promiscuous 
gene expression in LN cells is still missing. Preliminary reports seem to suggest that the 
transcription factor AIRE is only expressed in DNs and in rare extra-thymic AIRE-expressing 
LN stromal cells of unknown lineage. On the other hand, the transcription factor Deaf1, 
recently associated with promiscuous gene expression and regulation of immunity and 
autoimmunity 13, could be instrumental in the regulation of promiscuous gene expression in 
the periphery as it is broadly expressed in all of the four LN stromal cell populations and in 
LN CD45+ cells (Fig. 4.1b) 9,12. 
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Figure 4.1 Promiscuous gene expression in LN cell populations. (a) Flow cytometric separation of 
LN CD45- stromal cells according to staining of gp38 (podoplanin) and CD31. (b) Gene expression 
analysis of PTA-coding genes (the main murine insulin-coding gene Ins2, the neuro-specific Gad67, 
the hepatocyte-specific α-1 microglobulin/bikunin precursor or Ambp, pancreatic polypeptide or Ppy, 
the melanocyte-specific genes tyrosinase or Tyr and Mart1, and the colon epithelium-expressed A33) 
and promiscuous gene expression transcriptional regulators (AIRE and Deaf1) in CD45+ and CD45- 
stromal cells of the LNs (adapted from Lee, J. W. et al., Nat. Immunol., 2007; Gardner, J. M. et al., 
Science, 2008; Yip, L. et al., Nat. Immunol., 2009;  Cohen, J. N. et al., J. Exp. Med., 2010; Fletcher, A. 
L. et al., J. Exp. Med., 2010; Yip, L. et al., J. Mol. Cell Biol., 2013). 
 
Similarly to LN stromal cells, non-hematopoietic CD45- cells composing the liver, 
especially LSECs and hepatocytes, have also been reported to have antigen-presenting 
functions and to participate in the establishment of CD4+ and CD8+ T cell peripheral tolerance 
14-16. Moreover, LSECs present several phenotypic and functional similarities to LN LECs. 
For example, both cell types are in direct contact with circulating fluids (blood and lymph, 
respectively) and therefore with T cells and they both show efficient extracellular-antigen 
scavenging and MHC presentation capacity. Antigen presentation by both LSECs and LECs 
has been associated to the induction of antigen-specific tolerance rather than immunity 
because of lack of co-stimulation 14-18. Due to the peculiar fenestrated endothelium of the liver 
(Fig. 3.1a,b), hepatocytes are also in direct physical contact with circulating lymphocytes and 
show antigen scavenging ability, leading to cross-presentation of extracellular antigens on 
MHC-I molecules without co-stimulation and tolerance of antigen-specific CD8+ T 
lymphocytes (Chapter 3 and Damo M. et al., manuscript in preparation) 19. 
Because of these characteristics, we asked whether also liver cells could utilize 
promiscuous gene expression and presentation of PTAs as mechanisms of peripheral 
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tolerance, similarly to LN stromal cells. We therefore purified hepatocytes and LSECs from 
adult C57BL/6 livers in order to extract total mRNA and quantify the expression of AIRE, 
Deaf1 and some of the best characterized PTA-coding genes. We found that while 
transcription of AIRE could not be detected in either primary hepatocytes or LSECs, 
expression of Deaf1 could be measured in hepatocytes. Deaf1 expression at the protein level 
was confirmed by confocal microscopy in hepatocytes. Expression of some PTA-coding 
genes hypothesized to be dependent on Deaf1 transcriptional regulation in LNs 12, specifically 
Ins1 (insulin 1), Ins2 (insulin 2), the fetal liver-specific version of albumin Afp (α-
Fetoprotein), the melanocyte-specific Tyr (tyrosinase) and the neuronal and pancreatic β-cell-
specific GAD1 or GAD67 (glutamic acid decarboxylase 1), was also confirmed in hepatocytes 
at the mRNA level. As a preliminary validation of the role of hepatocyte-dependent 
promiscuous gene expression in the protection from autoimmunity, we analyzed the gene 
expression profile of Deaf1 variants (both the variant coding for the functional native or wild-
type Deaf1 and the variant coding for an inhibitory dominant-negative form of Deaf1), Ins1, 
Ins2 and GAD67 in hepatocytes harvested from 6 week-old female nonobese diabetic (NOD) 
mice and compared it to that of age-matched male NOD mice. A trend for reduced relative 
expression levels of native Deaf1, Ins1 and GAD67, significantly reduced expression of Ins2 
and significantly increased expression of dominant-negative Deaf1 could be observed in 
diabetes-prone NOD females as compared to diabetes-resistant NOD males. 
 
 
4.3 Results 
4.3.1 Deaf1 and Deaf1-dependent PTA-coding genes are expressed in murine 
hepatocytes  
Hepatocytes and LSECs are the two most abundant cellular components of the liver and the 
major determinants of its immune tolerogenic properties (Fig. 4.2a) 21. In order to investigate 
whether hepatocytes and LSECs are capable of promiscuous gene expression, we set up a cell 
purification protocol to harvest either hepatocytes or LSECs from adult C57BL/6 liver cell 
suspensions by serial centrifugation or fluorescence-activated cell sorting (FACS), 
respectively.  Hepatocytes are the biggest cells in the liver, with an average cell diameter of  ≈ 
15 μm and could therefore be isolated by low-speed serial centrifugations, as previously 
reported by other groups 15,22. Flow cytometric analysis of the cells after the isolation 
procedure indicated the presence of an homogeneous cell population, confirmed as bona-fide 
hepatocytes due to their lack of CD45 expression together with positivity for H-2Kb and the 
non-conventional MHC-I molecule CD1d 32 (Fig. 4.2b). Purification of LSECs was instead 
performed by FACS of non-parenchymal cells (NPCs) stained for CD45, CD31 and CD146. 
?
?
?
???
LSECs were identified as the CD45-CD31+CD146+ fraction of hepatic NPCs, as previously 
reported 15 (Fig. 4.2c). 
 
Figure 4.2 Isolation of hepatocytes and LSECs from total murine liver cell suspensions. (a) 
Schematic representation of liver cells and their distribution in the liver parenchyma (adapted from 
Crispe, I. N., Annu. Rev. Immunol., 2009). (b) Flow cytometric analysis of murine hepatocytes after 
centrifugation-based separation. Negativity for CD45 together with positivity for H-2Kb and the non-
conventional MHC-I molecule CD1d confirm the identity of bona-fide hepatocytes. (c) Flow 
cytometric sorting strategy of LSECs (CD45-CD31+CD146+) from liver NPCs. Data in (b,c) are 
representative of 2 independent experiments (n = 8). 
 
We next asked whether AIRE and Deaf1, the two master regulators of promiscuous 
gene expression, could be detected in isolated hepatocytes and LSECs. Quantitative PCR 
(qPCR) analysis showed that while AIRE expression is not detectable in either hepatocytes or 
LSECs, Deaf1 is expressed in hepatocytes but not in LSECs (Fig. 4.3a). Total thymic tissue 
was used as positive control and, interestingly, we could measure higher relative expression 
of Deaf1 in hepatocytes as compared to thymic cells, with 3.5E-03 and 0.5E-03 gene 
expression fold change over β-Actin, respectively (Fig. 4.3b). Expression of Deaf1 was 
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confirmed at the protein level in both the cytoplasm and nucleus of purified hepatocytes by 
confocal microscopy (Fig. 4.3c). 
Detection of Deaf1 in hepatocytes prompted us to investigate whether PTAs could 
also be expressed in the same cell type. We therefore analyzed by qPCR the expression of 
some of the most characterized PTA-coding genes, whose expression has been linked to 
Deaf1-dependent regulation in previous reports 12. In particular, we could detect higher 
relative expression of the two murine insulin genes, Ins1 (0.6E-04 fold change) and Ins2 
(0.41E-04 fold change), as well as of Tyr (0.12E-04 fold change), of the fetal version of 
albumin Afp (0.75E-04 fold change) and of the neuronal and β-cell-expressed GAD67 (0.68E-
04) in hepatocytes as compared to thymic cells (0.0015E-04, 0.13E-04, 0.0026E-04, 0.21E-04 
and 0.4E-05 fold change, respectively) (Fig. 4.3a,d). Expression of the PTA genes analyzed in 
our study could not be detected in LSECs (Fig. 4.3a). 
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Figure 4.3 Characterization of promiscuous gene expression in adult C57BL/6 hepatocytes and 
LSECs. (a) Electrophoretic separation of the amplicons obtained by qPCR of the indicated genes from 
total thymus, hepatocytes or LSECs of adult C57BL/6 mice. Expected amplicon length in base pairs 
(bp): AIRE = 89 bp; Deaf1 = 71 bp; Ins1 = 80 bp; Ins2 = 99 bp; Afp = 96 bp; Tyr = 88 bp; β-Actin = 86 
bp. (b) Gene expression analysis by qPCR of Deaf1 in isolated hepatocytes and thymic tissue from 
adult C57BL/6. Values indicate gene expression fold change relative to β-Actin. (c) Confocal 
microscopy of C57BL/6 hepatocytes stained for Deaf1 and with DAPI and phalloidin. Scale bar = 10 
μm. (d) Gene expression analysis by qPCR of Ins1, Ins2, Tyr, Afp and GAD67 in isolated hepatocytes 
and thymic tissue from adult C57BL/6. Values indicate gene expression fold change relative to β-Actin. 
* P < 0.05 (unpaired t test). Data are representative of 2 independent experiments (n = 8; mean and 
s.e.m. in (b,d)). 
 
Our findings indicate that hepatocytes, but not LSECs, significantly express both at 
the RNA and at the protein level the transcription factor Deaf1. Deaf1 is detected not only in 
the cytoplasm but also in the nuclei of hepatocytes, suggesting active transcriptional 
regulation. AIRE expression could not be measured in either hepatocytes or LSECs. 
Nonetheless, Deaf1 has been indicated as AIRE-independent transcriptional regulator of 
PTA-coding genes such as Ins1, Ins2, Tyr, Afp and GAD67, which were all found expressed 
at the RNA level in hepatocytes but not in LSECs. 
 
4.3.2 Expression analysis of Deaf1 and PTA genes in pre-diabetic female NOD mice 
versus male NOD mice 
Dysregulation of promiscuous gene expression has been indicated as one of the genetic 
susceptibility factors of autoimmune diseases such as type 1 diabetes (T1D) 23. In particular, 
reduced expression and functionality of Deaf1, also associated with up-regulation of a 
dominant-negative form of Deaf1 inhibiting the transcriptional regulatory activity of native 
Deaf1, and decreased expression of islet-specific PTAs have been described in the pancreatic 
LN of NOD mice 9,12. We hypothesized that defective PTA expression could also occur in 
hepatocytes, contributing to the development of T1D. 
To test our hypothesis, we analyzed the expression of native and dominant-negative 
Deaf1 variants, Ins1, Ins2 and GAD67 in hepatocytes isolated from the liver of pre-diabetic (6 
weeks of age) female NOD mice and compared it to that of hepatocytes from age-matched 
male NOD mice. It is known, in fact, that the incidence of diabetes in NOD mice is 
significantly different between the two sexes, with 70% of females developing diabetes at 
around 12-13 weeks of age versus only 20% of males. Overt diabetes, indicated by fasting 
hyperglycemia, is preceded by leukocyte infiltration of pancreatic islets (insulitis) appearing 
at around 5-7 weeks of age in female NOD mice and only later in life in males 24. As 
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appearance of insulitis marks the initial phase of immune aggression against pancreatic islets, 
we decided to investigate whether any difference in promiscuous gene expression could be 
detected in NOD hepatocytes from diabetes-prone females and diabetes-resistant males at the 
age of insulitis onset. 
qPCR analysis showed a non-significant trend for reduced native Deaf1 relative 
expression in pre-diabetic female NOD mice as compared to male mice, as indicated by 7.8E-
03 and 1.05E-02 gene expression fold change over β-Actin, respectively (Fig. 4.4a, left). 
Interestingly, the gene expression level of the inhibitory dominant-negative Deaf1 splice 
variant was significantly higher in pre-diabetic female NOD hepatocytes as compared to male 
NOD hepatocytes, with 1.05E-03 and 4.03E-04 fold change, respectively (Fig. 4.4a, right). 
Most importantly, non statistically significant reduction of Ins1 and GAD67 relative 
expression (0.75E-03 and 1.31E-04 fold change, respectively) together with a statistically 
significant 171-fold reduction of Ins2 relative expression (0.0033E-03 fold change) could also 
be measured in females as compared to males (0.56E-03, 6.25E-04 and 1.87 fold change, 
respectively) (Fig. 4.4b). 
 
Figure 4.4 Comparison of Deaf1, Ins1, GAD67 and Ins2 relative expression in hepatocytes from 
pre-diabetic female and male NOD mice. (a) Gene expression analysis by qPCR of native and 
inhibitory dominant-negative Deaf1 variants in hepatocytes isolated from 6 week-old female and male 
NOD mice. Values indicate gene expression fold change relative to β-Actin. (b) Gene expression 
analysis by qPCR of Ins1, GAD67 and Ins2 in hepatocytes isolated from 6 week-old female and male 
NOD mice. Values indicate gene expression fold change relative to β-Actin. * P < 0.05 and n.s. = not 
significant (unpaired t test). Data are representative of 2 independent experiments (n = 10 per sex; 
mean and s.e.m.). 
 
Our results suggest a non-significant reduction of native Deaf1, Ins1 and GAD67 
relative expression but show significant reduction of Ins2 and significant increase of 
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dominant-negative Deaf1 relative expression in the hepatocytes isolated from diabetes-prone 
NOD female mice as compared to diabetes-resistant NOD males already at the pre-diabetic 
age of 6 weeks. 
 
 
4.4 Discussion 
In this project we have shown preliminary data indicating that hepatocytes express Deaf1, a 
gene coding for a transcription factor recently involved in the regulation of promiscuous gene 
expression in peripheral lymphoid organs and in the pathogenesis of autoimmunity 9,12,13. 
Some of the most characterized PTA-coding genes, in particular Ins1, Ins2, Afp, Tyr and 
GAD67 genes, are also expressed in hepatocytes. Moreover, our data indicate a possible 
reduction of the expression levels of native Deaf1 and Ins1 and significant reduction of Ins2 
and significant increase of inhibitory Deaf1 relative expression in the hepatocytes of T1D-
prone NOD female mice as opposed to T1D-resistant NOD male mice. 
Expression of PTAs has long been considered a unique feature of mTECs to allow the 
negative selection of potentially auto-reactive thymocytes during their development 1-5. In 
recent years, expression of PTAs has been described also in both hematopoietic and stromal 
cell populations of the LNs and has been shown to play an important role in the maintenance 
of peripheral tolerance via clonal deletion of PTA-specific CD8+ T lymphocytes 7-12. In fact, 
in physiologic conditions, locally expressed antigens are continuously sampled from the 
extracellular space by immature tissue-resident DCs, which then migrate to regional LNs. In 
alternative, local extracellular antigens can also be directly drained through lymphatic or 
blood circulation to regional LNs, where hematopoietic resident APCs (such as DCs) and 
non-hematopoietic resident APCs (such as LECs) uptake the antigens and present them in the 
context of MHC class I and II to T lymphocytes 25. Under non-inflammatory conditions, 
antigen presentation only provides a suboptimal milieu for antigen-specific T cells to activate 
and, as a consequence, lymphocytes either die by apoptosis (clonal deletion), acquire an 
anergic phenotype or develop into suppressive Treg cells 26. In this scenario, the 
establishment of peripheral tolerance would be limited to those antigens expressed locally. 
Promiscuous gene expression has therefore the role to amplify the repertoire of self antigens 
presented to peripheral T cells in regional LNs, thus increasing the likelihood of auto-reactive 
T cell deletion 25. 
Because of the immunological similarities between certain LN stromal cells, in 
particular LECs, with non-hematopoietic cells of the liver, in particular LSECs, we 
hypothesized that promiscuous gene expression could also be part of the tolerogenic 
mechanisms employed by hepatic cells. Our preliminary findings indicate that hepatocytes are 
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the only non-hematopoietic cells in the liver and, to our knowledge, the only parenchymal 
cells in a non-lymphoid organ so far shown to express regulators of promiscuous gene 
expression (Deaf1) and PTA-coding genes. The observation that the relative expression level 
of all the genes we analyzed is higher in hepatocytes than in thymic cells could be an artifact 
due to the use of total thymic tissue as opposed to isolated hepatocytes for gene expression 
analysis. Nonetheless, Deaf1 expression was confirmed both at the RNA and at the protein 
level in hepatocytes and, most importantly, Deaf1 could be detected in the nuclei of 
hepatocytes, suggesting transcriptional regulatory activity. Further studies are needed to 
confirm expression at the protein level also of Ins1, Ins2, Afp, Tyr and GAD67 in hepatocytes 
and to analyze the expression of other transcriptional regulators and PTAs. Most importantly, 
we will investigate whether and how such PTAs are transcriptionally regulated by Deaf1, 
presented on the MHC-I and correlate to tolerance induction. 
Autoimmunity results from failure of the immune system to protect self tissues from 
immune aggression 27. For example, T1D is a chronic autoimmune disease resulting from 
aggression of pancreatic insulin-producing β cells by auto-reactive CD4+ and CD8+ T 
lymphocytes. Genetic susceptibility and exposure to environmental triggers are the major 
factors involved in T1D etiopathogenesis 28. In particular, mutations in genes involved in the 
establishment of both central and peripheral tolerance have been associated with increased 
T1D susceptibility, as they would lead to defective immune tolerance towards β cell auto-
antigens, such as insulin. For example, mutations in the gene coding for AIRE have been 
found in patients affected by APECED, which is a syndrome characterized by multiple 
autoimmune manifestations, including T1D 23. 
The NOD mouse is a useful model to study the biology and genetics of 
autoimmunity, as NOD mice spontaneously develop several autoimmune manifestations, 
among which T1D is the most characterized. Despite relevant differences with human T1D, 
the NOD mouse model has been extensively used to understand the etiopathogenesis of 
autoimmune diabetes 24. Confirming the involvement of altered PTA expression in the 
development of T1D, previous reports have shown that T cell precursors from the thymus of 
NOD mice are relatively resistant to negative selection 29 and show similar defects as 
compared to thymocytes purified from AIRE-deficient mice 30. In addition, reduced insulin 
expression in the murine thymus has been associated with increased T cell reactivity against 
insulin in the periphery 31. Moreover, Deaf1 and genes coding for several islet-specific 
antigens, including Ins1 and Ins2, are significantly downregulated in the pancreatic LN of 
NOD mice at the time of diabetes onset 9. Interestingly, the expression of a dominant negative 
form of Deaf1, resulting from alternative splicing and inhibiting the transcriptional activity of 
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native Deaf1, has been shown in the pancreatic LN of NOD mice. A similar variant of Deaf1 
has also been found highly expressed in the pancreatic LN of T1D patients 12. 
We hypothesized that if promiscuous gene expression by hepatocytes is relevant in 
the maintenance of immune tolerance, alterations could be detected in an organism 
susceptible to autoimmunity, such as the female NOD mouse. When we compared pre-
diabetic T1D-prone female NOD mice to age-matched T1D-resistant male NOD mice, we 
could in fact observe a trend for reduced relative expression of native Deaf1, Ins1 and 
GAD67, significant reduction of Ins2 and significant increase of dominant-negative Deaf1 in 
females, suggesting a possible correlation with their autoimmunity-prone phenotype. 
Interestingly, we found that the relative expression of the main murine insulin-coding gene, 
Ins2, was significantly reduced by a 171 fold factor in NOD female hepatocytes as compared 
to NOD male hepatocytes, possibly suggesting that disruption of hepatocyte-dependent 
promiscuous gene expression could have a primary role in the pathogenesis of autoimmune 
diabetes. Nonetheless, more solid studies and age-related comparisons are needed to obtain 
conclusive evidence that altered promiscuous gene expression in hepatocytes has a role in the 
development of autoimmunity in these mice, especially considering the technical challenges 
of the NOD mouse model. In fact, diabetes incidence in NOD mice does not reach 100% and 
environmental variables dramatically affect the onset of autoimmunity 24. 
In summary, we suggest that hepatocytes are instrumental in the maintenance of 
CD8+ T cell peripheral tolerance in the organism by both antigen cross-presentation and direct 
PTA expression and MHC-I presentation. 
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4.5 Materials and methods 
4.5.1 Mice 
8-10 week old female C57BL/6 mice were obtained from Harlan Laboratories (Gannat, 
France) and 6 week old female and male NOD/ShiLtJ mice were purchased from Charles 
River (Saint-Germain-Nuelles, France). Animals were housed in pathogen-free conditions at 
the animal facility of the Ecole Polytechnique Fédérale de Lausanne and all experiments were 
performed in accordance with Swiss law and with approval from the Cantonal Veterinary 
Office of Canton de Vaud, Switzerland. 
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4.5.2 Cell isolation, flow cytometry and confocal microscopy 
Hepatocytes were isolated from the liver of C57BL/6 or NOD/ShiLtJ mice as previously 
described 15,22. LSECs were isolated from the liver of C57BL/6 by FACS of liver NPC 
suspensions by modification of the purification procedure published by Ebraimkhani M. R. et 
al. 15 Briefly, mice were euthanized and livers perfused with 0.5 mg/ml Collagenase D 
(Sigma-Aldrich) HBSS solution. Livers were then homogenized through a 100 μm cell 
strainer followed by filtration through a 70 μm cell strainer. Liver cell suspensions were 
centrifuged for 5 min at 50 g at 4°C to collect hepatocyte pellets. For LSECs isolation, the 
supernatant, containing NPCs, was cleared from hepatocytes by centrifugation at 50 g for 5 
min repeated for 3 times. The NPC-containing supernatant was spun down for 10 min at 800 
g at 4°C, stained with Abs specific for CD45 (eBioscience), CD31 (BioLegend) and CD146 
(BioLegend) in 2% FBS PBS solution and sorted with a FACSAria cell sorter (BD 
Biosciences). For flow cytometric analysis, LSECs and hepatocytes stained with Abs specific 
for CD45 (eBioscience), CD1d (BioLegend) and H-2Kb (BioLegend) were acquired on an 
LSR II cytometer (BD Biosciences) and data analyzed with FlowJo software (Tree Star). For 
confocal microscopy, primary hepatocytes were adhered onto 3T3 NIH fibroblast-coated 
glass coverslips, fixed in 4% paraformaldehyde solution, permeabilized in 3% BSA 0.1% 
saponin PBS and stained with a primary Ab specific for Deaf1 (Aviva Systems Biology), 
followed by a fluorescently labeled secondary Ab (Life Technologies) and fluorochrome-
conjugated phalloidin (Life Technologies). Samples were mounted using ProLong Gold 
antifade reagent with DAPI (Life Technologies), imaged with a LSM 700 inverted confocal 
microscope (Zeiss) and data were analyzed with ImageJ software. 
 
4.5.3 RNA extraction, RT-PCR and gene expression analysis by qPCR 
Total RNA was extracted from isolated hepatocytes and LSECs and biopsies of thymic tissue 
using the RNeasy micro kit isolation protocol (Qiagen) according to manufacturer’s 
instructions. cDNA was obtained by reverse transcription PCR (RT-PCR) of total RNA 
performed using the SuperScript III First Strand Synthesis SuperMix (Life Technologies) 
following manufacturer’s instructions. Gene expression analysis was performed by cDNA 
qPCR using TaqMan gene expression assays specific for AIRE (Mm00477461_m1), wild-
type or native Deaf1 (Mm00516805_m1), dominant-negative Deaf1 (custom-made, lot. 
1467978) 9, Ins1 (Mm01950294_s1), Ins2 (Mm00731595_gH), Afp (Mm00431715_m1), Tyr 
(Mm00453201_m1), GAD67 (Mm04207432_g1) and β-Actin (Mm01268569_m1) (Life 
Technolgies) in a LightCycler 96 System (Roche). Relative gene expression was quantified 
using the formula (gene expression fold change) = 2(Cq Actin – Cq Gene of interest) with β-Actin as 
reference gene. 
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4.5.4 Statistics 
Statistically significant differences between experimental groups were determined by 
unpaired t test.  * P < 0.05 and n.s. = not significant. Statistical analyses were performed using 
Prism software (v6.0f, GraphPad Software). 
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Chapter 5 
 
Conclusions 
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5.1 Final considerations, new scientific questions and future directions 
In this Ph. D. thesis aspects of biology and bioengineering were combined to investigate the 
immune system and its function, either for translational applications (Chapter 2) or for basic 
studies (Chapter 3 and 4). 
 
The project presented in Chapter 2 describes the development of an improved vaccine 
suitable for cancer immunotherapy. Since evasion of tumor cells from immunosurveillance 
has been recognized as a major factor leading to clinical disease 1, several therapies aimed at 
enhancing anti-tumor immunity have been adopted in the fight against cancer and are now 
either clinically available or under experimental testing 2. Unfortunately, clinical data have 
pointed out the need for more efficacious immunotherapies, therefore much scientific interest, 
public attention and, more importantly, funding, have been given to the quest for better, safer 
and more specific therapies 3,4. 
When exosomes were first described almost 20 years ago, their employment in cancer 
research was one of the first applications to be explored. Since then, a plethora of pre-clinical 
data has indicated that exosomes derived from tumor antigen-loaded DCs could be used as a 
vaccine to stimulate anti-tumor immunity for the control of tumor growth in murine models 5. 
Clinical trials testing DC-derived exosomes for the vaccination of human cancer patients 
provided useful information on the feasibility and safety of this approach, yet showed limited 
therapeutic benefits due to weak immunogenicity 6,7. 
Because of the experience of our group in the development of vaccines based on 
nanoparticles, we decided to investigate DC-derived exosomes as cancer immunotherapy. In 
particular, the aim of our project was to establish a protocol for the production of an exosome 
vaccine with increased immunogenicity in a murine melanoma model, thus providing an 
improved alternative to the exosome formulations previously tested on humans. As immunity 
is the result of antigen presentation in the context of a pro-inflammatory milieu 8, we adapted 
the procedure for the isolation of DC exosomes in order to couple loading of the DCs with a 
melanoma lysate, that provided antigens, to maturation of the DCs with poly(I:C), that 
provided pro-inflammatory danger signals. Exosomes inherit proteins and nucleic acids from 
the cells of origin, therefore our exosome production protocol resulted in a vaccine capable of 
inducing potent anti-melanoma immunity associated to significant reduction of tumor growth 
and prolonged survival of treated melanoma-bearing mice. Our findings suggest that the 
protocol proposed by our group is a valid and therapeutically promising alternative to the 
existing pre-clinical and clinical protocols for the production of exosome-based vaccines for 
cancer immunotherapy. 
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Even though our vaccine was capable of negatively affecting tumor growth, 
vaccination did not result in complete tumor eradication and, most importantly, almost half of 
the experimental mice treated with our vaccine formulation still died of melanoma. Therefore, 
further improvements are needed. In order to address these issues, we are currently evaluating 
the use of alternative TLR ligands during exosome production and, among others, we have 
decided to use MPLA due to the favorable safety and immunogenicity showed in several 
clinical trials employing MPLA as adjuvant for cancer immunotherapy 9. In addition, we will 
also assess whether the combination of two or more TLR ligands could provide additional 
benefits to increase exosome immunogenicity. 
 
The health of our organism critically depends on the unique ability of the immune 
system to discriminate self from non-self or mutated-self. Because of the complexity of the 
subject, a comprehensive understanding of the mechanisms that make this discrimination 
possible is still missing, even though enormous advancements have been made in recent 
years. For example, it is now accepted that specific subsets of peripheral non-hematopoietic 
cells display features of hematopoietic APCs and are therefore capable of presenting antigens 
to both CD4+ and CD8+ T lymphocytes, significantly contributing to immune tolerance 18-19. 
The aim of the project presented in Chapter 3 was to show that the most abundant cell 
type of the liver, the hepatocyte, is also capable of antigen uptake and processing leading to 
MHC-I presentation (cross-presentation) and tolerance of antigen-specific CD8+ T cells 
(cross-tolerance). Our findings suggest that the biggest blood-filtering organ of the organism 
is not only an essential metabolic compartment of the body but is also instrumental in the 
maintenance of immune homeostasis. In fact, the multitude of extracellular antigens 
circulating in the blood and filtered through the liver is directly accessible to both LSECs and 
hepatocytes. Continuous antigen sampling and presentation by LSECs and hepatocytes could 
be a major contributor to the maintenance of a tolerant TCR repertoire. 
Persistency of hepatic infections, such as HBV and HCV, has been indicated as a 
drawback of liver tolerogenesis 10. Our studies indicate that hepatocyte-dependent cross-
tolerance can be significantly prevented by blocking PD-1/PD-L1 interactions between CD8+ 
T lymphocytes and hepatocytes, respectively. We therefore propose that hepatocyte-specific 
blockade or down-regulation of PD-L1 could be a valid therapeutic alternative for the 
treatment of chronic viral hepatitis as compared to general and therefore unspecific blockade 
of PD-1/PD-L1 interactions, which has been proposed for clinical testing 11. 
 
The results described in Chapter 3 prompted us to hypothesize that the liver may have 
a much more fundamental role in the maintenance of immune homeostasis. Since it has been 
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recently shown that stromal cells of the LNs contribute to the establishment of peripheral 
tolerance also by directly expressing and presenting otherwise peripheral tissue-restricted 
antigens 12-16, the aim of the project presented in Chapter 4 was to investigate whether 
promiscuous gene expression could also be part of the tolerogenic mechanisms employed by 
hepatic cells. We analyzed the expression of the two most characterized master regulators of 
promiscuous gene expression, AIRE and Deaf1, and observed that hepatocytes, but not 
LSECs, significantly express Deaf1 and a list of other PTA-coding genes. In the NOD mouse 
model, that spontaneously develops T1D as well as other autoimmune manifestations 17, we 
could observe a trend pointing at a reduction of hepatocyte-dependent expression of Deaf1, 
Ins1 and Ins2 in autoimmunity-prone females as compared to autoimmunity-resistant males. 
Even though preliminary, our data suggest that hepatocytes are capable of promiscuous gene 
expression. It is therefore tempting to speculate that autoimmune manifestations could result 
from a multi-organ failure in tolerance development and that the liver could be one of the 
organs involved. 
Many scientific questions are raised by our findings. We are currently performing 
experiments to investigate whether transcriptional regulators of promiscuous gene expression 
other than Deaf1 and other PTA-coding genes are expressed in hepatocytes. Most 
importantly, in order to claim any role for hepatocyte-dependent promiscuous gene 
expression in the physiology of the immune system and in the pathogenesis of autoimmunity, 
we first need to prove that PTA genes expressed in hepatocytes are also presented on MHC-I 
complexes to antigen-specific CD8+ T lymphocytes, leading to tolerance. If the role of Deaf1 
as master regulator of promiscuous gene expression in hepatocytes and induction of tolerance 
are proven, a mouse model of hepatocyte-specific Deaf1 knock-out could be developed in 
order to analyze its immune phenotype. In fact, lack or reduction of promiscuous gene 
expression in the liver may be responsible for profound alterations of immune homeostasis, 
such as the development of multiple autoimmune manifestations as in NOD mice. 
 
Last, the findings described in both Chapter 3 and 4 suggest that hepatocytes could 
represent a favorable target for therapeutic strategies aimed at either inducing tolerance, as in 
the case of autoimmunity or protein-replacement therapies for genetic diseases, or braking 
tolerance, as in the case of chronic viral infections. 
In particular, hepatocyte-targeted delivery of tissue-specific antigens could be 
exploited to develop cross-tolerance as a prophylactic tolerogenic treatment prior to 
transplantation of the tissue or organ expressing those antigens. As a proof of concept, 
experiments of skin transplantation from skin-donor OVA-transgenic mice into wild-type 
recipient mice are ongoing in order to assess the survival rate of skin grafts in those animals 
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receiving OVA cross-presenting hepatocytes prior to skin transplantation. Results from these 
experiments will allow us to propose cross-presenting hepatocytes as an alternative to 
immunosuppressive drugs in transplantation. 
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